184475-35-2 | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$7.00	$5.00
500mg	98%	in stock	$9.00	$6.00
1g	98%	in stock	$13.00	$9.00
5g	98%	in stock	$38.00	$27.00
10g	98%	in stock	$62.00	$44.00
25g	98%	in stock	$123.00	$86.00
100g	98%	in stock	$409.00	$287.00

Description

• Catalog Number: AB52186
• Chemical Name: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
• CAS Number: 184475-35-2
• Molecular Formula: C22H24ClFN4O3
• Molecular Weight: 446.9024
• MDL Number: MFCD04307832
• SMILES: COc1cc2ncnc(c2cc1OCCCN1CCOCC1)Nc1ccc(c(c1)Cl)F

Computed Properties

• Complexity: 545
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 8
• XLogP3: 4.1

Literature

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• Arsenic Attenuates Heparin-Binding EGF-Like Growth Factor/EGFR Signaling That Promotes Matrix Metalloprotease 9-Dependent Astrocyte Damage in the Developing Rat Brain.

  Toxicological sciences : an official journal of the Society of Toxicology 20180401

• Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.

  Toxicology and applied pharmacology 20171115

• Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

  The Lancet. Oncology 20171101

• Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20171001

• The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.

  The Journal of biological chemistry 20170908

• Induction of ABCG2/BCRP restricts the distribution of zidovudine to the fetal brain in rats.

  Toxicology and applied pharmacology 20170901

• Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.

  Toxicology and applied pharmacology 20161101

• Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

  Journal of medicinal chemistry 20160908

• Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress.

  Toxicology letters 20160611

• Gallic acid abolishes the EGFR/Src/Akt/Erk-mediated expression of matrix metalloproteinase-9 in MCF-7 breast cancer cells.

  Chemico-biological interactions 20160525

• Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

  Journal of structural biology 20151201

• Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.

  Toxicology and applied pharmacology 20151101

• Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

  The Lancet. Oncology 20150901

• Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.

  Toxicology and applied pharmacology 20150815

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).

  Archives of toxicology 20150401

• Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

  Current opinion in oncology 20150301

• Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

  Proceedings of the National Academy of Sciences of the United States of America 20150210

• Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

  Journal of medicinal chemistry 20141009

• Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.

  Molecular cancer therapeutics 20140501

• A high-throughput screen for teratogens using human pluripotent stem cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• NF-κB acts downstream of EGFR in regulating low dose cadmium induced primary lung cell proliferation.

  Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.

  Chemico-biological interactions 20130425

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol.

  Molecular oncology 20130201

• Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.

  International journal of cancer 20130101

• EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.

  International journal of cancer 20121215

• Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis.

  The Journal of biological chemistry 20121207

• New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

  Medical oncology (Northwood, London, England) 20121201

• The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

  Lung cancer (Amsterdam, Netherlands) 20121201

• Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.

  Bioorganic & medicinal chemistry 20121115

• Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.

  Head & neck 20121101

• Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.

  Clinical lung cancer 20121101

• Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.

  Clinical lung cancer 20121101

• Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.

  Journal of cancer research and clinical oncology 20121101

• Targeted therapy in brain metastasis.

  Current opinion in oncology 20121101

• ATP serves as an endogenous inhibitor of UDP-glucuronosyltransferase (UGT): a new insight into the latency of UGT.

  Drug metabolism and disposition: the biological fate of chemicals 20121101

• Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.

  Cancer science 20121101

• Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.

  Journal of pharmaceutical sciences 20121101

• Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

  International journal of oncology 20121101

• Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.

  Oncology reports 20121101

• Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance.

  Cancer science 20121101

• Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.

  Cancer chemotherapy and pharmacology 20121101

• Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma.

  Journal of the American Academy of Dermatology 20121101

• Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121101

• The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.

  Life sciences 20121015

• A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

  Experimental cell research 20121001

• JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.

  Cancer science 20121001

• Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window.

  Biomedical microdevices 20121001

• Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

  Lung cancer (Amsterdam, Netherlands) 20121001

• Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.

  Lung cancer (Amsterdam, Netherlands) 20121001

• A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.

  American journal of respiratory and critical care medicine 20121001

• The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.

  Cancer epidemiology 20121001

• Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.

  Molecular bioSystems 20121001

• Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors.

  Lung cancer (Amsterdam, Netherlands) 20121001

• Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

  Molecular cancer therapeutics 20121001

• Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.

  International journal of clinical pharmacology and therapeutics 20121001

• EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis.

  Cell proliferation 20121001

• The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.

  Pathology 20121001

• Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.

  Current medical research and opinion 20121001

• Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.

  The Tohoku journal of experimental medicine 20121001

• The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.

  Gan to kagaku ryoho. Cancer & chemotherapy 20121001

• [Two cases of long-term response treated by S-1 with concurrent radiotherapy followed by S-1 treatment for non-small cell lung cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20121001

• EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells.

  Translational oncology 20121001

• [EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120920

• Do companion diagnostics make economic sense for drug developers?

  New biotechnology 20120915

• High-expression EGFR/cell membrane chromatography-online-high-performance liquid chromatography/mass spectrometry: rapid screening of EGFR antagonists from Semen Strychni.

  Rapid communications in mass spectrometry : RCM 20120915

• Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.

  Medical oncology (Northwood, London, England) 20120901

• Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models.

  International journal of cancer 20120901

• Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.

  Critical reviews in oncology/hematology 20120901

• 'Combi-targeting' mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.

  The Prostate 20120901

• Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.

  Clinical lung cancer 20120901

• Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.

  Oral oncology 20120901

• T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.

  The Journal of investigative dermatology 20120901

• A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.

  Cellular signalling 20120901

• Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

  Lung cancer (Amsterdam, Netherlands) 20120901

• Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.

  International journal of oncology 20120901

• MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.

  International journal of oncology 20120901

• Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.

  The American journal of pathology 20120901

• Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120901

• Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20120901

• Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.

  European journal of medicinal chemistry 20120901

• Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

  Yonsei medical journal 20120901

• First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.

  Asia-Pacific journal of clinical oncology 20120901

• Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.

  Asia-Pacific journal of clinical oncology 20120901

• Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.

  Asia-Pacific journal of clinical oncology 20120901

• Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells.

  Experimental biology and medicine (Maywood, N.J.) 20120901

• Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

  Anticancer research 20120901

• [Timing the change of chemotherapy for non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

  Respiratory investigation 20120901

• Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma?

  Cancer research and treatment : official journal of Korean Cancer Association 20120901

• [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120820

• The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120815

• Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

  Cancer research 20120815

• EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth.

  Journal of proteome research 20120803

• A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

  Investigational new drugs 20120801

• A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.

  Investigational new drugs 20120801

• Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20120801

• Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.

  Head & neck 20120801

• EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.

  Cancer treatment reviews 20120801

• Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20120801

• Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

  Lung cancer (Amsterdam, Netherlands) 20120801

• Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120801

• Gutter method: noninvasive management of ingrown nails caused by epidermal growth factor inhibitor treatment.

  Clinical and experimental dermatology 20120801

• Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

  Biochemical pharmacology 20120801

• A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery.

  Journal of biomolecular screening 20120801

• Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?

  Lung cancer (Amsterdam, Netherlands) 20120801

• National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China.

  Lung cancer (Amsterdam, Netherlands) 20120801

• Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.

  Journal of pharmaceutical sciences 20120801

• Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120801

• Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.

  European journal of medicinal chemistry 20120801

• Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.

  Cancer chemotherapy and pharmacology 20120801

• Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.

  Expert opinion on therapeutic targets 20120801

• Bif-1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation.

  Cancer biology & therapy 20120801

• EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.

  Future oncology (London, England) 20120801

• [Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120801

• Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.

  Bioorganic & medicinal chemistry 20120715

• CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

  Cancer research 20120715

• Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.

  International journal of cancer 20120701

• Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.

  Journal of cellular and molecular medicine 20120701

• Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.

  Journal of cellular physiology 20120701

• A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies.

  Biomedical chromatography : BMC 20120701

• Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.

  Clinical lung cancer 20120701

• Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.

  Lung cancer (Amsterdam, Netherlands) 20120701

• Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

  Lung cancer (Amsterdam, Netherlands) 20120701

• Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.

  Lung cancer (Amsterdam, Netherlands) 20120701

• Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition.

  Veterinary journal (London, England : 1997) 20120701

• Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

  Journal of hepatology 20120701

• Influence of precursor solvent properties on matrix crystallinity and drug release rates from nanoparticle aerosol lipid matrices.

  International journal of pharmaceutics 20120701

• The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).

  Lung cancer (Amsterdam, Netherlands) 20120701

• Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.

  Lung cancer (Amsterdam, Netherlands) 20120701

• Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120701

• Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature.

  Medicine 20120701

• Novel liposomal gefitinib (L-GEF) formulations.

  Anticancer research 20120701

• Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

  Expert review of molecular diagnostics 20120701

• The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.

  Cancer letters 20120628

• Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.

  Biochemistry 20120626

• [Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120620

• [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120620

• Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.

  Drugs 20120619

• Comprehensive two-dimensional HepG2/cell membrane chromatography/monolithic column/time-of-flight mass spectrometry system for screening anti-tumor components from herbal medicines.

  Journal of chromatography. A 20120615

• Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.

  Bioorganic & medicinal chemistry 20120615

• Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20120601

• Colonic metastasis from primary lung adenocarcinoma: case report and review of the literature.

  Medical oncology (Northwood, London, England) 20120601

• PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20120601

• The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.

  Cancer chemotherapy and pharmacology 20120601

• Targeted therapy in head and neck cancer.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20120601

• Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.

  The Journal of pharmacology and experimental therapeutics 20120601

• Clinical highlights from the 2011 ERS Congress in Amsterdam.

  The European respiratory journal 20120601

• A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

  Breast cancer research and treatment 20120601

• Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

  Oncology reports 20120601

• Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

  Japanese journal of clinical oncology 20120601

• An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.

  Analytical and bioanalytical chemistry 20120601

• A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI).

  Cancer chemotherapy and pharmacology 20120601

• Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.

  Cancer investigation 20120601

• Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.

  The oncologist 20120601

• [Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].

  No shinkei geka. Neurological surgery 20120601

• [The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120601

• Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report.

  Journal of clinical medicine research 20120601

• Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation.

  Journal of thoracic disease 20120601

• Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.

  Current oncology (Toronto, Ont.) 20120601

• Supportive care treatments for toxicities of anti-egfr and other targeted agents.

  Current oncology (Toronto, Ont.) 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120520

• [Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120520

• Design, synthesis and antiproliferative activity of novel 2-substituted-4-amino-6-halogenquinolines.

  Molecules (Basel, Switzerland) 20120516

• Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.

  Cell 20120511

• Pathological complete response in younger and older breast cancer patients.

  Archives of medical science : AMS 20120509

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• Problems involved in the clinical trials for non-small cell lung carcinoma.

  Cancer treatment reviews 20120501

• Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.

  Breast cancer research and treatment 20120501

• Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

  Cancer 20120501

• Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds.

  Anti-cancer agents in medicinal chemistry 20120501

• Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120501

• Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.

  Lung cancer (Amsterdam, Netherlands) 20120501

• Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.

  Journal of cellular biochemistry 20120501

• A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

  Gut 20120501

• Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cells.

  Oncology reports 20120501

• Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptor-dependent pathway.

  The Journal of allergy and clinical immunology 20120501

• MicroRNA in cancer: new hopes for antineoplastic chemotherapy.

  Upsala journal of medical sciences 20120501

• Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis.

  Journal of the American Society of Nephrology : JASN 20120501

• Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.

  Molecular cancer therapeutics 20120501

• Of mice and men: a comparative study of cancer-associated fibroblasts in mammary carcinoma.

  Upsala journal of medical sciences 20120501

• FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.

  Acta pharmacologica Sinica 20120501

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  The Lancet. Oncology 20120501

• Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

  The Lancet. Oncology 20120501

• Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?

  The Lancet. Oncology 20120501

• Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.

  International journal of radiation oncology, biology, physics 20120501

• The risk for anemia with targeted therapies for solid tumors.

  The oncologist 20120501

• Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

  The oncologist 20120501

• Advances in treatment of lung cancer with targeted therapy.

  Archives of pathology & laboratory medicine 20120501

• [Long-term survival of patient with brain metastases from lung cancer treated by pemetrexed monotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• [Rapid multidisciplinary therapy for an advanced lung cancer patient with severe tracheal stenosis resulting in long-term survival].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• Occupy EGFR.

  Cancer discovery 20120501

• (E)-2-[2-(4-Chloro-benzyl-idene)hydrazin-1-yl]-4-{[3-(dimethyl-aza-nium-yl)prop-yl]amino}-quinazolin-1-ium bis-(perchlorate).

  Acta crystallographica. Section E, Structure reports online 20120501

• Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.

  Anticancer research 20120501

• Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis.

  Anticancer research 20120501

• Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.

  Pharmacogenomics 20120501

• Personalized targeted therapy in advanced non-small cell lung cancer.

  Cleveland Clinic journal of medicine 20120501

• [Diagnostic and therapeutic biomarkers for lung cancer patients].

  Nihon rinsho. Japanese journal of clinical medicine 20120501

• Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.

  PLoS genetics 20120501

• Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

  Clinics (Sao Paulo, Brazil) 20120501

• Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120501

• [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20120501

• [Mutation testing for non-small-cell lung cancer].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20120430

• Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

  Investigational new drugs 20120401

• Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.

  The pharmacogenomics journal 20120401

• Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1α via epidermal growth factor receptor-mediated signaling pathways.

  Journal of applied toxicology : JAT 20120401

• Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.

  International journal of clinical oncology 20120401

• Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response.

  Skeletal radiology 20120401

• Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

  Cancer chemotherapy and pharmacology 20120401

• Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.

  Acta oncologica (Stockholm, Sweden) 20120401

• A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20120401

• Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.

  Molecular biology reports 20120401

• The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

  Molecular therapy : the journal of the American Society of Gene Therapy 20120401

• Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.

  Biochemical pharmacology 20120401

• Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

  Molecular cancer therapeutics 20120401

• A 2,6-disubstituted 4-anilinoquinazoline derivative facilitates cardiomyogenesis of embryonic stem cells.

  ChemMedChem 20120401

• Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.

  Cancer biology & therapy 20120401

• SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.

  Molecular cancer therapeutics 20120401

• Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.

  ChemMedChem 20120401

• Recent advances in treatment of advanced urothelial carcinoma.

  Current urology reports 20120401

• First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120401

• Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation.

  Expert opinion on pharmacotherapy 20120401

• Erlotinib for whole-brain-radiotherapy-refractory leptomeningeal metastases after gefitinib failure in a lung adenocarcinoma patient.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401

• Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

  The oncologist 20120401

• Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.

  Expert opinion on therapeutic targets 20120401

• Targeting the Met pathway in lung cancer.

  Expert review of anticancer therapy 20120401

• EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.

  Current oncology (Toronto, Ont.) 20120401

• Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis.

  PLoS pathogens 20120401

• [Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].

  Zhongguo shi yan xue ye xue za zhi 20120401

• Recent advances in non-small cell lung cancer biology and clinical management.

  Discovery medicine 20120401

• Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel.

  Neoplasia (New York, N.Y.) 20120401

• Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.

  The Medical journal of Malaysia 20120401

• Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.

  Journal of medicinal chemistry 20120322

• [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120320

• NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

  Cancer cell 20120320

• Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells.

  Oncogene 20120315

• EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.

  British journal of cancer 20120313

• Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.

  British journal of cancer 20120313

• Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.

  Experimental cell research 20120310

• Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.

  Journal of medicinal chemistry 20120308

• Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20120305

• EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.

  The Journal of surgical research 20120301

• In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database.

  Journal of molecular modeling 20120301

• RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.

  The European respiratory journal 20120301

• Personalized medicine for lung cancer: new challenges for pathology.

  Histopathology 20120301

• Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.

  Clinical lung cancer 20120301

• Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

  Lung cancer (Amsterdam, Netherlands) 20120301

• EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.

  Oncology reports 20120301

• The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.

  Molecular cancer therapeutics 20120301

• Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer.

  Current cancer drug targets 20120301

• A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120301

• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

  The Lancet. Oncology 20120301

• Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.

  European journal of medicinal chemistry 20120301

• Clinical trials and biomarker research on lung cancer in China.

  Expert opinion on therapeutic targets 20120301

• Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.

  Asia-Pacific journal of clinical oncology 20120301

• Association of CTTN polymorphisms with the risk of colorectal cancer.

  Journal of the Korean Surgical Society 20120301

• Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.

  PLoS pathogens 20120301

• 2,4-Dichloro-7-fluoro-quinazoline.

  Acta crystallographica. Section E, Structure reports online 20120301

• Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

  Oncotarget 20120301

• Present status and problems on molecular targeted therapy of cancer.

  Cancer research and treatment : official journal of Korean Cancer Association 20120301

• Five cases report of solid tumor synchronously with hematologic malignancy.

  Cancer research and treatment : official journal of Korean Cancer Association 20120301

• [Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].

  Zhonghua yi xue za zhi 20120227

• [Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120220

• [Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120220

• Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.

  Cancer 20120215

• Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.

  Journal of proteomics 20120202

• [EGFR/HER1: a target life].

  Bulletin du cancer 20120201

• The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.

  Lung cancer (Amsterdam, Netherlands) 20120201

• Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.

  Cellular signalling 20120201

• Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.

  Cancer prevention research (Philadelphia, Pa.) 20120201

• A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.

  Breast cancer research and treatment 20120201

• Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

  Anti-cancer agents in medicinal chemistry 20120201

• Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer.

  Gut 20120201

• Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).

  European journal of cancer (Oxford, England : 1990) 20120201

• Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.

  Molecular & cellular proteomics : MCP 20120201

• Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition.

  Biochimica et biophysica acta 20120201

• Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells.

  Assay and drug development technologies 20120201

• Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.

  Chest 20120201

• [Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120201

• Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.

  Nagoya journal of medical science 20120201

• [Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20120201

• [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20120201

• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

  Nature 20120126

• Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

  Nature medicine 20120122

• [Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20120120

• Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment.

  Genes & nutrition 20120101

• The use of optical technology to monitor the antiangiogenic effects of gefitinib treatment for advanced head and neck squamous cell carcinoma: a brief report.

  Lasers in medical science 20120101

• Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20120101

• Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20120101

• Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

  The Lancet. Oncology 20120101

• The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.

  Clinical lung cancer 20120101

• Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101

• Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101

• Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.

  Cancer science 20120101

• EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.

  Cellular signalling 20120101

• Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101

• Automated synthesis of [18F]gefitinib on a modular system.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20120101

• Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.

  Cancer chemotherapy and pharmacology 20120101

• XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101

• Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120101

• New targeted therapies for anaplastic thyroid cancer.

  Anti-cancer agents in medicinal chemistry 20120101

• MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.

  Molecular cancer therapeutics 20120101

• EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101

• Angiogenesis in head and neck cancer: a review of the literature.

  Journal of oncology 20120101

• Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.

  European journal of medicinal chemistry 20120101

• A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy.

  Acta oncologica (Stockholm, Sweden) 20120101

• EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.

  Nature medicine 20120101

• Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101

• ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.

  Medicinal research reviews 20120101

• A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis.

  Yonsei medical journal 20120101

• The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes.

  Journal of oncology 20120101

• Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.

  PharmacoEconomics 20120101

• Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.

  Journal of Cancer 20120101

• A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.

  Anticancer research 20120101

• Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma.

  Diagnostic pathology 20120101

• Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.

  Therapeutic advances in medical oncology 20120101

• Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.

  Prostate cancer 20120101

• Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

  PloS one 20120101

• A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer.

  Radiation oncology (London, England) 20120101

• Role of chemotherapy on brain metastasis.

  Progress in neurological surgery 20120101

• A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells.

  Cell death & disease 20120101

• Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas.

  Journal of experimental & clinical cancer research : CR 20120101

• Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.

  World journal of surgical oncology 20120101

• Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.

  PloS one 20120101

• Up-regulation of Mcl-1 and Bak by coronavirus infection of human, avian and animal cells modulates apoptosis and viral replication.

  PloS one 20120101

• p63 expression defines a lethal subset of muscle-invasive bladder cancers.

  PloS one 20120101

• Ancillary testing in lung cancer diagnosis.

  Pulmonary medicine 20120101

• Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer.

  BMC cancer 20120101

• Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad.

  PloS one 20120101

• Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.

  Proteome science 20120101

• Identification of unique expression signatures and therapeutic targets in esophageal squamous cell carcinoma.

  BMC research notes 20120101

• Personalized therapy of lung cancer.

  Onkologie 20120101

• Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

  Oncotarget 20120101

• A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.

  Oncotarget 20120101

• Single sample expression-anchored mechanisms predict survival in head and neck cancer.

  PLoS computational biology 20120101

• The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling.

  PloS one 20120101

• Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.

  BMC cancer 20120101

• Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

  Frontiers in pharmacology 20120101

• Grape seed proanthocyanidins inhibit the invasiveness of human HNSCC cells by targeting EGFR and reversing the epithelial-to-mesenchymal transition.

  PloS one 20120101

• Immunohistochemical profile for unknown primary adenocarcinoma.

  PloS one 20120101

• Cytoplasmic p21 induced by p65 prevents doxorubicin-induced cell death in pancreatic carcinoma cell line.

  Journal of biomedical science 20120101

• Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.

  Onkologie 20120101

• Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.

  Onkologie 20120101

• Drug development in pediatric psychiatry: current status, future trends.

  Child and adolescent psychiatry and mental health 20120101

• Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance.

  PloS one 20120101

• STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.

  PloS one 20120101

• Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.

  Internal medicine (Tokyo, Japan) 20120101

• miRNAs versus oncogenes: the power of social networking.

  Molecular systems biology 20120101

• Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.

  BMC cancer 20120101

• Shortening of 3'UTRs correlates with poor prognosis in breast and lung cancer.

  PloS one 20120101

• ALK-activating homologous mutations in LTK induce cellular transformation.

  PloS one 20120101

• Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.

  ClinicoEconomics and outcomes research : CEOR 20120101

• Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma.

  PloS one 20120101

• Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

  PloS one 20120101

• Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells.

  PloS one 20120101

• Prescriptions of traditional Chinese medicine are specific to cancer types and adjustable to temperature changes.

  PloS one 20120101

• Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.

  PloS one 20120101

• Lung Cancer and Human Papilloma Viruses (HPVs): Examining the Molecular Evidence.

  Journal of oncology 20120101

• Novel protein kinase signaling systems regulating lifespan identified by small molecule library screening using Drosophila.

  PloS one 20120101

• Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.

  PloS one 20120101

• Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.

  PloS one 20120101

• A novel classification of lung cancer into molecular subtypes.

  PloS one 20120101

• Identifying regulational alterations in gene regulatory networks by state space representation of vector autoregressive models and variational annealing.

  BMC genomics 20120101

• Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies.

  PloS one 20120101

• EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.

  PloS one 20120101

• Therapy for metastatic melanoma: the past, present, and future.

  BMC medicine 20120101

• Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.

  Die Pharmazie 20120101

• The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.

  Journal of translational medicine 20120101

• The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.

  BMC cancer 20120101

• Translatability scoring in drug development: eight case studies.

  Journal of translational medicine 20120101

• Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours.

  Chemotherapy research and practice 20120101

• Kinase inhibitors in the treatment of immune-mediated disease.

  F1000 medicine reports 20120101

• Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma.

  BMC cancer 20120101

• Long-term treatment of metastatic colorectal cancer with panitumumab.

  Clinical Medicine Insights. Oncology 20120101

• The mTOR signalling pathway in human cancer.

  International journal of molecular sciences 20120101

• Pyrrolo[3,2-d]pyrimidine derivatives as type II kinase insert domain receptor (KDR) inhibitors: CoMFA and CoMSIA studies.

  International journal of molecular sciences 20120101

• Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.

  PloS one 20120101

• CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis.

  BMC veterinary research 20120101

• The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.

  TheScientificWorldJournal 20120101

• A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma.

  PloS one 20120101

• Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.

  BMC cancer 20120101

• Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

  BMC medicine 20120101

• Efficacy and tolerability of lapatinib in the management of breast cancer.

  Breast cancer : basic and clinical research 20120101

• Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.

  Journal of carcinogenesis 20120101

• Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.

  Internal medicine (Tokyo, Japan) 20120101

• Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats.

  The journal of medical investigation : JMI 20120101

• MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation through facilitating EGFR activation.

  PloS one 20120101

• Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis.

  PloS one 20120101

• Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway.

  PloS one 20120101

• Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.

  European journal of medical research 20120101

• EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma.

  Journal of biomedical science 20120101

• Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.

  Journal of oncology 20120101

• Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

  Journal of oncology 20120101

• Computational identification and modeling of crosstalk between phosphorylation, O-β-glycosylation and methylation of FoxO3 and implications for cancer therapeutics.

  International journal of molecular sciences 20120101

• Curcumin: updated molecular mechanisms and intervention targets in human lung cancer.

  International journal of molecular sciences 20120101

• Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

  PloS one 20120101

• MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

  PloS one 20120101

• Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

  PloS one 20120101

• Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.

  PloS one 20120101

• The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries.

  Journal of signal transduction 20120101

• Integrin signaling in mammary epithelial cells and breast cancer.

  ISRN oncology 20120101

• Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma.

  ISRN surgery 20120101

• Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer.

  Journal of biomedicine & biotechnology 20120101

• Novel therapies in glioblastoma.

  Neurology research international 20120101

• The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.

  Neurology research international 20120101

• Current trends in targeted therapies for glioblastoma multiforme.

  Neurology research international 20120101

• Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

  Journal of thyroid research 20120101

• Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

  Journal of oncology 20120101

• Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.

  TheScientificWorldJournal 20120101

• The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer.

  Clinical Medicine Insights. Oncology 20120101

• Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.

  Sarcoma 20120101

• Capability of tissue stem cells to organize into salivary rudiments.

  Stem cells international 20120101

• Major Functional Transcriptome of an Inferred Center Regulator of an ER(-) Breast Cancer Model System.

  Cancer informatics 20120101

• Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation.

  PloS one 20120101

• Integrin signaling in cancer cell survival and chemoresistance.

  Chemotherapy research and practice 20120101

• Inhibitory effects and underlying mechanism of 7-hydroxyflavone phosphate ester in HeLa cells.

  PloS one 20120101

• Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions.

  ISRN gastroenterology 20120101

• Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment.

  Clinical sarcoma research 20120101

• The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

  Clinical sarcoma research 20120101

• Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.

  PloS one 20120101

• Non-antioxidant properties of α-tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitro.

  PloS one 20120101

• Frequent gene amplification predicts poor prognosis in gastric cancer.

  International journal of molecular sciences 20120101

• A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer.

  PloS one 20120101

• Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial.

  BMC cancer 20120101

• Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression.

  PloS one 20120101

• Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

  International journal of nanomedicine 20120101

• Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.

  Journal of oncology 20120101

• Combination drug delivery approaches in metastatic breast cancer.

  Journal of drug delivery 20120101

• EGFR soluble isoforms and their transcripts are expressed in meningiomas.

  PloS one 20120101

• Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.

  PloS one 20120101

• Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence.

  Frontiers in oncology 20120101

• Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment.

  OncoTargets and therapy 20120101

• Epigenetics modifications and therapeutic prospects in human thyroid cancer.

  Frontiers in endocrinology 20120101

• The genomic landscape of prostate cancer.

  Frontiers in endocrinology 20120101

• Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer.

  Frontiers in oncology 20120101

• Professional exposure to goats increases the risk of pneumonic-type lung adenocarcinoma: results of the IFCT-0504-Epidemio study.

  PloS one 20120101

• Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations.

  Frontiers in oncology 20120101

• ALK Inhibitors, a Pharmaceutical Perspective.

  Frontiers in oncology 20120101

• A Screening Method for the ALK Fusion Gene in NSCLC.

  Frontiers in oncology 20120101

• Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.

  PloS one 20120101

• The molecular biology of soft-tissue sarcomas and current trends in therapy.

  Sarcoma 20120101

• Emerging targeted therapies for castration-resistant prostate cancer.

  Frontiers in endocrinology 20120101

• Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

  Chemotherapy research and practice 20120101

• Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.

  ISRN oncology 20120101

• A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.

  Frontiers in oncology 20120101

• Mechanistic insights into aging, cell-cycle progression, and stress response.

  Frontiers in physiology 20120101

• Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response.

  PloS one 20120101

• The current state of targeted agents in rectal cancer.

  International journal of surgical oncology 20120101

• Nucleic acids in human glioma treatment: innovative approaches and recent results.

  Journal of signal transduction 20120101

• Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.

  International journal of proteomics 20120101

• Design, synthesis and cytotoxicity of novel 2-arylvinyl-4-aminoquinoline derivatives.

  Chemical & pharmaceutical bulletin 20120101

• Targeted therapy in Ewing sarcoma.

  ISRN oncology 20120101

• [Will targeted therapies replace chemotherapy?].

  Revue medicale de Liege 20120101

• Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

  Anemia 20120101

• Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

  PloS one 20120101

• EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.

  PloS one 20120101

• Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer.

  Acta naturae 20120101

• HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• Metastatic gastric cancer - focus on targeted therapies.

  Biologics : targets & therapy 20120101

• Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

  PloS one 20120101

• Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.

  PloS one 20120101

• Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.

  PloS one 20120101

• CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib.

  Journal of cancer research and therapeutics 20120101

• [Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].

  Voprosy onkologii 20120101

• Analysis of chemotherapy and molecular therapy efficiency in advanced or metastatic non-small cell lung cancer.

  Medical archives (Sarajevo, Bosnia and Herzegovina) 20120101

• [EGFR mutations in patients with advanced NSCLC].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101

• Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.

  Dermatology (Basel, Switzerland) 20120101

• Synthesis and antitumor activity evaluation of new asiatic acid derivatives.

  Journal of Asian natural products research 20120101

• [Gefitinib in patients with advanced non-small-cell lung cancer].

  Pneumonologia i alergologia polska 20120101

• Miliary brain metastasis presenting with calcification in a patient with lung cancer: a case report.

  Journal of medical case reports 20120101

• An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs.

  PloS one 20120101

• EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia.

  Case reports in pulmonology 20120101

• Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.

  Current topics in medicinal chemistry 20120101

• Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer.

  Onkologie 20120101

• Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.

  PloS one 20120101

• An anilinoquinazoline derivative inhibits tumor growth through interaction with hCAP-G2, a subunit of condensin II.

  PloS one 20120101

• Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.

  PloS one 20120101

• The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.

  Internal medicine (Tokyo, Japan) 20120101

• A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.

  PloS one 20120101

• Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

  PloS one 20120101

• EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.

  PloS one 20120101

• Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.

  Nutrition and cancer 20120101

• EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111215

• A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.

  Circulation research 20111209

• Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

  Journal of medicinal chemistry 20111208

• PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.

  British journal of cancer 20111206

• Role of randomized phase III trials in an era of effective targeted therapies.

  Nature reviews. Clinical oncology 20111206

• Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer.

  Molecular pharmaceutics 20111205

• Role of genotyping in non-small cell lung cancer treatment: current status.

  Drugs 20111203

• Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

  Investigational new drugs 20111201

• The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.

  Cancer chemotherapy and pharmacology 20111201

• An early event of EGFR mutation in pleomorphic carcinoma of the lung.

  International journal of clinical oncology 20111201

• Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.

  Lung cancer (Amsterdam, Netherlands) 20111201

• Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.

  Annals of surgical oncology 20111201

• Ileal perforation induced by acute radiation injury under gefitinib treatment.

  International journal of clinical oncology 20111201

• Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.

  Journal of neuro-oncology 20111201

• Revisiting the role of molecular targeted therapies in patients with brain metastases.

  Journal of neuro-oncology 20111201

• Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20111201

• Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives.

  Chemical biology & drug design 20111201

• Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.

  Molecular & cellular proteomics : MCP 20111201

• The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.

  Lung 20111201

• Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

  Cancer research 20111201

• Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111201

• Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111201

• Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111201

• Pulmonary toxicities from targeted therapies: a review.

  Targeted oncology 20111201

• Mechanistic insights into the activation of oncogenic forms of EGF receptor.

  Nature structural & molecular biology 20111201

• A new medical therapy for Cushing disease?

  The Journal of clinical investigation 20111201

• EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

  The Journal of clinical investigation 20111201

• [Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20111201

• Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.

  Journal of Korean medical science 20111201

• Non-coding rRNA-mediated preferential killing in cancer cells is enhanced by suppression of autophagy in non-transformed counterpart.

  Cell death & disease 20111201

• PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.

  Oncotarget 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• The membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell components.

  PLoS pathogens 20111201

• Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.

  Anticancer research 20111201

• Reliability of direct sequencing of EGFR: comparison between cytological and histological samples from the same patient.

  Anticancer research 20111201

• Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.

  Anticancer research 20111201

• Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment.

  Cancer research and treatment : official journal of Korean Cancer Association 20111201

• Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).

  Oncotarget 20111201

• Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancer.

  Oncotarget 20111201

• NCI's provocative questions on cancer: some answers to ignite discussion.

  Oncotarget 20111201

• Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

  Cancer discovery 20111201

• New targeted therapies for thyroid cancer.

  Current genomics 20111201

• [Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20111120

• Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.

  Biochemical pharmacology 20111115

• Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.

  Biochemical pharmacology 20111115

• Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.

  World journal of clinical oncology 20111110

• Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

  British journal of cancer 20111108

• Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

  British journal of cancer 20111108

• An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.

  British journal of cancer 20111108

• MEMS microwell and microcolumn arrays: novel methods for high-throughput cell-based assays.

  Lab on a chip 20111107

• Advances in the biology of malignant pleural mesothelioma.

  Cancer treatment reviews 20111101

• Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.

  International journal of radiation oncology, biology, physics 20111101

• Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20111101

• Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.

  Chest 20111101

• Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

  Lung cancer (Amsterdam, Netherlands) 20111101

• Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.

  Clinical lung cancer 20111101

• Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.

  Journal of clinical pathology 20111101

• Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.

  Clinical lung cancer 20111101

• DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.

  Gastroenterology 20111101

• PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

  Molecular cancer therapeutics 20111101

• A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.

  Journal of pharmaceutical and biomedical analysis 20111101

• Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma.

  Oncology reports 20111101

• Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.

  Gynecologic oncology 20111101

• Signaling network state predicts twist-mediated effects on breast cell migration across diverse growth factor contexts.

  Molecular & cellular proteomics : MCP 20111101

• Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

• Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity.

  Cancer gene therapy 20111101

• Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.

  Molecular cancer therapeutics 20111101

• The critical role of the epidermal growth factor receptor in endochondral ossification.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20111101

• Gefitinib for non-small-cell lung cancer treatment.

  Expert opinion on drug safety 20111101

• Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.

  Lung cancer (Amsterdam, Netherlands) 20111101

• Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

• Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111101

• Modeling tumor invasion and metastasis in Drosophila.

  Disease models & mechanisms 20111101

• Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance.

  Social science & medicine (1982) 20111101

• Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

• The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer.

  The oncologist 20111101

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Pharmacokinetics of gefitinib and erlotinib.

  The Lancet. Oncology 20111101

• Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111101

• Non-small cell lung cancer in never smokers: a clinical entity to be identified.

  Clinics (Sao Paulo, Brazil) 20111101

• The nuclear epidermal growth factor receptor signaling network and its role in cancer.

  Discovery medicine 20111101

• Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

  Neoplasia (New York, N.Y.) 20111101

• Pulmonary toxicities of tyrosine kinase inhibitors.

  Clinical advances in hematology & oncology : H&O 20111101

• [Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT].

  Zhonghua yi xue za zhi 20111101

• Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib.

  Chinese medical journal 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.

  Journal of natural products 20111028

• [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20111020

• Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.

  British journal of cancer 20111011

• Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.

  Oncogene 20111006

• A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

  Investigational new drugs 20111001

• Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

  Investigational new drugs 20111001

• Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer.

  The pharmacogenomics journal 20111001

• How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111001

• Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20111001

• Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

  Cancer treatment reviews 20111001

• Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20111001

• A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.

  International journal of clinical oncology 20111001

• Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

  Lung cancer (Amsterdam, Netherlands) 20111001

• Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111001

• Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

  Cancer chemotherapy and pharmacology 20111001

• Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.

  Clinical & experimental metastasis 20111001

• Role of β4 integrin phosphorylation in human invasive squamous cell carcinoma: regulation of hemidesmosome stability modulates cell migration.

  Laboratory investigation; a journal of technical methods and pathology 20111001

• Treatment of high-grade glioma in children and adolescents.

  Neuro-oncology 20111001

• A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

  Breast cancer research and treatment 20111001

• A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).

  European journal of cancer (Oxford, England : 1990) 20111001

• Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.

  Oncology reports 20111001

• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111001

• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111001

• Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.

  European journal of medicinal chemistry 20111001

• 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111001

• A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111001

• Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells.

  Translational research : the journal of laboratory and clinical medicine 20111001

• EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.

  Chinese journal of cancer 20111001

• Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.

  International journal of clinical pharmacology and therapeutics 20111001

• Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.

  Korean journal of ophthalmology : KJO 20111001

• Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.

  PLoS computational biology 20111001

• Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

  Expert review of anticancer therapy 20111001

• Identification of potent EGFR inhibitors from TCM Database@Taiwan.

  PLoS computational biology 20111001

• Resistance to EGFR targeting therapies in lung cancer.

  Minerva chirurgica 20111001

• [Synthesis and anti-tumor activity of oleanolic acid derivatives].

  Yao xue xue bao = Acta pharmaceutica Sinica 20111001

• β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.

  Oncogene 20110929

• [Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110920

• Differential detection of KRAS mutations in codons 12 and 13 with a modified loop-hybrid (LH) mobility shift assay using an insert-type LH-generator.

  Clinica chimica acta; international journal of clinical chemistry 20110918

• Interstitial lung disease induced by gefitinib and toll-like receptor ligands is mediated by Fra-1.

  Oncogene 20110908

• Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.

  Molecular cell 20110902

• The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.

  Medical oncology (Northwood, London, England) 20110901

• The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

  Breast cancer research and treatment 20110901

• Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.

  Lung cancer (Amsterdam, Netherlands) 20110901

• Screening for EGFR mutations in lung cancer, a report from India.

  Lung cancer (Amsterdam, Netherlands) 20110901

• Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.

  The Journal of pathology 20110901

• Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders.

  Molecular pharmacology 20110901

• EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20110901

• Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

  Journal of cellular physiology 20110901

• HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

  Journal of cellular physiology 20110901

• Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.

  Lung cancer (Amsterdam, Netherlands) 20110901

• Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

  Cancer biology & therapy 20110901

• Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.

  Proteomics 20110901

• Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.

  Nature medicine 20110901

• Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.

  Diagnostic cytopathology 20110901

• Prediction of synergistic antitumour effect of gefitinib and radiation in vitro.

  Anticancer research 20110901

• Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.

  Anticancer research 20110901

• Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.

  Oncotarget 20110901

• A computational approach to finding novel targets for existing drugs.

  PLoS computational biology 20110901

• [KRAS and epidermal growth factor receptor gene mutation in non-small cell lung cancer].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20110901

• Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture.

  The EMBO journal 20110831

• Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.

  British journal of cancer 20110823

• Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820

• [Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib 
in Patients with Non-small Cell Lung Cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110820

• HGF-independent potentiation of EGFR action by c-Met.

  Oncogene 20110818

• Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.

  Journal of the Royal Society, Interface 20110807

• Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.

  Lung cancer (Amsterdam, Netherlands) 20110801

• The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.

  Lung cancer (Amsterdam, Netherlands) 20110801

• Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.

  Lung cancer (Amsterdam, Netherlands) 20110801

• Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.

  Lung cancer (Amsterdam, Netherlands) 20110801

• An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing.

  International journal of clinical oncology 20110801

• FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.

  Current drug targets 20110801

• VEGF inhibitor (Iressa) arrests histone deacetylase expression: single-cell cotransfection imaging cytometry for multi-target-multi-drug analysis.

  Journal of cellular physiology 20110801

• Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features.

  International journal of clinical oncology 20110801

• Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.

  Journal of cancer research and clinical oncology 20110801

• Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110801

• KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.

  Respirology (Carlton, Vic.) 20110801

• Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

• Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801

• Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

  Peptides 20110801

• Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.

  Japanese journal of clinical oncology 20110801

• Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.

  Bioorganic & medicinal chemistry 20110801

• A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801

• A phase II study of gefitinib in patients with metastatic melanoma.

  Melanoma research 20110801

• Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

  The Lancet. Oncology 20110801

• Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.

  The oncologist 20110801

• Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.

  Chinese medical journal 20110801

• Radish (Raphanus sativus L. leaf) ethanol extract inhibits protein and mRNA expression of ErbB(2) and ErbB(3) in MDA-MB-231 human breast cancer cells.

  Nutrition research and practice 20110801

• Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.

  British journal of cancer 20110726

• Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.

  Biochemical and biophysical research communications 20110722

• KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110720

• Molecular selection trumps clinical selection.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110720

• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110720

• DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.

  Cancer 20110715

• Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110715

• Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

  Science translational medicine 20110706

• Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110701

• Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20110701

• PI3Kinase signaling in glioblastoma.

  Journal of neuro-oncology 20110701

• New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.

  Lung cancer (Amsterdam, Netherlands) 20110701

• The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.

  Lung cancer (Amsterdam, Netherlands) 20110701

• Recurrent myocardial infarction associated with gefitinib therapy.

  Journal of thrombosis and thrombolysis 20110701

• Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy.

  Journal of cancer research and clinical oncology 20110701

• Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.

  Sociology of health & illness 20110701

• Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.

  British journal of pharmacology 20110701

• Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.

  Cancer letters 20110701

• High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.

  Cancer immunology, immunotherapy : CII 20110701

• Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.

  Lung cancer (Amsterdam, Netherlands) 20110701

• Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer.

  Breast cancer research and treatment 20110701

• Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

  Current opinion in oncology 20110701

• Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

  International journal of oncology 20110701

• Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.

  Clinical biochemistry 20110701

• EGFR signaling regulates tumor cell migration in craniopharyngiomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

• Design, synthesis of novel quinazolone alkaloids derivatives as potential antitumor agents.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20110701

• Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110701

• Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

• Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

  Yonsei medical journal 20110701

• An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data.

  Bioinformatics (Oxford, England) 20110701

• Personalized medicine: new genomics, old lessons.

  Human genetics 20110701

• Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.

  Pathology international 20110701

• Targeting cancer with peptide aptamers.

  Oncotarget 20110701

• Gefitinib versus docetaxel for previously treated NSCLC--letter.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

• Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.

  The Annals of thoracic surgery 20110701

• Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.

  International journal of clinical pharmacology and therapeutics 20110701

• Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.

  Clinical lung cancer 20110701

• Afatinib (BIBW 2992) development in non-small-cell lung cancer.

  Future oncology (London, England) 20110701

• Pancreatic endocrine tumors: a report on a patient treated with sorafenib.

  Journal of Korean medical science 20110701

• Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.

  Pharmacogenomics 20110701

• Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20110701

• 'Persisters': survival at the cellular level.

  PLoS pathogens 20110701

• [A case of alveolar hemorrhage caused by gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20110701

• Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110701

• [Expression of epidermal growth factor receptor and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin in rats].

  Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20110701

• PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma.

  British journal of cancer 20110628

• Use of epidermal growth factor receptor mutation analysis in patients with advanced non-small-cell lung cancer to determine erlotinib use as first-line therapy.

  PLoS currents 20110621

• [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110620

• Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

  Lancet (London, England) 20110618

• Erlotinib or gefitinib for non-small-cell lung cancer.

  The New England journal of medicine 20110616

• Erlotinib or gefitinib for non-small-cell lung cancer.

  The New England journal of medicine 20110616

• Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.

  Experimental cell research 20110610

• Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.

  Journal of proteomics 20110610

• Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.

  The Journal of biological chemistry 20110610

• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

  British journal of cancer 20110607

• Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.

  The Journal of biological chemistry 20110603

• BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20110601

• Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

  International journal of radiation oncology, biology, physics 20110601

• Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.

  Journal of neuro-oncology 20110601

• Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.

  Integrative cancer therapies 20110601

• Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors.

  British journal of clinical pharmacology 20110601

• Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.

  Cancer chemotherapy and pharmacology 20110601

• Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors.

  Clinical & experimental metastasis 20110601

• Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

  The AAPS journal 20110601

• A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110601

• Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110601

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20110601

• Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.

  International journal of oncology 20110601

• Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors.

  Cancer biology & therapy 20110601

• Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.

  Molecular cancer therapeutics 20110601

• Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20110601

• Adaptive informatics for multifactorial and high-content biological data.

  Nature methods 20110601

• Effectiveness of tyrosine kinase inhibitors on 'uncommon' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110601

• Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

  Clinical pharmacokinetics 20110601

• P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20110601

• Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110601

• The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma.

  Surgery today 20110601

• [Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].

  No shinkei geka. Neurological surgery 20110601

• Elevated PI3K signaling drives multiple breast cancer subtypes.

  Oncotarget 20110601

• Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

  Current medicinal chemistry 20110601

• p21-activated kinase 1: PAK'ed with potential.

  Oncotarget 20110601

• [Erlotinib in non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• [Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20110601

• Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.

  PLoS computational biology 20110601

• Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.

  Expert review of respiratory medicine 20110601

• Endoscopic cryotherapy of lung and bronchial tumors: a systematic review.

  The Korean journal of internal medicine 20110601

• [Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].

  Revue de pneumologie clinique 20110601

• [What choice of first-line treatment?].

  Revue de pneumologie clinique 20110601

• [What is the best sequence of treatment for patients with EGFR mutations?].

  Revue de pneumologie clinique 20110601

• [Management of patients with resistance to EGFR-TKI].

  Revue de pneumologie clinique 20110601

• [Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].

  Revue de pneumologie clinique 20110601

• [Sampling and search for the EGFR mutation: what's taking, when and how to test?].

  Revue de pneumologie clinique 20110601

• Epidermal growth factor receptor mutations in colorectal cancer patients.

  Journal of the Korean Society of Coloproctology 20110601

• [Association of serum EGFR protein concentration with the efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110601

• [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110601

• Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

  British journal of cancer 20110524

• Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110520

• Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.

  Clinica chimica acta; international journal of clinical chemistry 20110512

• Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.

  British journal of cancer 20110510

• Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.

  International journal of radiation oncology, biology, physics 20110501

• Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

  Lung cancer (Amsterdam, Netherlands) 20110501

• Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

  Lung cancer (Amsterdam, Netherlands) 20110501

• The transforming growth factor-beta (TGF-β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells.

  Journal of cellular physiology 20110501

• Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

  Acta oncologica (Stockholm, Sweden) 20110501

• Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck.

  Recent patents on anti-cancer drug discovery 20110501

• Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

  Cancer science 20110501

• Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

  European journal of clinical pharmacology 20110501

• Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.

  Cancer investigation 20110501

• Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.

  Oncology reports 20110501

• Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

  Expert opinion on drug metabolism & toxicology 20110501

• EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20110501

• Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?

  Medicine 20110501

• Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.

  Medicine 20110501

• Importance of molecular features of non-small cell lung cancer for choice of treatment.

  The American journal of pathology 20110501

• Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110501

• The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.

  Expert review of anticancer therapy 20110501

• [Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].

  Wiener klinische Wochenschrift 20110501

• EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.

  Inhalation toxicology 20110501

• Combined treatment with anticancer vaccine using genetically modified endothelial cells and imatinib in bladder cancer.

  Korean journal of urology 20110501

• [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110501

• Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.

  Therapeutic advances in medical oncology 20110501

• Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.

  International journal of clinical and experimental pathology 20110430

• [Gefitinib for non-small cell lung cancer: a meta analysis].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110420

• p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

  International journal of cancer 20110415

• Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.

  American journal of respiratory and critical care medicine 20110415

• Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• 'Un-slugging' resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.

  American journal of respiratory and critical care medicine 20110415

• The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.

  British journal of cancer 20110412

• Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.

  Biochemical and biophysical research communications 20110408

• A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20110401

• The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.

  Journal of cancer research and clinical oncology 20110401

• Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20110401

• Use of molecular markers for predicting therapy response in cancer patients.

  Cancer treatment reviews 20110401

• The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.

  Cellular signalling 20110401

• A high content screening assay for identifying lysosomotropic compounds.

  Toxicology in vitro : an international journal published in association with BIBRA 20110401

• Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

  Lung cancer (Amsterdam, Netherlands) 20110401

• Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.

  Breast cancer research and treatment 20110401

• KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.

  Oncology reports 20110401

• MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).

  Neuro-oncology 20110401

• Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110401

• Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20110401

• [Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].

  Presse medicale (Paris, France : 1983) 20110401

• Transforming growth factor-α attenuates hepatic fibrosis: possible involvement of matrix metalloproteinase-1.

  Liver international : official journal of the International Association for the Study of the Liver 20110401

• [Adverse effects of new biological therapies for non-small-cell bronchial cancer].

  Presse medicale (Paris, France : 1983) 20110401

• [Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].

  Presse medicale (Paris, France : 1983) 20110401

• Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

  Translational oncology 20110401

• Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.

  Oncotarget 20110401

• [A simple view on lung cancer biology: The EGFR pathway].

  Revue des maladies respiratoires 20110401

• ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.

  PLoS genetics 20110401

• [A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20110401

• Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

  North American journal of medical sciences 20110401

• Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

  Science translational medicine 20110323

• EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium.

  American journal of respiratory and critical care medicine 20110315

• Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20110315

• A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

• Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

  The New England journal of medicine 20110310

• Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

  World journal of clinical oncology 20110310

• NSCLC drug targets acquire new visibility.

  Journal of the National Cancer Institute 20110302

• Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.

  Medical oncology (Northwood, London, England) 20110301

• Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.

  Medical oncology (Northwood, London, England) 20110301

• In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

  Cancer chemotherapy and pharmacology 20110301

• Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.

  Lung cancer (Amsterdam, Netherlands) 20110301

• Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck.

  European journal of cancer (Oxford, England : 1990) 20110301

• A novel hybrid peptide targeting EGFR-expressing cancers.

  European journal of cancer (Oxford, England : 1990) 20110301

• Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110301

• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110301

• The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.

  Cancer science 20110301

• Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

  Lung cancer (Amsterdam, Netherlands) 20110301

• Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110301

• Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110301

• Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.

  Molecular cancer therapeutics 20110301

• Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110301

• Establishment of A431 cell membrane chromatography-RPLC method for screening target components from Radix Caulophylli.

  Journal of separation science 20110301

• MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1.

  Molecular cancer research : MCR 20110301

• Is FISH floating or still swimming in the lung cancer ocean?

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.

  Neuro-oncology 20110301

• Targeted therapies for metastatic esophagogastric cancer.

  Current treatment options in oncology 20110301

• Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.

  British journal of cancer 20110301

• Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.

  Cell cycle (Georgetown, Tex.) 20110301

• BIBW 2992 in non-small cell lung cancer.

  Expert opinion on investigational drugs 20110301

• A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative.

  The oncologist 20110301

• Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives.

  European respiratory review : an official journal of the European Respiratory Society 20110301

• [Survival-related clinical factors of patients with advanced non-small cell lung cancer after 2000].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• Development of targeted therapy for squamous cell carcinomas of the head and neck.

  Expert review of anticancer therapy 20110301

• Personalizing therapy with targeted agents in non-small cell lung cancer.

  Oncotarget 20110301

• CAERUS: predicting CAncER oUtcomeS using relationship between protein structural information, protein networks, gene expression data, and mutation data.

  PLoS computational biology 20110301

• Depressogenic effects of medications: a review.

  Dialogues in clinical neuroscience 20110301

• Novel strategies of protecting non-cancer cells during chemotherapy: are they ready for clinical testing?

  Oncotarget 20110301

• Lack of direct association between EGFR mutations and ER beta expression in lung cancer.

  Anticancer research 20110301

• Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.

  Anticancer research 20110301

• Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer.

  Cancer research and treatment : official journal of Korean Cancer Association 20110301

• Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer.

  Chinese medical journal 20110301

• First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.

  Clinical lung cancer 20110301

• Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.

  Clinical lung cancer 20110301

• Control of advanced cancer: the road to chronicity.

  International journal of environmental research and public health 20110301

• [Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110301

• Colorectal cancer.

  The West Indian medical journal 20110301

• The effect of combining interferon-alpha and gefitinib in human colon cancer cell lines.

  The West Indian medical journal 20110301

• T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

  Journal of thoracic disease 20110301

• [Gefitinib-induced acute lung injury: a case report and review of the literature].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110220

• Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.

  Cancer 20110215

• ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer.

  British journal of cancer 20110215

• PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

  British journal of cancer 20110215

• Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.

  Biochemical and biophysical research communications 20110211

• Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20110201

• Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.

  American journal of clinical dermatology 20110201

• Characteristics of triple-negative breast cancer.

  Journal of cancer research and clinical oncology 20110201

• Calcium-induced apoptosis is delayed by HER1 receptor signalling through the Akt and PLCγ pathways in bladder cancer cells.

  Scandinavian journal of clinical and laboratory investigation 20110201

• Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.

  Cancer research 20110201

• Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

  Advances in therapy 20110201

• A systems view of epithelial-mesenchymal transition signaling states.

  Clinical & experimental metastasis 20110201

• Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110201

• A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

  British journal of cancer 20110201

• The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110201

• Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.

  Surgery today 20110201

• Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.

  Cancer research 20110201

• Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?

  Journal of Korean medical science 20110201

• Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

  Molecular cancer therapeutics 20110201

• Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

  Pharmacogenomics 20110201

• [Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110201

• [A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110201

• The need for third-line treatment in non-small cell lung cancer: an overview of new options.

  Anticancer research 20110201

• A robust approach to enhance tumor-selective accumulation of nanoparticles.

  Oncotarget 20110201

• Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis.

  Molecular diagnosis & therapy 20110201

• AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

  Cancer cell 20110118

• Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo.

  Chemico-biological interactions 20110115

• Targeting IGF-1R: throwing out the baby with the bathwater?

  British journal of cancer 20110104

• Ganoderma lucidum Polysaccharides Induce Macrophage-Like Differentiation in Human Leukemia THP-1 Cells via Caspase and p53 Activation.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

  Lung cancer (Amsterdam, Netherlands) 20110101

• Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.

  Lung cancer (Amsterdam, Netherlands) 20110101

• Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

  Journal of cellular physiology 20110101

• Targeted therapy: an evolving world of lung cancer.

  Respirology (Carlton, Vic.) 20110101

• Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

  Cancer 20110101

• Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.

  The British journal of dermatology 20110101

• Factors driving the choice of the best second-line treatment of advanced NSCLC.

  Reviews on recent clinical trials 20110101

• Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

  Clinical rheumatology 20110101

• Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.

  The European respiratory journal 20110101

• Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.

  Current opinion in oncology 20110101

• DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.

  Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 20110101

• Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.

  Cancer biology & therapy 20110101

• Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa).

  Antiviral research 20110101

• HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.

  Molecular endocrinology (Baltimore, Md.) 20110101

• Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.

  International journal of oncology 20110101

• Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.

  Drugs 20110101

• Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• Best of the month: A round up of articles published in recent months.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.

  Pathology research international 20110101

• Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

  BMC cancer 20110101

• Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.

  Frontiers in bioscience (Landmark edition) 20110101

• Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.

  Frontiers in bioscience (Landmark edition) 20110101

• EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives.

  Frontiers in bioscience (Landmark edition) 20110101

• EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

  Frontiers in bioscience (Landmark edition) 20110101

• Targeting EGFR in bilio-pancreatic and liver carcinoma.

  Frontiers in bioscience (Scholar edition) 20110101

• Advances in EGFR-directed therapy in head and neck cancer.

  Frontiers in bioscience (Scholar edition) 20110101

• EGFR pathway in advanced non-small cell lung cancer.

  Frontiers in bioscience (Scholar edition) 20110101

• Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis.

  Journal of oncology 20110101

• A network-based biomarker approach for molecular investigation and diagnosis of lung cancer.

  BMC medical genomics 20110101

• Deciphering squamous cell carcinoma using multidimensional genomic approaches.

  Journal of skin cancer 20110101

• Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells.

  Journal of Cancer 20110101

• Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma.

  Journal of Cancer 20110101

• Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center.

  Journal of experimental & clinical cancer research : CR 20110101

• Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.

  Neoplasia (New York, N.Y.) 20110101

• Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

  Sarcoma 20110101

• Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.

  Journal of hematology & oncology 20110101

• Chemosensitization of tumors by resveratrol.

  Annals of the New York Academy of Sciences 20110101

• Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

  BMC cancer 20110101

• Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.

  Clinical lung cancer 20110101

• Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer.

  Clinical lung cancer 20110101

• Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations.

  Pathology research international 20110101

• Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay.

  PloS one 20110101

• Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.

  PloS one 20110101

• Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.

  Molecular cancer 20110101

• Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway.

  Journal of experimental & clinical cancer research : CR 20110101

• Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

  BMC cancer 20110101

• Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.

  PloS one 20110101

• Immunotherapy for lung cancers.

  Journal of biomedicine & biotechnology 20110101

• dPORE-miRNA: polymorphic regulation of microRNA genes.

  PloS one 20110101

• Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.

  BMC systems biology 20110101

• Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.

  Dermatology (Basel, Switzerland) 20110101

• Orbital metastases as the first manifestation of lung adenocarcinoma.

  Case reports in ophthalmology 20110101

• Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.

  Breast cancer research : BCR 20110101

• The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

  Head & neck oncology 20110101

• Analysis of multiple compound-protein interactions reveals novel bioactive molecules.

  Molecular systems biology 20110101

• Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study.

  PloS one 20110101

• Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.

  BMC cancer 20110101

• Functional characterization of human cancer-derived TRKB mutations.

  PloS one 20110101

• Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.

  BMC cancer 20110101

• EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.

  Journal of experimental & clinical cancer research : CR 20110101

• EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis.

  Molecular cancer 20110101

• Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.

  Breast cancer research : BCR 20110101

• Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

  Breast cancer research : BCR 20110101

• Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.

  Breast cancer research : BCR 20110101

• EGFR Signaling in Colorectal Carcinoma.

  Pathology research international 20110101

• Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.

  PloS one 20110101

• Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.

  PloS one 20110101

• Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.

  PloS one 20110101

• Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.

  Journal of experimental & clinical cancer research : CR 20110101

• Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis.

  Molecular cancer 20110101

• Impact of KRAS Mutations on Management of Colorectal Carcinoma.

  Pathology research international 20110101

• Focal leptomeningeal metastasis following curative surgery for lung cancer: case report.

  Neurologia medico-chirurgica 20110101

• Finding complex biological relationships in recent PubMed articles using Bio-LDA.

  PloS one 20110101

• Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

  Breast cancer research : BCR 20110101

• HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.

  PloS one 20110101

• Advanced computational biology methods identify molecular switches for malignancy in an EGF mouse model of liver cancer.

  PloS one 20110101

• Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.

  Internal medicine (Tokyo, Japan) 20110101

• Gefitinib induces mitochondrial-dependent apoptosis in Saccharomyces cerevisiae.

  Molecular medicine reports 20110101

• Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.

  PloS one 20110101

• Chemotherapy and radiotherapy for mesothelioma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Spotlight on differentially expressed genes in urinary bladder cancer.

  PloS one 20110101

• Epidermal growth factor receptor targeted therapies for solid tumours.

  Acta clinica Belgica 20110101

• Blue-black discoloration of the nails associated with gefitinib.

  Acta clinica Belgica 20110101

• A theoretical entropy score as a single value to express inhibitor selectivity.

  BMC bioinformatics 20110101

• Current status of methods to assess cancer drug resistance.

  International journal of medical sciences 20110101

• Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

  Breast cancer research : BCR 20110101

• Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.

  Breast cancer research : BCR 20110101

• Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.

  Clinical Medicine Insights. Oncology 20110101

• Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).

  BMC cancer 20110101

• Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.

  Current topics in medicinal chemistry 20110101

• Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

  Sarcoma 20110101

• Multiple myeloma emerging after prolonged gefitinib treatment for non-small cell lung carcinoma.

  Case reports in oncology 20110101

• Network modeling of the transcriptional effects of copy number aberrations in glioblastoma.

  Molecular systems biology 20110101

• Acute respiratory distress due to thymoma in a patient treated with TK inhibitor: a case report and review of the current treatment options.

  Case reports in oncology 20110101

• Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer.

  International journal of molecular sciences 20110101

• MicroRNA gene dosage alterations and drug response in lung cancer.

  Journal of biomedicine & biotechnology 20110101

• Target therapies in lung cancer.

  Journal of biomedicine & biotechnology 20110101

• Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.

  Journal of biomedicine & biotechnology 20110101

• Maintenance therapy in NSCLC: why? To whom? Which agent?

  Journal of experimental & clinical cancer research : CR 20110101

• Network meta-analysis of survival data with fractional polynomials.

  BMC medical research methodology 20110101

• Novel therapeutic strategies for targeting liver cancer stem cells.

  International journal of biological sciences 20110101

• The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

  PloS one 20110101

• Critical appraisal of trastuzumab in treatment of advanced stomach cancer.

  Cancer management and research 20110101

• NNK-Induced Lung Tumors: A Review of Animal Model.

  Journal of oncology 20110101

• Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.

  PloS one 20110101

• Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

  Journal of translational medicine 20110101

• Benchmarking of mutation diagnostics in clinical lung cancer specimens.

  PloS one 20110101

• A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells.

  PloS one 20110101

• Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis.

  Radiation oncology (London, England) 20110101

• Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.

  Journal of experimental & clinical cancer research : CR 20110101

• Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.

  Journal of translational medicine 20110101

• Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.

  BMC cancer 20110101

• Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer.

  Journal of circadian rhythms 20110101

• Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients.

  Journal of translational medicine 20110101

• The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer.

  BMC cancer 20110101

• Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer.

  Onkologie 20110101

• Interpreting clinical assays for histone deacetylase inhibitors.

  Cancer management and research 20110101

• [Indication of EGFR kinase inhibitors should be refined].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101

• Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.

  PloS one 20110101

• EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.

  PloS one 20110101

• Gefitinib in non small cell lung cancer.

  Journal of biomedicine & biotechnology 20110101

• Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

  PloS one 20110101

• Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

  Breast cancer research : BCR 20110101

• Notch signaling as a therapeutic target for breast cancer treatment?

  Breast cancer research : BCR 20110101

• Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.

  Journal of biomedicine & biotechnology 20110101

• Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization.

  Molecular cytogenetics 20110101

• Thrombotic thrombocytopenic purpura and gemcitabine.

  Case reports in oncology 20110101

• Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC.

  OncoTargets and therapy 20110101

• Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer.

  Clinical Medicine Insights. Oncology 20110101

• GENT: gene expression database of normal and tumor tissues.

  Cancer informatics 20110101

• Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer.

  Clinical Medicine Insights. Oncology 20110101

• Prognostic association of YB-1 expression in breast cancers: a matter of antibody.

  PloS one 20110101

• Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis.

  BMC genomics 20110101

• Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines.

  PloS one 20110101

• Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.

  Diagnostic pathology 20110101

• Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics.

  Proteome science 20110101

• Promising molecular targeted therapies in breast cancer.

  Indian journal of pharmacology 20110101

• Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.

  Molecular cancer 20110101

• Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validation.

  Current medicinal chemistry 20110101

• Targeting insulin-like growth factor axis in hepatocellular carcinoma.

  Journal of hematology & oncology 20110101

• MicroRNA expression and clinical outcome of small cell lung cancer.

  PloS one 20110101

• Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.

  PloS one 20110101

• Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

  Cancer management and research 20110101

• Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene.

  Case reports in dermatology 20110101

• Hepatic actinomycosis mimicking an isolated tumor recurrence.

  World journal of surgical oncology 20110101

• EGF and TGF-β1 Effects on Thyroid Function.

  Journal of thyroid research 20110101

• How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.

  Journal of thyroid research 20110101

• Hypoxia-inducible factor in thyroid carcinoma.

  Journal of thyroid research 20110101

• Tracheoesophageal fistula closed by chemoradiotherapy in lung cancer.

  Case reports in oncology 20110101

• The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.

  Journal of oncology 20110101

• Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.

  Journal of oncology 20110101

• From smoking to cancers: novel targets to neuronal nicotinic acetylcholine receptors.

  Journal of oncology 20110101

• Outcomes of recurrent head and neck cutaneous squamous cell carcinoma.

  Journal of skin cancer 20110101

• The Gap between Tobacco Treatment Guidelines, Health Service Organization, and Clinical Practice in Comprehensive Cancer Centres.

  Journal of oncology 20110101

• Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma.

  Pathology research international 20110101

• Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.

  Journal of signal transduction 20110101

• Combination therapy: the next opportunity and challenge of medicine.

  Journal of translational medicine 20110101

• From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.

  Pathology research international 20110101

• Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.

  Journal of translational medicine 20110101

• AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

  PloS one 20110101

• Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.

  BMC cancer 20110101

• Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.

  Respiratory research 20110101

• Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.

  PloS one 20110101

• Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.

  Annals of Saudi medicine 20110101

• Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management.

  Pathology research international 20110101

• Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.

  BMC cancer 20110101

• Epidermal growth factor receptor expression in urinary bladder cancer.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• Targeted drug therapies and cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Targeting ErbB receptors in high-grade glioma.

  Current pharmaceutical design 20110101

• A systems biology-based classifier for hepatocellular carcinoma diagnosis.

  PloS one 20110101

• Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.

  PloS one 20110101

• Simulating EGFR-ERK signaling control by scaffold proteins KSR and MP1 reveals differential ligand-sensitivity co-regulated by Cbl-CIN85 and endophilin.

  PloS one 20110101

• Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma.

  Journal of experimental & clinical cancer research : CR 20110101

• Government use licenses in Thailand: an assessment of the health and economic impacts.

  Globalization and health 20110101

• Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.

  Journal of Cancer 20110101

• EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization.

  PloS one 20110101

• LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis.

  Molecular cancer 20110101

• Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.

  PloS one 20110101

• Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51.

  PloS one 20110101

• Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma.

  PloS one 20110101

• Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

  PloS one 20110101

• Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor.

  PloS one 20110101

• Management options in triple-negative breast cancer.

  Breast cancer : basic and clinical research 20110101

• Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.

  BMC cancer 20110101

• A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.

  BMC cancer 20110101

• Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis.

  Obstetrics and gynecology international 20110101

• RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers.

  Journal of clinical bioinformatics 20110101

• Androgen receptor signaling in prostate cancer development and progression.

  Journal of carcinogenesis 20110101

• Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-x(L) inhibition.

  PloS one 20110101

• Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics.

  Drug metabolism and pharmacokinetics 20110101

• Cell-specific aptamers as emerging therapeutics.

  Journal of nucleic acids 20110101

• Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251.

  Journal of experimental & clinical cancer research : CR 20110101

• Chemotherapy in advanced bladder cancer: current status and future.

  Journal of hematology & oncology 20110101

• The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

  Clinical proteomics 20110101

• A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.

  PloS one 20110101

• Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?

  Cancer management and research 20110101

• High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

  PloS one 20110101

• Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.

  PloS one 20110101

• The effect on survival of continuing chemotherapy to near death.

  BMC palliative care 20110101

• erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.

  Breast cancer research : BCR 20110101

• Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer.

  Molecular cancer 20110101

• Bioactive properties and clinical safety of a novel milk protein peptide.

  Nutrition journal 20110101

• Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.

  BMC cancer 20110101

• Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.

  OncoTargets and therapy 20110101

• Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.

  PloS one 20110101

• Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses.

  Proteome science 20110101

• Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma.

  Journal of translational medicine 20110101

• The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

  BMC cancer 20110101

• Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.

  BMC cancer 20110101

• Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.

  Molecular cancer 20110101

• Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.

  PloS one 20110101

• EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma.

  Journal of translational medicine 20110101

• Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.

  BMC cancer 20110101

• Up-regulation of kin17 is essential for proliferation of breast cancer.

  PloS one 20110101

• VEGFR2 translocates to the nucleus to regulate its own transcription.

  PloS one 20110101

• INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.

  BMC cancer 20110101

• Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.

  Arthritis research & therapy 20110101

• Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

  BMC health services research 20110101

• Mucoepidermoid carcinoma of the lung: a case report.

  Journal of cardiothoracic surgery 20110101

• Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?

  Onkologie 20110101

• Targeted therapy in hepatocellular carcinoma.

  International journal of hepatology 20110101

• Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.

  Frontiers in pharmacology 20110101

• Comparison of ROCK and EGFR activation pathways in the progression of glomerular injuries in AngII-infused rats.

  Renal failure 20110101

• N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.

  American journal of cancer research 20110101

• Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.

  PloS one 20110101

• Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells.

  PloS one 20110101

• Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.

  Journal of immune based therapies and vaccines 20110101

• The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.

  BMC medical genetics 20110101

• Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells.

  Clinical laboratory 20110101

• SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.

  BMC cancer 20110101

• Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.

  Advances in medical sciences 20110101

• Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

  Journal of the National Cancer Institute. Monographs 20110101

• Network based consensus gene signatures for biomarker discovery in breast cancer.

  PloS one 20110101

• Altered expression of insulin receptor isoforms in breast cancer.

  PloS one 20110101

• Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

  PloS one 20110101

• Identification of microRNAs as potential prognostic markers in ependymoma.

  PloS one 20110101

• DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance.

  PloS one 20110101

• Metastasis from endometrial carcinoma to bilateral breasts presenting as inflammatory breast lesions.

  European journal of gynaecological oncology 20110101

• Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.

  Journal of translational medicine 20110101

• Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays.

  International journal of nanomedicine 20110101

• Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

  International journal of molecular sciences 20110101

• ALK and NSCLC: Targeted therapy with ALK inhibitors.

  F1000 medicine reports 20110101

• Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr.

  Radiation oncology (London, England) 20110101

• A rare bladder cancer--small cell carcinoma: review and update.

  Orphanet journal of rare diseases 20110101

• Scutellarin attenuates human-neutrophil-elastase-induced mucus production by inhibiting the PKC-ERK signaling pathway in vitro and in vivo.

  The American journal of Chinese medicine 20110101

• Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.

  Clinical Medicine Insights. Oncology 20110101

• 'Il corpo ritrovato': dermocosmetological skin care project for the oncologic patient.

  ISRN oncology 20110101

• Near Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the Literature.

  Case reports in oncology 20110101

• EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells.

  PloS one 20110101

• Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro.

  Cancer cell international 20110101

• Signatures of drug sensitivity in nonsmall cell lung cancer.

  International journal of proteomics 20110101

• Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.

  ISRN oncology 20110101

• Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer.

  ISRN oncology 20110101

• Innovative Therapies against Human Glioblastoma Multiforme.

  ISRN oncology 20110101

• Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy.

  PloS one 20110101

• Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis.

  PloS one 20110101

• Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies.

  PloS one 20110101

• Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.

  PloS one 20110101

• Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report.

  Journal of medical case reports 20110101

• Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.

  Molecular cancer 20110101

• Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease.

  Case reports in oncology 20110101

• Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?

  Case reports in oncology 20110101

• Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.

  The Journal of international medical research 20110101

• Receptor tyrosine kinases and targeted cancer therapeutics.

  Biological & pharmaceutical bulletin 20110101

• Activation of epidermal growth factor receptor is required for NTHi-induced NF-κB-dependent inflammation.

  PloS one 20110101

• Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.

  Diagnostic pathology 20110101

• Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy.

  Pulmonary circulation 20110101

• A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients.

  Journal of experimental & clinical cancer research : CR 20110101

• Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.

  Journal of translational medicine 20110101

• Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

  Drug design, development and therapy 20110101

• Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells.

  PloS one 20110101

• Aberrant signaling pathways in squamous cell lung carcinoma.

  Cancer informatics 20110101

• Arsenic exposure and the induction of human cancers.

  Journal of toxicology 20110101

• Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.

  PloS one 20110101

• A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.

  Breast cancer research : BCR 20110101

• Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

  Genome biology 20110101

• Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab.

  Molecular cancer 20110101

• Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.

  Internal medicine (Tokyo, Japan) 20110101

• Treatment with gefitinib after erlotinib-induced liver injury: a case report.

  Journal of medical case reports 20110101

• Radiotherapy and 'new' drugs-new side effects?

  Radiation oncology (London, England) 20110101

• Grape seed proanthocyanidins inhibit the invasive potential of head and neck cutaneous squamous cell carcinoma cells by targeting EGFR expression and epithelial-to-mesenchymal transition.

  BMC complementary and alternative medicine 20110101

• The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases.

  Pulmonary medicine 20110101

• Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.

  Breast cancer research : BCR 20110101

• Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers.

  PloS one 20110101

• Genomic sequencing in clinical trials.

  Journal of translational medicine 20110101

• Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.

  Journal of experimental & clinical cancer research : CR 20110101

• Folic acid supplementary reduce the incidence of adenocarcinoma in a mouse model of colorectal cancer: microarray gene expression profile.

  Journal of experimental & clinical cancer research : CR 20110101

• Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells.

  PloS one 20110101

• KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

  PloS one 20110101

• Targeted therapies development in the treatment of advanced nonsmall cell lung cancer.

  Journal of biomedicine & biotechnology 20110101

• Napsin a and thyroid transcription factor-1-positive cerebellar tumor with epidermal growth factor receptor mutation.

  Case reports in oncology 20110101

• Lung cancer proteomics: recent advances in biomarker discovery.

  International journal of proteomics 20110101

• New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.

  Therapeutics and clinical risk management 20110101

• Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer.

  OncoTargets and therapy 20110101

• Novel immunotherapeutic strategies of gastric cancer treatment.

  Journal of biomedicine & biotechnology 20110101

• Biochip-based detection of KRAS mutation in non-small cell lung cancer.

  International journal of molecular sciences 20110101

• New drug therapies, dedicated specialists and desperately-ill patients-but who will fly the flag for service developments in lung cancer as NHS budgets come under pressure?

  Ecancermedicalscience 20110101

• The state of research into children with cancer across Europe: new policies for a new decade.

  Ecancermedicalscience 20110101

• Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe: can we get a consensus?

  Ecancermedicalscience 20110101

• Neoadjuvant treatment in rectal cancer: actual status.

  Chemotherapy research and practice 20110101

• New agents targeting angiogenesis in glioblastoma.

  Chemotherapy research and practice 20110101

• A role for estrogen receptor phosphorylation in the resistance to tamoxifen.

  International journal of breast cancer 20110101

• Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer.

  International journal of breast cancer 20110101

• MicroRNAs - Important Molecules in Lung Cancer Research.

  Frontiers in genetics 20110101

• Functionally Relevant Residues of Cdr1p: A Multidrug ABC Transporter of Human Pathogenic Candida albicans.

  Journal of amino acids 20110101

• Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.

  International journal of surgical oncology 20110101

• Subacute transient encephalopathy induced by erlotinib.

  Oncology research 20110101

• Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs.

  Scientific reports 20110101

• A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data.

  BMC genomics 20110101

• Personalized therapy for non-small cell lung cancer: which drug for which patient?

  Seminars in thoracic and cardiovascular surgery 20110101

• Non-small cell lung cancer: the challenges of the next decade.

  Frontiers in oncology 20110101

• Past, present, and future of molecular and cellular oncology.

  Frontiers in oncology 20110101

• Therapeutic targeting of cancer stem cells.

  Frontiers in oncology 20110101

• Adjuvant chemotherapy for early stage non-small cell lung cancer.

  Frontiers in oncology 20110101

• Investigational approaches for mesothelioma.

  Frontiers in oncology 20110101

• Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.

  BMJ case reports 20110101

• The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells.

  Oncology research 20110101

• Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib.

  Case reports in pulmonology 20110101

• The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.

  The Journal of biological chemistry 20101217

• Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

  Journal of cellular biochemistry 20101215

• Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

  Cancer research 20101215

• IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.

  The Journal of biological chemistry 20101210

• Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.

  British journal of cancer 20101207

• Cancer and renal insufficiency results of the BIRMA study.

  British journal of cancer 20101207

• Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.

  Oncogene 20101202

• Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.

  Investigational new drugs 20101201

• Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.

  International journal of andrology 20101201

• Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.

  American journal of clinical oncology 20101201

• Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20101201

• Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).

  Lung cancer (Amsterdam, Netherlands) 20101201

• Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.

  Journal of neuro-oncology 20101201

• Biomarkers in lung oncology.

  Pulmonary pharmacology & therapeutics 20101201

• [Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].

  Pneumologie (Stuttgart, Germany) 20101201

• Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

  European radiology 20101201

• Advances in chemotherapy in advanced non-small-cell lung cancer.

  Expert opinion on pharmacotherapy 20101201

• Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.

  Surgical oncology 20101201

• A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.

  European journal of cancer (Oxford, England : 1990) 20101201

• Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.

  Toxicology and applied pharmacology 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101201

• Parameters for individualizing systemic therapy in non-small cell lung cancer.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20101201

• Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication.

  American journal of clinical pathology 20101201

• Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101201

• One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.

  Chinese journal of cancer 20101201

• Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.

  Genes & development 20101201

• Warfarin therapy: how the less interesting half just got interesting.

  Journal of thrombosis and haemostasis : JTH 20101201

• The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.

  Future oncology (London, England) 20101201

• Treatment of unresectable and metastatic cutaneous squamous cell carcinoma.

  The oncologist 20101201

• Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).

  The oncologist 20101201

• Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.

  Current opinion in molecular therapeutics 20101201

• Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.

  Molecular cancer therapeutics 20101201

• [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].

  Revue de pneumologie clinique 20101201

• [Gefitinib inhibits α-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20101201

• Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer.

  PLoS medicine 20101201

• Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.

  Anticancer research 20101201

• Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.

  Anticancer research 20101201

• [Dose finding methods for targeted agents: new perspectives].

  Bulletin du cancer 20101201

• Estrogen receptors, antiestrogens, and non-small cell lung cancer.

  Biochemistry. Biokhimiia 20101201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• [Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20101120

• Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

  Journal of the National Cancer Institute 20101117

• Autoproteolysis of the SEA module of rMuc3 C-terminal domain modulates its functional composition.

  Archives of biochemistry and biophysics 20101115

• Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.

  Leukemia research 20101101

• Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?

  Liver international : official journal of the International Association for the Study of the Liver 20101101

• Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

  Japanese journal of clinical oncology 20101101

• Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.

  The Journal of thoracic and cardiovascular surgery 20101101

• Molecular diagnostics of gliomas: state of the art.

  Acta neuropathologica 20101101

• Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.

  European journal of cancer (Oxford, England : 1990) 20101101

• Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.

  Lung cancer (Amsterdam, Netherlands) 20101101

• A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101101

• Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101

• Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability.

  Acta biochimica et biophysica Sinica 20101101

• Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

  The American journal of pathology 20101101

• Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

  Gut 20101101

• Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.

  Cancer research 20101101

• Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.

  Wiener medizinische Wochenschrift (1946) 20101101

• SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20101101

• ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101101

• Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

  Nature reviews. Clinical oncology 20101101

• Radiation recall with anticancer agents.

  The oncologist 20101101

• A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

  British journal of cancer 20101101

• Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

  British journal of cancer 20101101

• Chemoprevention of pancreatic cancer: ready for the clinic?

  Cancer prevention research (Philadelphia, Pa.) 20101101

• The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.

  Cancer prevention research (Philadelphia, Pa.) 20101101

• [A case of non-small cell lung cancer responding to S-1 over a year].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• EGFR-mutated lung cancer: a paradigm of molecular oncology.

  Oncotarget 20101101

• Lung cancer: recent advances.

  Annals of the Academy of Medicine, Singapore 20101101

• [Lung cancer in pregnancy: report of two cases and review of literature].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20101101

• [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101101

• Lung Cancer: Are we up to the Challenge?

  Current genomics 20101101

• Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.

  Cancer letters 20101028

• Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.

  Journal of medicinal chemistry 20101028

• Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.

  British journal of cancer 20101026

• Computational oral absorption simulation of free base drugs.

  International journal of pharmaceutics 20101015

• Interstitial lung disease and gefitinib.

  The New England journal of medicine 20101014

• Interstitial lung disease and gefitinib.

  The New England journal of medicine 20101014

• MicroRNA in lung cancer.

  British journal of cancer 20101012

• How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.

  British journal of cancer 20101012

• A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

  The pharmacogenomics journal 20101001

• A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20101001

• Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.

  Lung cancer (Amsterdam, Netherlands) 20101001

• Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101001

• Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

  The Journal of steroid biochemistry and molecular biology 20101001

• Metabolism considerations for kinase inhibitors in cancer treatment.

  Expert opinion on drug metabolism & toxicology 20101001

• Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.

  European journal of cancer (Oxford, England : 1990) 20101001

• Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

• TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.

  Molecular cancer therapeutics 20101001

• Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

• Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

• Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.

  Head & neck 20101001

• Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

• Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.

  The oncologist 20101001

• Personalized medicine for non-small-cell lung cancer.

  Expert review of anticancer therapy 20101001

• [Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101001

• [Molecular targeted therapy in lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20101001

• Predictive biomarkers in the management of EGFR mutant lung cancer.

  Annals of the New York Academy of Sciences 20101001

• Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

  Health technology assessment (Winchester, England) 20101001

• Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers.

  Hormones & cancer 20101001

• Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

  British journal of cancer 20100928

• Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.

  British journal of cancer 20100928

• Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

  British journal of cancer 20100928

• A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100915

• Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism.

  Bioinformatics (Oxford, England) 20100915

• Current approach in the treatment of hepatocellular carcinoma.

  World journal of gastrointestinal oncology 20100915

• Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

  British journal of cancer 20100907

• Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.

  British journal of cancer 20100907

• Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.

  Medical oncology (Northwood, London, England) 20100901

• Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.

  Medical oncology (Northwood, London, England) 20100901

• Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

  Breast cancer research and treatment 20100901

• The current status of targeted therapy for non-small cell lung cancer.

  Internal medicine journal 20100901

• A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.

  International journal of radiation oncology, biology, physics 20100901

• Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20100901

• Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.

  Cancer chemotherapy and pharmacology 20100901

• The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100901

• High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.

  Journal of neuro-oncology 20100901

• Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.

  Journal of cancer research and clinical oncology 20100901

• Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.

  Lung cancer (Amsterdam, Netherlands) 20100901

• Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.

  Biochemical pharmacology 20100901

• Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

  Nature reviews. Clinical oncology 20100901

• Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.

  Cancer science 20100901

• Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors.

  The Prostate 20100901

• Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.

  Cancer science 20100901

• Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100901

• Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901

• Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901

• American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA.

  Journal of neuro-oncology 20100901

• Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.

  The Korean journal of internal medicine 20100901

• Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

  Clinical lung cancer 20100901

• Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

  Clinical lung cancer 20100901

• Second-line treatment for non-small-cell lung cancer: one size does not fit all.

  Clinical lung cancer 20100901

• [Ocular disorders of anticancer drugs--ocular side effects].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100901

• The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells.

  PLoS pathogens 20100901

• Clinical trials and approval of anti-cancer agents.

  Japanese journal of clinical oncology 20100901

• Lung cancer working group report.

  Japanese journal of clinical oncology 20100901

• The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer.

  European respiratory review : an official journal of the European Respiratory Society 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• Targeted therapy for non-small-cell lung cancer.

  The journal of the Royal College of Physicians of Edinburgh 20100901

• Chemotherapy for advanced non-small-cell lung cancer patients with poor performance.

  Expert review of clinical pharmacology 20100901

• The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.

  Journal of thoracic disease 20100901

• Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

  British journal of cancer 20100824

• [Clinical investigation of efficacy of pemetrexed in 32 patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100820

• Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.

  Oncogene 20100819

• A simple procedure for the derivation of electron density based surfaces of drug-receptor complexes from a combination of X-ray data and theoretical calculations.

  Bioorganic & medicinal chemistry 20100815

• Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.

  Cancer research 20100815

• Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide.

  Journal of medicinal chemistry 20100812

• Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands.

  British journal of cancer 20100810

• A new A431/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening epidermal growth factor receptor antagonists from Radix sophorae flavescentis.

  Journal of chromatography. A 20100806

• Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

  Investigational new drugs 20100801

• EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.

  Cancer letters 20100801

• Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells.

  Molecular oncology 20100801

• Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.

  International journal of clinical oncology 20100801

• mTOR signaling in glioblastoma: lessons learned from bench to bedside.

  Neuro-oncology 20100801

• Structure-based and ligand-based drug design for HER 2 receptor.

  Journal of biomolecular structure & dynamics 20100801

• Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.

  Experimental biology and medicine (Maywood, N.J.) 20100801

• Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.

  Journal of separation science 20100801

• Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.

  Experimental dermatology 20100801

• [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801

• Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100801

• Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats.

  The Journal of toxicological sciences 20100801

• Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.

  Biomarkers in medicine 20100801

• Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801

• Targeted therapy at the end of life for patients with lung cancer.

  Journal of palliative medicine 20100801

• Rational approach to the synthesis, evaluation, and (68)ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase.

  Cancer biotherapy & radiopharmaceuticals 20100801

• [A case of advanced adenocarcinoma of the lung which maintained complete response for 5 years by treatment with gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20100801

• Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin.

  Chinese medical journal 20100801

• Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib.

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20100801

• Discovering tumor suppressor genes through genome-wide copy number analysis.

  Current genomics 20100801

• BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.

  British journal of cancer 20100727

• [Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100720

• Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.

  Biochemical pharmacology 20100715

• Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

  British journal of cancer 20100713

• Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.

  European journal of pharmacology 20100710

• Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710

• Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

  Journal of medicinal chemistry 20100708

• Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

  Cancer chemotherapy and pharmacology 20100701

• The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.

  Human pathology 20100701

• Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line.

  European journal of medicinal chemistry 20100701

• Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.

  Current drug targets 20100701

• Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.

  The Journal of pharmacology and experimental therapeutics 20100701

• Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context.

  Molecular bioSystems 20100701

• Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations.

  Cancer science 20100701

• Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Integrating molecular diagnostics into anticancer drug discovery.

  Nature reviews. Drug discovery 20100701

• Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment.

  The clinical respiratory journal 20100701

• Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.

  Cancer research 20100701

• Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100701

• Annual review of advances in lung cancer clinical research: a report for the year 2009.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer.

  Nature reviews. Clinical oncology 20100701

• Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.

  European journal of cancer (Oxford, England : 1990) 20100701

• Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.

  Clinical lung cancer 20100701

• [Lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• [Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

  Current oncology (Toronto, Ont.) 20100701

• Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.

  Current oncology (Toronto, Ont.) 20100701

• Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

  Anticancer research 20100701

• [A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20100701

• Treating advanced non-small cell lung cancer in the elderly.

  Therapeutic advances in medical oncology 20100701

• Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.

  British journal of cancer 20100629

• Probing the probes: fitness factors for small molecule tools.

  Chemistry & biology 20100625

• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  The New England journal of medicine 20100624

• Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100615

• Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM.

  Bioinformatics (Oxford, England) 20100615

• Sparse multitask regression for identifying common mechanism of response to therapeutic targets.

  Bioinformatics (Oxford, England) 20100615

• Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

  Cancer 20100615

• The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine.

  Proceedings of the Japan Academy. Series B, Physical and biological sciences 20100611

• Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100610

• Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.

  Investigational new drugs 20100601

• Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

  International journal of radiation oncology, biology, physics 20100601

• RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.

  European radiology 20100601

• Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

  Lung cancer (Amsterdam, Netherlands) 20100601

• Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells.

  European journal of medicinal chemistry 20100601

• Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.

  Lung cancer (Amsterdam, Netherlands) 20100601

• Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.

  Current cancer drug targets 20100601

• EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

  Expert opinion on emerging drugs 20100601

• Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100601

• Gefitinib for the treatment of non-small-cell lung cancer.

  Expert opinion on pharmacotherapy 20100601

• Kisspeptin is released from human prostate cancer cell lines but plasma kisspeptin is not elevated in patients with prostate cancer.

  Oncology reports 20100601

• Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.

  Cancer research 20100601

• Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.

  Bioorganic & medicinal chemistry 20100601

• Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer.

  Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 20100601

• Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.

  Nature medicine 20100601

• Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.

  Journal of mammary gland biology and neoplasia 20100601

• Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

  The Lancet. Oncology 20100601

• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  The Lancet. Oncology 20100601

• Gallbladder cancer with tumor thrombus in the superior vena cava.

  Hepatobiliary & pancreatic diseases international : HBPD INT 20100601

• Two lung masses with different responses to pemetrexed.

  The Korean journal of internal medicine 20100601

• Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.

  Molecular cancer research : MCR 20100601

• Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.

  Molecular cancer therapeutics 20100601

• Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib.

  The Journal of dermatology 20100601

• A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond.

  Expert review of anticancer therapy 20100601

• [Oncology 2010].

  Deutsche medizinische Wochenschrift (1946) 20100601

• Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

  Current oncology (Toronto, Ont.) 20100601

• [Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].

  Magyar onkologia 20100601

• Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.

  Discovery medicine 20100601

• Targeted therapies in renal cell cancer: recent developments in imaging.

  Targeted oncology 20100601

• Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.

  Anticancer research 20100601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100601

• Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

  The Journal of clinical and aesthetic dermatology 20100601

• Gefitinib. Still no convincing results in non-small cell lung cancer.

  Prescrire international 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

  British journal of cancer 20100511

• The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing.

  Toxicology letters 20100504

• Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100501

• Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20100501

• Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

  Lung cancer (Amsterdam, Netherlands) 20100501

• Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20100501

• Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20100501

• The molecular pathology of cancer.

  Nature reviews. Clinical oncology 20100501

• Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100501

• Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.

  Cancer research 20100501

• Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene.

  Respirology (Carlton, Vic.) 20100501

• Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.

  Acta pharmacologica Sinica 20100501

• Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.

  The oncologist 20100501

• EGFR mutations in non-small-cell lung cancer.

  The Lancet. Oncology 20100501

• Commentary: tackling the challenges of developing targeted therapies for cancer.

  The oncologist 20100501

• [Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20100501

• [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20100501

• Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.

  Oncology (Williston Park, N.Y.) 20100430

• Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma.

  British journal of cancer 20100427

• Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.

  Oncogene 20100422

• [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100420

• Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib.

  Scandinavian journal of clinical and laboratory investigation 20100419

• The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

  International journal of cancer 20100415

• Mechanisms of resistance to HER family targeting antibodies.

  Experimental cell research 20100415

• Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.

  Cancer biology & therapy 20100415

• alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate.

  British journal of cancer 20100413

• EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

  British journal of cancer 20100413

• Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy.

  Molecular pharmaceutics 20100405

• Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100401

• Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.

  Journal of cancer research and clinical oncology 20100401

• [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20100401

• KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

  Annals of surgical oncology 20100401

• Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100401

• PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.

  Pigment cell & melanoma research 20100401

• Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.

  The Journal of urology 20100401

• Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

  Acta oncologica (Stockholm, Sweden) 20100401

• Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100401

• Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100401

• Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas.

  Oncology reports 20100401

• Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.

  Expert review of anticancer therapy 20100401

• Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy.

  The oncologist 20100401

• Recent advances in combined modality therapy.

  The oncologist 20100401

• Gefitinib improves outcome in patients with advanced non-small cell lung cancer compared with standard chemotherapy.

  Maedica 20100401

• MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.

  Chemico-biological interactions 20100330

• [Maintenance treatment of non-small cell lung cancer].

  Ugeskrift for laeger 20100322

• [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100320

• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

  Cancer research 20100315

• Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100315

• Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.

  Oncogene 20100311

• Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.

  Journal of medicinal chemistry 20100311

• In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.

  Applied biochemistry and biotechnology 20100301

• Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100301

• Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

  Lung cancer (Amsterdam, Netherlands) 20100301

• EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100301

• Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

  Molecular therapy : the journal of the American Society of Gene Therapy 20100301

• Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.

  Molecular therapy : the journal of the American Society of Gene Therapy 20100301

• Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib.

  Japanese journal of clinical oncology 20100301

• Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

  Current opinion in oncology 20100301

• Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

  Angiogenesis 20100301

• Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.

  Biochimica et biophysica acta 20100301

• Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.

  Cancer chemotherapy and pharmacology 20100301

• Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

  European journal of cancer (Oxford, England : 1990) 20100301

• Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.

  Cancer 20100301

• Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.

  Current cancer drug targets 20100301

• Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.

  The Journal of molecular diagnostics : JMD 20100301

• Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301

• First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301

• Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.

  Cancer metastasis reviews 20100301

• Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.

  Oncology reports 20100301

• Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy.

  Cancer metastasis reviews 20100301

• Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.

  Oral oncology 20100301

• Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.

  Molecular cancer therapeutics 20100301

• HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.

  Cancer research 20100301

• [Management of metastatic HER2-positive breast cancer: present and future].

  Bulletin du cancer 20100301

• Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

  Molecular cancer therapeutics 20100301

• De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301

• New molecular targeted therapies integrated with radiation therapy in lung cancer.

  Clinical lung cancer 20100301

• Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.

  The oncologist 20100301

• Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer.

  Chinese medical journal 20100220

• Treatment options for small cell lung cancer - do we have more choice?

  British journal of cancer 20100216

• Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

• AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

• Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report.

  Journal of medicine and life 20100215

• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• Epidermal growth factor signalling and bone metastasis.

  British journal of cancer 20100202

• Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

  Breast cancer research and treatment 20100201

• Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.

  American journal of clinical oncology 20100201

• Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.

  BJU international 20100201

• [Molecular diagnostics in lung carcinoma for therapy stratification].

  Der Pathologe 20100201

• Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20100201

• A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100201

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  The Lancet. Oncology 20100201

• Advances in target therapy for lung cancer.

  Japanese journal of clinical oncology 20100201

• Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents.

  Bioorganic & medicinal chemistry 20100201

• Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20100201

• Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100201

• First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100201

• Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

  Gynecologic oncology 20100201

• A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

  Nature reviews. Clinical oncology 20100201

• [A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100201

• Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100201

• Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.

  The oncologist 20100201

• EGFR overexpression in squamous cell carcinoma of the penis.

  Current oncology (Toronto, Ont.) 20100201

• Management of hot flashes in women with breast cancer.

  Current oncology (Toronto, Ont.) 20100201

• [Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20100201

• Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.

  Acta medica Okayama 20100201

• [Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].

  Rinsho byori. The Japanese journal of clinical pathology 20100201

• Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.

  Anticancer research 20100201

• Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.

  Anticancer research 20100201

• First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

  Clinical advances in hematology & oncology : H&O 20100201

• Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes.

  Genes & cancer 20100201

• Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.

  Biochemical and biophysical research communications 20100122

• [Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100120

• Whole-genome cancer analysis as an approach to deeper understanding of tumour biology.

  British journal of cancer 20100119

• C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer.

  British journal of cancer 20100119

• Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

  American journal of respiratory and critical care medicine 20100115

• Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.

  Bioorganic & medicinal chemistry 20100115

• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100110

• Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

  British journal of cancer 20100105

• Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

  British journal of cancer 20100105

• A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.

  British journal of cancer 20100105

• Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.

  Urologic oncology 20100101

• Long-term survivors of more than 5 years in advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100101

• Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

  Cancer chemotherapy and pharmacology 20100101

• Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

  International journal of cancer 20100101

• Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

  Journal of neuro-oncology 20100101

• Breast carcinoma cells in primary tumors and effusions have different gene array profiles.

  Journal of oncology 20100101

• Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

  Cancer science 20100101

• Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

  Pediatric blood & cancer 20100101

• Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

  Drug metabolism and disposition: the biological fate of chemicals 20100101

• Cancer systems biology: a network modeling perspective.

  Carcinogenesis 20100101

• Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100101

• Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts.

  Journal of cellular biochemistry 20100101

• A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100101

• EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.

  The FEBS journal 20100101

• Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.

  The FEBS journal 20100101

• Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

  The FEBS journal 20100101

• Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).

  Bioorganic & medicinal chemistry letters 20100101

• A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.

  International journal of oncology 20100101

• Resveratrol down-regulates survivin and induces apoptosis in human multidrug-resistant SPC-A-1/CDDP cells.

  Oncology reports 20100101

• The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.

  Journal of neuro-oncology 20100101

• The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

  Journal of neuro-oncology 20100101

• Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

  Disease models & mechanisms 20100101

• Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.

  PharmacoEconomics 20100101

• Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.

  Journal of cellular and molecular medicine 20100101

• Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.

  AJR. American journal of roentgenology 20100101

• A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100101

• Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

  Journal of oncology 20100101

• [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].

  Chinese journal of cancer 20100101

• Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan.

  The Kaohsiung journal of medical sciences 20100101

• Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

  Journal of oncology 20100101

• Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.

  BMC cancer 20100101

• Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.

  BMC cancer 20100101

• Targeting the EGF receptor for ovarian cancer therapy.

  Journal of oncology 20100101

• A current review of targeted therapeutics for ovarian cancer.

  Journal of oncology 20100101

• Antivascular therapy for epithelial ovarian cancer.

  Journal of oncology 20100101

• Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?

  Archives of pathology & laboratory medicine 20100101

• Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.

  Internal medicine (Tokyo, Japan) 20100101

• Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.

  Clinical lung cancer 20100101

• Histology matters: individualizing treatment in non-small cell lung cancer.

  The oncologist 20100101

• Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy.

  Journal of experimental & clinical cancer research : CR 20100101

• Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.

  PloS one 20100101

• [Cutaneous side effects of EGFR inhibitors--appearance and management].

  Deutsche medizinische Wochenschrift (1946) 20100101

• Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.

  BMC cancer 20100101

• Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.

  PloS one 20100101

• Targeted therapies in epithelial ovarian cancer.

  Journal of oncology 20100101

• MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

  BMC cancer 20100101

• Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model.

  BMC cancer 20100101

• Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

  Molecular cancer 20100101

• CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

  PloS one 20100101

• Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.

  PloS one 20100101

• Targeted therapy in ovarian cancer.

  Journal of oncology 20100101

• TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.

  Journal of translational medicine 20100101

• Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

  Obstetrics and gynecology international 20100101

• Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.

  Cancer journal (Sudbury, Mass.) 20100101

• Whole brain radiotherapy with a conformational external beam radiation boost for lung cancer patients with 1-3 brain metastasis: a multi institutional study.

  Radiation oncology (London, England) 20100101

• Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.

  BMC cancer 20100101

• Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.

  Molecular cancer 20100101

• SplicerAV: a tool for mining microarray expression data for changes in RNA processing.

  BMC bioinformatics 20100101

• Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.

  BMC medical genetics 20100101

• Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.

  Chang Gung medical journal 20100101

• Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report.

  BMC urology 20100101

• A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.

  Proteome science 20100101

• Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.

  BMC cancer 20100101

• Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

  BMC cancer 20100101

• [Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100101

• Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  Onkologie 20100101

• Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.

  Journal of hematology & oncology 20100101

• A state space representation of VAR models with sparse learning for dynamic gene networks.

  Genome informatics. International Conference on Genome Informatics 20100101

• Late presentation of a mucinous ovarian adenocarcinoma which was initially diagnosed as a primary pancreatic carcinoma: a case report and review of the literature.

  Journal of medical case reports 20100101

• Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.

  PloS one 20100101

• Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

  Journal of ovarian research 20100101

• Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial.

  BMC clinical pharmacology 20100101

• [Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].

  Voprosy onkologii 20100101

• Molecular profiling of endometrial malignancies.

  Obstetrics and gynecology international 20100101

• Cancer-drug associations: a complex system.

  PloS one 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib.

  European journal of ophthalmology 20100101

• Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

  Molecular cancer 20100101

• Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

  BMC cancer 20100101

• Biology-driven cancer drug development: back to the future.

  BMC biology 20100101

• Molecular targeted therapies in head and neck cancer--an update of recent developments-.

  Head & neck oncology 20100101

• DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing.

  BMC genomics 20100101

• Melanoma: a model for testing new agents in combination therapies.

  Journal of translational medicine 20100101

• Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

  Journal of oncology 20100101

• A comprehensive molecular interaction map for rheumatoid arthritis.

  PloS one 20100101

• Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?

  Swiss medical weekly 20100101

• Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology.

  Journal of hematology & oncology 20100101

• Tumor angiogenesis: insights and innovations.

  Journal of oncology 20100101

• Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

  BMC cancer 20100101

• Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.

  BMC cancer 20100101

• Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.

  Journal of biomedical science 20100101

• Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.

  Molecular systems biology 20100101

• Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi.

  Marine drugs 20100101

• HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.

  PloS one 20100101

• Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

  Molecular cancer 20100101

• High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.

  Onkologie 20100101

• Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.

  Molecular cancer 20100101

• Interstitial lung disease associated to erlotinib treatment: a case report.

  Cases journal 20100101

• Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

  Radiation oncology (London, England) 20100101

• Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

  Molecular cancer 20100101

• Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.

  Oncology research 20100101

• Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.

  Molecular cancer 20100101

• EGFL7 meets miRNA-126: an angiogenesis alliance.

  Journal of angiogenesis research 20100101

• Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).

  Drug design, development and therapy 20100101

• Management of patients with advanced non-small cell lung cancer: role of gefitinib.

  Biologics : targets & therapy 20100101

• Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy.

  PloS one 20100101

• T cells enhance stem-like properties and conditional malignancy in gliomas.

  PloS one 20100101

• Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.

  BMC cancer 20100101

• Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

  BMC cancer 20100101

• Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques.

  BMC bioinformatics 20100101

• An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.

  BMC medical genomics 20100101

• RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

  Breast cancer research : BCR 20100101

• Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells.

  BMC cancer 20100101

• EGFR isoforms and gene regulation in human endometrial cancer cells.

  Molecular cancer 20100101

• The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

  Breast cancer research : BCR 20100101

• Analysis of inhibitor of apoptosis protein family expression during mammary gland development.

  BMC developmental biology 20100101

• A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

  BMC medical genomics 20100101

• A novel mechanism of cell growth regulation by Cell Cycle and Apoptosis Regulatory Protein (CARP)-1.

  Journal of molecular signaling 20100101

• A report of laryngeal adenocystic carcinoma metastatic to the spleen and the role of splenectomy in the management of metastatic disease: a case report.

  Journal of medical case reports 20100101

• Controversies in the management of endometrial carcinoma.

  Obstetrics and gynecology international 20100101

• Novel molecular imaging platform for monitoring oncological kinases.

  Cancer cell international 20100101

• The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

  OncoTargets and therapy 20100101

• Clinical relevance of KRAS in human cancers.

  Journal of biomedicine & biotechnology 20100101

• MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN.

  BMC cancer 20100101

• EGFR/Met association regulates EGFR TKI resistance in breast cancer.

  Journal of molecular signaling 20100101

• Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

  Molecular cancer 20100101

• A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene.

  Journal of biomedicine & biotechnology 20100101

• Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

  Journal of oncology 20100101

• Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient.

  BMC research notes 20100101

• Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas.

  BMC cancer 20100101

• p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance.

  BMC cancer 20100101

• Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.

  BMC cancer 20100101

• Biological markers in lung cancer: A clinician's perspective.

  Cancer biomarkers : section A of Disease markers 20100101

• Personalized therapies in the cancer 'omics' era.

  Molecular cancer 20100101

• Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer.

  Journal of biomedicine & biotechnology 20100101

• Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer.

  Current gerontology and geriatrics research 20100101

• Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.

  Genome biology 20100101

• Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization.

  Journal of biomedicine & biotechnology 20100101

• The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.

  Biologics : targets & therapy 20100101

• RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

  Molecular cancer 20100101

• Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.

  Molecular cancer 20100101

• The Met oncogene and basal-like breast cancer: another culprit to watch out for?

  Breast cancer research : BCR 20100101

• [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.

  PloS one 20100101

• MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis.

  Journal of carcinogenesis 20100101

• Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.

  PloS one 20100101

• Gene set analysis exploiting the topology of a pathway.

  BMC systems biology 20100101

• Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials.

  Annals of thoracic medicine 20100101

• Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.

  Onkologie 20100101

• Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.

  PloS one 20100101

• Molecular biomarker analyses using circulating tumor cells.

  PloS one 20100101

• Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.

  BMC cancer 20100101

• Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review.

  Journal of Cancer 20100101

• Vitamin D in combination cancer treatment.

  Journal of Cancer 20100101

• Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.

  Journal of experimental & clinical cancer research : CR 20100101

• First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

  Journal of experimental & clinical cancer research : CR 20100101

• Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

  PloS one 20100101

• A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.

  PloS one 20100101

• Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

  PloS one 20100101

• Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.

  Biologics : targets & therapy 20100101

• Pharmacogenetics and pharmacogenomics: practical applications in routine medical practice.

  Genome medicine 20100101

• Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

  Journal of oncology 20100101

• Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV.

  Journal of oncology 20100101

• Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.

  PloS one 20100101

• Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

  Breast cancer research : BCR 20100101

• A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples.

  Journal of experimental & clinical cancer research : CR 20100101

• Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough.

  Cough (London, England) 20100101

• Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

  World journal of surgical oncology 20100101

• Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

  Molecular cancer 20100101

• A colliding maxillary sinus cancer of adenosquamous carcinoma and small cell neuroendocrine carcinoma--a case report with EGFR copy number analysis.

  World journal of surgical oncology 20100101

• EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells.

  Cancer cell international 20100101

• Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling.

  PloS one 20100101

• Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.

  Core evidence 20100101

• Old and new insights in the treatment of thyroid carcinoma.

  Journal of thyroid research 20100101

• Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.

  PloS one 20100101

• Present and future evolution of advanced breast cancer therapy.

  Breast cancer research : BCR 20100101

• Triple-negative breast cancer.

  Breast cancer research : BCR 20100101

• The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.

  Journal of Cancer 20100101

• Anti-angiogenic therapy induces integrin-linked kinase 1 up-regulation in a mouse model of glioblastoma.

  PloS one 20100101

• [TARCEVA Clinical Registry].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma.

  PloS one 20100101

• FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

  PloS one 20100101

• [Consolidation therapy in advanced non-small cell lung cancer].

  Pneumonologia i alergologia polska 20100101

• Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.

  PloS one 20100101

• Human papillomavirus-16 presence and physical status in lung carcinomas from Asia.

  Infectious agents and cancer 20100101

• Estimating Shared Copy Number Aberrations for Array CGH Data: The Linear-Median Method.

  Cancer informatics 20100101

• Pre-clinical drug prioritization via prognosis-guided genetic interaction networks.

  PloS one 20100101

• Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

  BMC cancer 20100101

• A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.

  BMC cancer 20100101

• Quantitative analysis of tumor vascular structure after drug treatment.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20100101

• Targeted inhibition of kinases in cancer therapy.

  The Mount Sinai journal of medicine, New York 20100101

• Lung adenocarcinoma: lessons in translation from bench to bedside.

  The Mount Sinai journal of medicine, New York 20100101

• The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.

  Biologics : targets & therapy 20100101

• Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.

  BMC genomics 20100101

• Geftinib.

  Journal of cancer research and therapeutics 20100101

• Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status.

  Journal of cancer research and therapeutics 20100101

• Targeting the epidermal growth factor receptor in non-small cell lung cancer.

  Onkologie 20100101

• Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

  PloS one 20100101

• Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

  Pathology research international 20100101

• Genomic aberrations in lung adenocarcinoma in never smokers.

  PloS one 20100101

• Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

  PloS one 20100101

• Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.

  Journal of translational medicine 20100101

• Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.

  PloS one 20100101

• Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours.

  BMC biotechnology 20100101

• The therapeutic implications of plasticity of the cancer stem cell phenotype.

  PloS one 20100101

• Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.

  Cancer management and research 20100101

• Role of bevacizumab therapy in the management of glioblastoma.

  Cancer management and research 20100101

• Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.

  Cancer management and research 20100101

• Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.

  Advances in pharmacological sciences 20100101

• Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.

  BMC cancer 20100101

• Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing.

  Gastroenterology research and practice 20100101

• 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.

  PloS one 20100101

• Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.

  Journal of experimental therapeutics & oncology 20100101

• Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.

  Journal of oncology 20100101

• Cell adhesion signaling and its impact on tumorigenesis.

  Journal of oncology 20100101

• Lung cancer.

  BMJ clinical evidence 20100101

• Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.

  Oncology 20100101

• Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.

  Oncology 20100101

• Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.

  Clinical and experimental gastroenterology 20100101

• Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.

  Frontiers in pharmacology 20100101

• The role of funding and policies on innovation in cancer drug development.

  Ecancermedicalscience 20100101

• Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment.

  Ecancermedicalscience 20100101

• From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions.

  Chemotherapy research and practice 20100101

• Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20100101

• Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.

  Ontario health technology assessment series 20100101

• [Gefitinib improves insulin sensitivity in Wistar diabetes rats models].

  Zhonghua yi xue za zhi 20091229

• Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• [EGFR Mutations Detection in Non-small Cell Lung Cancer Tissues by Real-time PCR and DNA Sequencing.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20091220

• Treatment of lung cancer.

  The New England journal of medicine 20091217

• Treatment of lung cancer.

  The New England journal of medicine 20091217

• Treatment of lung cancer.

  The New England journal of medicine 20091217

• Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

  British journal of cancer 20091215

• Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice.

  American journal of respiratory cell and molecular biology 20091201

• Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

  Pathology oncology research : POR 20091201

• A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20091201

• The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.

  Microvascular research 20091201

• Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.

  Molecular & cellular proteomics : MCP 20091201

• Estrogen replacement in female lung cancer during gefitinib therapy.

  Japanese journal of clinical oncology 20091201

• ABCG2: the key to chemoresistance in cancer stem cells?

  Expert opinion on drug metabolism & toxicology 20091201

• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  Cancer treatment reviews 20091201

• Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.

  Drug metabolism and disposition: the biological fate of chemicals 20091201

• Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.

  Cancer biology & therapy 20091201

• Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201

• Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.

  Therapeutic drug monitoring 20091201

• Treatment of advanced non-small-cell lung cancer in the elderly.

  Lung cancer (Amsterdam, Netherlands) 20091201

• Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity.

  International journal of oncology 20091201

• Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures.

  Journal of cell science 20091201

• Emerging treatment combinations: integrating therapy into clinical practice.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201

• Bim-targeted cancer therapy: a link between drug action and underlying molecular changes.

  Molecular cancer therapeutics 20091201

• Small-molecule inhibitors of the human epidermal receptor family.

  Expert opinion on investigational drugs 20091201

• Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.

  Expert opinion on investigational drugs 20091201

• Tyrosine kinase inhibitors and the thyroid.

  Best practice & research. Clinical endocrinology & metabolism 20091201

• Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.

  Seminars in oncology 20091201

• Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data.

  PLoS computational biology 20091201

• [Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• [A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• New frontiers in biomarker-targeted molecular imaging.

  Cancer biology & therapy 20091201

• [KRAS status versus EGFR status in lung cancer therapy].

  Bulletin du cancer 20091201

• [Cutaneous side effects of EGF receptor inhibitors].

  Bulletin du cancer 20091201

• Screening for EGFR mutations in lung cancer.

  Discovery medicine 20091201

• A small step towards personalized medicine for non-small cell lung cancer.

  Discovery medicine 20091201

• Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.

  Anticancer research 20091201

• Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.

  Anticancer research 20091201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091201

• Histologic subtype in NSCLC: does it matter?

  Oncology (Williston Park, N.Y.) 20091130

• Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

  British journal of cancer 20091117

• Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

  British journal of cancer 20091117

• Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.

  International journal of cancer 20091115

• Current data and strategy in glioblastoma multiforme.

  Journal of medicine and life 20091115

• Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

  Drugs 20091112

• Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.

  Journal of medicinal chemistry 20091112

• A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

  Journal of the National Cancer Institute 20091104

• Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.

  British journal of cancer 20091103

• Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.

  Cancer chemotherapy and pharmacology 20091101

• Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091101

• Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

  Anti-cancer drugs 20091101

• Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.

  Cancer science 20091101

• Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091101

• Induced-fit docking studies of the active and inactive states of protein tyrosine kinases.

  Journal of molecular graphics & modelling 20091101

• Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.

  Expert opinion on investigational drugs 20091101

• Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

  Anti-cancer drugs 20091101

• Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091101

• EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.

  Journal of clinical pathology 20091101

• EGFR-TKI treatment and surgical resection for oligometastatic NSCLC?

  Onkologie 20091101

• Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.

  Onkologie 20091101

• The role of EGFR inhibition in the treatment of non-small cell lung cancer.

  The oncologist 20091101

• Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.

  PLoS computational biology 20091101

• Microglia are mediators of Borrelia burgdorferi-induced apoptosis in SH-SY5Y neuronal cells.

  PLoS pathogens 20091101

• [A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis in cases of primary lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091101

• Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.

  Therapeutic advances in medical oncology 20091101

• Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.

  Cancer letters 20091008

• Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

  Journal of the National Cancer Institute 20091007

• Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

  British journal of cancer 20091006

• Can treating the SYK cell cure leukemia?

  Cancer cell 20091006

• Proteomic and genetic approaches identify Syk as an AML target.

  Cancer cell 20091006

• Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20091001

• Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20091001

• New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.

  Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 20091001

• A case report of thyroid cancer showing a remarkable effect of gefitinib.

  Auris, nasus, larynx 20091001

• Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

  Breast cancer research and treatment 20091001

• Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.

  Head & neck 20091001

• Analytical methods for inferring functional effects of single base pair substitutions in human cancers.

  Human genetics 20091001

• Management of unfit older patients with advanced NSCLC.

  Cancer treatment reviews 20091001

• Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.

  Oral oncology 20091001

• Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells.

  Anti-cancer drugs 20091001

• Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.

  Cancer science 20091001

• Epidermal growth factor receptor-regulated miR-125a-5p--a metastatic inhibitor of lung cancer.

  The FEBS journal 20091001

• I am no one. No one is perfect...Therefore I am perfect.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001

• Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.

  Oncology reports 20091001

• Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.

  The Annals of pharmacotherapy 20091001

• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  The Journal of clinical investigation 20091001

• Lessons from the lung for targeted anticancer drugs.

  Nature reviews. Drug discovery 20091001

• Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

  Neoplasia (New York, N.Y.) 20091001

• [Progress in chemotherapy for advanced gastric cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20091001

• Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.

  Chemical research in toxicology 20091001

• The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

  Molecular cancer research : MCR 20091001

• [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.

  Anticancer research 20091001

• A mechanistic study on gefitinib-induced apoptosis reveals a new link between EGFR and hTERT in breast cancers.

  Archives of pharmacal research 20091001

• Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.

  Archives of pharmacal research 20091001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091001

• Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.

  P & T : a peer-reviewed journal for formulary management 20091001

• Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.

  Experimental cell research 20090910

• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910

• Quantitative prediction of fold resistance for inhibitors of EGFR.

  Biochemistry 20090908

• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  The New England journal of medicine 20090903

• Personalized medicine and inhibition of EGFR signaling in lung cancer.

  The New England journal of medicine 20090903

• Screening for epidermal growth factor receptor mutations in lung cancer.

  The New England journal of medicine 20090903

• Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

  Breast cancer research and treatment 20090901

• Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.

  Breast cancer research and treatment 20090901

• Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.

  Lung cancer (Amsterdam, Netherlands) 20090901

• Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.

  Lung cancer (Amsterdam, Netherlands) 20090901

• The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20090901

• Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20090901

• 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line.

  European journal of medicinal chemistry 20090901

• Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.

  Biochemical pharmacology 20090901

• Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

  Cancer science 20090901

• IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090901

• Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.

  Anti-cancer drugs 20090901

• Targeted therapies in the treatment of advanced/metastatic NSCLC.

  European journal of cancer (Oxford, England : 1990) 20090901

• Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies.

  Drug development and industrial pharmacy 20090901

• Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090901

• Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells.

  British journal of cancer 20090901

• Mutation of epidermal growth factor receptor is associated with MIG6 expression.

  The FEBS journal 20090901

• Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090901

• Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.

  Cancer research 20090901

• Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Bronchioloalveolar carcinoma: not as easy as 'BAC'.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090901

• Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090901

• Modeling glioma growth and invasion in Drosophila melanogaster.

  Neoplasia (New York, N.Y.) 20090901

• Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.

  Molecular cancer therapeutics 20090901

• The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

  Targeted oncology 20090901

• [The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell].

  Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery 20090901

• Divide and conquer: progress in the molecular stratification of cancer.

  Yonsei medical journal 20090831

• Preparation of heteroaryloxetanes and heteroarylazetidines by use of a Minisci reaction.

  The Journal of organic chemistry 20090821

• Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20090820

• Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

  British journal of cancer 20090818

• ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.

  Genes & development 20090815

• Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090815

• Epidermal growth factor receptor tyrosine kinase inhibitors and depression.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810

• [Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090810

• Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.

  Journal of the National Cancer Institute 20090805

• Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

  British journal of cancer 20090804

• Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.

  Lung cancer (Amsterdam, Netherlands) 20090801

• Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.

  Lung cancer (Amsterdam, Netherlands) 20090801

• An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

  American journal of clinical oncology 20090801

• Generating genome-scale candidate gene lists for pharmacogenomics.

  Clinical pharmacology and therapeutics 20090801

• Mechanisms of resistance to EGFR inhibitors in head and neck cancer.

  Head & neck 20090801

• Metabolic profiling identifies lung tumor responsiveness to erlotinib.

  Experimental and molecular pathology 20090801

• Radiosensitizing effects of gefitinib at different administration times in vitro.

  Cancer science 20090801

• Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

  Cancer science 20090801

• Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.

  Cancer biology & therapy 20090801

• Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

  Current cancer drug targets 20090801

• Differential effects of EGFR ligands on endocytic sorting of the receptor.

  Traffic (Copenhagen, Denmark) 20090801

• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090801

• Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090801

• Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090801

• Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.

  Anatomical record (Hoboken, N.J. : 2007) 20090801

• Gefitinib: phoenix from the flames.

  The Lancet. Oncology 20090801

• Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.

  Molecular cancer research : MCR 20090801

• Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.

  Molecular cancer research : MCR 20090801

• Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.

  Molecular cancer therapeutics 20090801

• Optimizing the management of advanced non-small-cell lung cancer: a personal view.

  Current oncology (Toronto, Ont.) 20090801

• Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

  Oncogene 20090801

• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

  Oncogene 20090801

• Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.

  Oncogene 20090801

• [Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.

  British journal of clinical pharmacology 20090801

• Effect of gefitinib on warfarin antithrombotic activity.

  International journal of clinical oncology 20090801

• Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.

  PLoS computational biology 20090801

• Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.

  Prescrire international 20090801

• Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.

  Cancer research 20090715

• Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.

  Cancer letters 20090708

• Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

  British journal of cancer 20090707

• Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

  International journal of pharmaceutics 20090706

• Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.

  European journal of medicinal chemistry 20090701

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

  Lung cancer (Amsterdam, Netherlands) 20090701

• An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible.

  Contemporary clinical trials 20090701

• Activated Akt prevents antitumor activity of gefitinib in renal cancer cells.

  Urology 20090701

• Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism.

  American journal of physiology. Renal physiology 20090701

• Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090701

• Investigational agents in the management of non-small cell lung cancer.

  Current oncology reports 20090701

• A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

  International journal of molecular medicine 20090701

• Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

  Neoplasia (New York, N.Y.) 20090701

• Outpacing cancer.

  Nature medicine 20090701

• Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.

  Anticancer research 20090701

• Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment.

  Anticancer research 20090701

• Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.

  Anticancer research 20090701

• The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.

  Anti-cancer agents in medicinal chemistry 20090701

• [Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome.

  PLoS computational biology 20090701

• Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

  Clinical lung cancer 20090701

• [A case of lung cancer combined with pregnancy; dramatically deteriorating condition after caesarian section].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20090701

• [Epidermal growth factor receptor aberrations in malignant mesotheliomas].

  Rinsho byori. The Japanese journal of clinical pathology 20090701

• Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.

  The clinical respiratory journal 20090701

• PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.

  Oncogene 20090618

• Anaplastic lymphoma kinase: signalling in development and disease.

  The Biochemical journal 20090615

• Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway.

  Cancer letters 20090608

• Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.

  Cancer letters 20090608

• Treatment in advanced colorectal cancer: what, when and how?

  British journal of cancer 20090602

• Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.

  Lung cancer (Amsterdam, Netherlands) 20090601

• EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.

  Lung cancer (Amsterdam, Netherlands) 20090601

• Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20090601

• EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.

  Journal of cancer research and clinical oncology 20090601

• Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

  Neuro-oncology 20090601

• Arsenic activates EGFR pathway signaling in the lung.

  Toxicological sciences : an official journal of the Society of Toxicology 20090601

• A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.

  Clinical and experimental dermatology 20090601

• Cross-talk between Notch and EGFR signaling in human breast cancer cells.

  Cancer investigation 20090601

• Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

  BJU international 20090601

• Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma.

  International journal of cancer 20090601

• Toward noninvasive genomic screening of lung cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Effects of an epidermal growth factor receptor inhibitor on arsenic associated toxicity in the rat bladder epithelium.

  Toxicology letters 20090601

• ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).

  Melanoma research 20090601

• Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• Emerging drugs for esophageal cancer.

  Expert opinion on emerging drugs 20090601

• ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.

  Current opinion in molecular therapeutics 20090601

• Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.

  Clinical nuclear medicine 20090601

• SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.

  Molecular cancer research : MCR 20090601

• [Advances in genome analysis of solid tumors].

  Nihon rinsho. Japanese journal of clinical medicine 20090601

• Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.

  Molecular cancer therapeutics 20090601

• Role of tyrosine kinase inhibitors in lung cancer.

  Anti-cancer agents in medicinal chemistry 20090601

• Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.

  Anticancer research 20090601

• Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.

  Journal of Korean medical science 20090601

• Enhancing the efficacy of hormonal agents with selected targeted agents.

  Clinical breast cancer 20090601

• [Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].

  Ai zheng = Aizheng = Chinese journal of cancer 20090601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090601

• Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

  Current drug metabolism 20090601

• Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.

  Clinical and translational science 20090601

• Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• [Gefitinib in Advanced Non-small-cell Lung Cancer.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20090520

• Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?

  JOP : Journal of the pancreas 20090518

• Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.

  Cancer 20090515

• Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.

  Cancer 20090515

• Heregulin regulates prolactinoma gene expression.

  Cancer research 20090515

• EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.

  Cancer research 20090515

• Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• Dual targeting of EGFR and HER-2 in colon cancer cell lines.

  Cancer chemotherapy and pharmacology 20090501

• Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.

  The Journal of pathology 20090501

• Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data.

  Journal of proteome research 20090501

• A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.

  European journal of cancer (Oxford, England : 1990) 20090501

• Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090501

• [Targeted therapies and their indications in solid neoplasias].

  La Revue de medecine interne 20090501

• MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.

  Journal of magnetic resonance imaging : JMRI 20090501

• Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.

  Nature reviews. Clinical oncology 20090501

• Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.

  The oncologist 20090501

• Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.

  IDrugs : the investigational drugs journal 20090501

• [Potent and continuous relief of spinal bone pain due to metastasis of non-small cell lung cancer by treatment with gefitinib--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• Targeted therapies for renal cell carcinoma: more gains from using them again.

  Current oncology (Toronto, Ont.) 20090501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090501

• Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.

  British journal of cancer 20090421

• KRAS mutations in non-small cell lung cancer.

  Proceedings of the American Thoracic Society 20090415

• Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090415

• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410

• Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.

  British journal of cancer 20090407

• Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials.

  British journal of cancer 20090407

• Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090401

• Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.

  International journal of radiation oncology, biology, physics 20090401

• Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090401

• ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20090401

• Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.

  Japanese journal of clinical oncology 20090401

• Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.

  Cancer 20090401

• Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene.

  Lung cancer (Amsterdam, Netherlands) 20090401

• MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090401

• Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?

  Annals of oncology : official journal of the European Society for Medical Oncology 20090401

• Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.

  American journal of clinical oncology 20090401

• Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090401

• In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.

  Nuclear medicine and biology 20090401

• Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

  The oncologist 20090401

• Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.

  The oncologist 20090401

• Gefitinib in the treatment of advanced non-small-cell lung cancer.

  Expert review of anticancer therapy 20090401

• [A case of non-small cell lung cancer with EGFR mutation responding to S-1 after a therapy with gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090401

• Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.

  Anticancer research 20090401

• ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.

  Anticancer research 20090401

• EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.

  Anticancer research 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Cetuximab-associated pulmonary toxicity.

  Clinical colorectal cancer 20090401

• Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.

  Biomarkers in medicine 20090401

• Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.

  British journal of cancer 20090324

• Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.

  British journal of cancer 20090324

• Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping.

  British journal of cancer 20090324

• The 'lazarus response' in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• microRNA-205 regulates HER3 in human breast cancer.

  Cancer research 20090315

• Trastuzumab-induced HER reprogramming in 'resistant' breast carcinoma cells.

  Cancer research 20090315

• Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.

  The Journal of biological chemistry 20090313

• AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

  Biochemical and biophysical research communications 20090313

• Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.

  British journal of cancer 20090310

• CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

  British journal of cancer 20090310

• Relation between outcomes and localisation of p-mTOR expression in gastric cancer.

  British journal of cancer 20090310

• Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

  Breast cancer research and treatment 20090301

• Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways.

  Purinergic signalling 20090301

• In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20090301

• Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.

  Molecular carcinogenesis 20090301

• Impact of EGFR mutation analysis in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090301

• Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.

  Journal of cancer research and clinical oncology 20090301

• The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current 'best evidence' with meta-analysis.

  Human pathology 20090301

• A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

  Journal of neuro-oncology 20090301

• Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer.

  Clinica chimica acta; international journal of clinical chemistry 20090301

• Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

  Japanese journal of clinical oncology 20090301

• HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53.

  DNA repair 20090301

• Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090301

• Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha.

  Oncology reports 20090301

• Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

  Expert opinion on investigational drugs 20090301

• EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090301

• Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

  Archives of pathology & laboratory medicine 20090301

• EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

  The Korean journal of internal medicine 20090301

• EGF-receptor regulates salivary gland branching morphogenesis by supporting proliferation and maturation of epithelial cells and survival of mesenchymal cells.

  Differentiation; research in biological diversity 20090301

• Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

  Current cancer drug targets 20090301

• Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.

  Molecular cancer therapeutics 20090301

• Histoculture drug response assay for gefitinib in non-small-cell lung cancer.

  General thoracic and cardiovascular surgery 20090301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090301

• Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.

  British journal of cancer 20090224

• Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.

  Cancer 20090215

• Gefitinib plus docetaxel in non-small-cell lung cancer.

  Lancet (London, England) 20090214

• Gefitinib plus docetaxel in non-small-cell lung cancer.

  Lancet (London, England) 20090214

• Gefitinib plus docetaxel in non-small-cell lung cancer.

  Lancet (London, England) 20090214

• A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

  British journal of cancer 20090210

• The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.

  British journal of cancer 20090210

• Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.

  Investigational new drugs 20090201

• Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation.

  Lung cancer (Amsterdam, Netherlands) 20090201

• Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.

  Lung cancer (Amsterdam, Netherlands) 20090201

• EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer.

  Journal of cancer research and clinical oncology 20090201

• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

  Oncology reports 20090201

• Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.

  Cancer research 20090201

• Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.

  Cancer prevention research (Philadelphia, Pa.) 20090201

• Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

  Cancer prevention research (Philadelphia, Pa.) 20090201

• Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201

• Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201

• EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.

  The European respiratory journal 20090201

• Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.

  Cancer biology & therapy 20090201

• Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090201

• [Lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090201

• Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.

  Cancer investigation 20090201

• Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20090201

• Binding site similarity analysis for the functional classification of the protein kinase family.

  Journal of chemical information and modeling 20090201

• [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090201

• Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

  Advanced drug delivery reviews 20090131

• Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.

  Oncogene 20090129

• Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

  British journal of cancer 20090127

• Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.

  British journal of cancer 20090127

• Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.

  British journal of cancer 20090127

• LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.

  British journal of cancer 20090127

• [Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20090120

• betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis.

  Molecular cell 20090116

• Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090115

• Molecular therapy for the treatment of hepatocellular carcinoma.

  British journal of cancer 20090113

• Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.

  British journal of cancer 20090113

• HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

  British journal of cancer 20090113

• Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.

  British journal of cancer 20090113

• A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.

  British journal of cancer 20090113

• Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090101

• Prolonged response to gefitinib in bone metastasis.

  Medical oncology (Northwood, London, England) 20090101

• Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.

  Journal of cancer research and clinical oncology 20090101

• EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report.

  Urologic oncology 20090101

• Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.

  Acta oncologica (Stockholm, Sweden) 20090101

• Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines.

  International journal of cancer 20090101

• Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

  Molecular pharmacology 20090101

• A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.

  Acta oncologica (Stockholm, Sweden) 20090101

• A population-based study of gefitinib in patients with non-small cell lung cancer.

  Medical oncology (Northwood, London, England) 20090101

• Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.

  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20090101

• Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20090101

• EGFR-targeted therapies in lung cancer: predictors of response and toxicity.

  Pharmacogenomics 20090101

• Gefitinib for the treatment of non-small-cell lung cancer.

  Expert review of anticancer therapy 20090101

• Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.

  BMC systems biology 20090101

• Carcinosarcoma of the breast: two case reports and review of the literature.

  Cases journal 20090101

• Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.

  BMC cancer 20090101

• Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.

  BMC cancer 20090101

• Tyrosine kinase blockers: new hope for successful cancer therapy.

  Anti-cancer agents in medicinal chemistry 20090101

• Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.

  Reviews on recent clinical trials 20090101

• Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer.

  Journal of hematology & oncology 20090101

• Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.

  Molecular systems biology 20090101

• How to deal with large models?

  Molecular systems biology 20090101

• Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report.

  Zeitschrift fur Gastroenterologie 20090101

• Recent advances of novel targeted therapy in non-small cell lung cancer.

  Journal of hematology & oncology 20090101

• Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines.

  BMC cancer 20090101

• The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model.

  Genetic vaccines and therapy 20090101

• Malignant pure pulmonary ground-glass opacity nodules: prognostic implications.

  Korean journal of radiology 20090101

• Heterogeneous activation of the TGFbeta pathway in glioblastomas identified by gene expression-based classification using TGFbeta-responsive genes.

  Journal of translational medicine 20090101

• Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.

  Journal of translational medicine 20090101

• Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6.

  PloS one 20090101

• Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

  Breast cancer research : BCR 20090101

• Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

  Current oncology (Toronto, Ont.) 20090101

• The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement.

  Current oncology (Toronto, Ont.) 20090101

• Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

  PloS one 20090101

• Mutation detection by real-time PCR: a simple, robust and highly selective method.

  PloS one 20090101

• Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.

  Journal of experimental & clinical cancer research : CR 20090101

• Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.

  Oncology 20090101

• APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.

  PloS one 20090101

• Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.

  Oncology 20090101

• Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

  Current pharmaceutical design 20090101

• Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.

  Head & neck oncology 20090101

• Toxicity of targeted therapy in non-small-cell lung cancer management.

  Clinical lung cancer 20090101

• Bayesian clustering and feature selection for cancer tissue samples.

  BMC bioinformatics 20090101

• Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.

  Urologia internationalis 20090101

• Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.

  Anti-cancer drugs 20090101

• Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.

  Targeted oncology 20090101

• Systems pharmacology and genome medicine: a future perspective.

  Genome medicine 20090101

• KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

  BMC cancer 20090101

• Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.

  PloS one 20090101

• Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.

  Journal of oncology 20090101

• Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.

  PloS one 20090101

• Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.

  Journal of oncology 20090101

• Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.

  PloS one 20090101

• Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.

  Journal of oncology 20090101

• MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

  BMC cancer 20090101

• [Targeting HER pathway in head and neck and thoracic cancers].

  Bulletin du cancer 20090101

• The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer.

  BMC cancer 20090101

• Challenging issues in molecular-targeted therapy.

  Therapeutics and clinical risk management 20090101

• A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer.

  BMC cancer 20090101

• Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis.

  PloS one 20090101

• Lung cancer.

  BMJ clinical evidence 20090101

• PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture.

  Breast cancer research : BCR 20090101

• Targeting targeted agents: open issues for clinical trial design.

  Journal of experimental & clinical cancer research : CR 20090101

• Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.

  BMC cancer 20090101

• In vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumors.

  Journal of carcinogenesis 20090101

• Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

  Molecular cancer 20090101

• Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival.

  BMC cancer 20090101

• Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

  PloS one 20090101

• Molecular characterization of lung dysplasia induced by c-Raf-1.

  PloS one 20090101

• Expression and function of the insulin receptor substrate proteins in cancer.

  Cell communication and signaling : CCS 20090101

• No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.

  Journal of biomedicine & biotechnology 20090101

• Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.

  PloS one 20090101

• Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases.

  Surgery today 20090101

• Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

  BMC cancer 20090101

• Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

  Breast cancer research : BCR 20090101

• Brain injury expands the numbers of neural stem cells and progenitors in the SVZ by enhancing their responsiveness to EGF.

  ASN neuro 20090101

• Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies.

  Journal of oncology 20090101

• Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.

  Journal of receptor and signal transduction research 20090101

• Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.

  BMC cancer 20090101

• Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.

  Journal of oncology 20090101

• Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

  Journal of oncology 20090101

• The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

  Genome medicine 20090101

• ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

  Journal of hematology & oncology 20090101

• MicroRNAs as New Players for Diagnosis, Prognosis, and Therapeutic Targets in Breast Cancer.

  Journal of oncology 20090101

• Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02.

  BMC research notes 20090101

• Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.

  PloS one 20090101

• Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens.

  Journal of biomedicine & biotechnology 20090101

• Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.

  Breast cancer research : BCR 20090101

• Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer.

  Breast cancer research : BCR 20090101

• Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis.

  PloS one 20090101

• Tumor biology and cancer therapy - an evolving relationship.

  Cell communication and signaling : CCS 20090101

• Biomolecular markers in cancer of the tongue.

  Journal of oncology 20090101

• Current available therapies and future directions in the treatment of malignant gliomas.

  Biologics : targets & therapy 20090101

• EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.

  Biologics : targets & therapy 20090101

• The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro.

  Journal of experimental & clinical cancer research : CR 20090101

• Using expression and genotype to predict drug response in yeast.

  PloS one 20090101

• Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.

  BMC cancer 20090101

• Cardiotoxicity induced by tyrosine kinase inhibitors.

  Acta oncologica (Stockholm, Sweden) 20090101

• Function, regulation and pathological roles of the Gab/DOS docking proteins.

  Cell communication and signaling : CCS 20090101

• Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

  Breast cancer research : BCR 20090101

• Treatment of recurrent epithelial ovarian cancer.

  Therapeutics and clinical risk management 20090101

• Gefitinib for non-small cell lung cancer patients with liver cirrhosis.

  Internal medicine (Tokyo, Japan) 20090101

• Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.

  BMC cancer 20090101

• Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

  Biologics : targets & therapy 20090101

• Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

  Biologics : targets & therapy 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

  PloS one 20090101

• Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.

  Molecular cancer 20090101

• Perfusion-CT monitoring of cryo-ablated renal cells tumors.

  Journal of experimental & clinical cancer research : CR 20090101

• Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.

  Breast cancer research : BCR 20090101

• Development of rheumatoid arthritis during the course of gefitinib therapy.

  Sao Paulo medical journal = Revista paulista de medicina 20090101

• NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.

  PloS one 20090101

• Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

  PloS one 20090101

• Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.

  Journal of experimental therapeutics & oncology 20090101

• HPV & head and neck cancer: a descriptive update.

  Head & neck oncology 20090101

• Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report.

  Cases journal 20090101

• Sequence and structure signatures of cancer mutation hotspots in protein kinases.

  PloS one 20090101

• Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

  PloS one 20090101

• Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT).

  BMC cancer 20090101

• Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

  Journal of hematology & oncology 20090101

• High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression.

  BMC cancer 20090101

• HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.

  BMC cell biology 20090101

• Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.

  Internal medicine (Tokyo, Japan) 20090101

• Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.

  Diagnostic pathology 20090101

• MALDI profiling of human lung cancer subtypes.

  PloS one 20090101

• Roles of pathologists in molecular targeted cancer therapy.

  Journal of cellular and molecular medicine 20090101

• A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.

  Breast cancer research : BCR 20090101

• Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

  Molecular cancer 20090101

• Algorithms for effective querying of compound graph-based pathway databases.

  BMC bioinformatics 20090101

• Profiling critical cancer gene mutations in clinical tumor samples.

  PloS one 20090101

• Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

  Molecular cancer 20090101

• Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

  BMC cancer 20090101

• Antiproliferative effect of exemestane in lung cancer cells.

  Molecular cancer 20090101

• A predictive phosphorylation signature of lung cancer.

  PloS one 20090101

• Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.

  BMC cell biology 20090101

• Successful treatment of pyogenic granulomas following gefitinib therapy with partial matricectomy and phenolization.

  The Journal of dermatological treatment 20090101

• MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.

  Journal of carcinogenesis 20090101

• Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

  Indian journal of urology : IJU : journal of the Urological Society of India 20090101

• Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies.

  PloS one 20090101

• Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.

  BMC cancer 20090101

• Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent.

  Journal of biomedical science 20090101

• Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?

  BMC medicine 20090101

• Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.

  Journal of experimental & clinical cancer research : CR 20090101

• Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8.

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? The scenario.

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.

  Breast cancer research : BCR 20090101

• MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

  Journal of oncology 20090101

• Medullary thyroid carcinoma: targeted therapies and future directions.

  Journal of oncology 20090101

• A review of kinases implicated in pancreatic cancer.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20090101

• Biological prognostic and predictive factors in lung cancer.

  Oncology 20090101

• Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?

  Oncology 20090101

• Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck.

  International journal of otolaryngology 20090101

• Targeted therapy in the treatment of malignant gliomas.

  OncoTargets and therapy 20090101

• Multiple roles and therapeutic implications of Akt signaling in cancer.

  OncoTargets and therapy 20090101

• Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.

  OncoTargets and therapy 20090101

• Gemcitabine for the treatment of advanced nonsmall cell lung cancer.

  OncoTargets and therapy 20090101

• Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.

  OncoTargets and therapy 20090101

• Rational use of cetuximab in the treatment of advanced non-small cell lung cancer.

  OncoTargets and therapy 20090101

• Emerging technologies for the genomic analysis of cancer.

  F1000 biology reports 20090101

• Individualization of treatment in non-small cell lung cancer.

  F1000 medicine reports 20090101

• Aromatase inhibitor strategies in metastatic breast cancer.

  International journal of women's health 20090101

• Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222.

  Cancer management and research 20090101

• Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer.

  Cancer management and research 20090101

• The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder.

  The Libyan journal of medicine 20090101

• Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.

  Breast cancer : basic and clinical research 20090101

• Gefitinib-induced hair alterations.

  BMJ case reports 20090101

• Role of traditional and new biomarkers in breast carcinogenesis.

  Ecancermedicalscience 20090101

• Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

  International journal of cancer 20081215

• An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.

  European journal of pharmacology 20081214

• Emerging ethnic differences in lung cancer therapy.

  British journal of cancer 20081202

• Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?

  Cancer chemotherapy and pharmacology 20081201

• A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.

  Journal of cancer research and clinical oncology 20081201

• Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.

  Biochemical pharmacology 20081201

• Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081201

• EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.

  International journal of cancer 20081201

• EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201

• Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

  Cancer biology & therapy 20081201

• The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).

  Current treatment options in oncology 20081201

• Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

  International journal of oncology 20081201

• Exploring multi-targeting strategies for the treatment of gliomas.

  Current opinion in investigational drugs (London, England : 2000) 20081201

• BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.

  Current opinion in investigational drugs (London, England : 2000) 20081201

• Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

  The oncologist 20081201

• High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.

  American journal of clinical oncology 20081201

• Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.

  Molecular cancer research : MCR 20081201

• A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.

  Molecular cancer therapeutics 20081201

• The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast.

  PLoS genetics 20081201

• Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib.

  Current oncology (Toronto, Ont.) 20081201

• [Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081201

• Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway.

  Journal of biosciences 20081201

• Gateways to clinical trials. December 2008.

  Methods and findings in experimental and clinical pharmacology 20081201

• Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.

  Therapeutics and clinical risk management 20081201

• Small molecule tyrosine kinase inhibitors in pancreatic cancer.

  Biologics : targets & therapy 20081201

• The insulin-like growth factor system and its receptors: A potential novel anticancer target.

  Biologics : targets & therapy 20081201

• The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -.

  Asian spine journal 20081201

• Gefitinib or docetaxel in advanced non-small-cell lung cancer.

  Lancet (London, England) 20081122

• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  Lancet (London, England) 20081122

• Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

  Bioorganic & medicinal chemistry letters 20081115

• [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  Cancer research 20081115

• Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

  British journal of cancer 20081104

• Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.

  Breast cancer research and treatment 20081101

• Tumor resensitization to erlotinib following brief substitution of cetuximab.

  Cancer chemotherapy and pharmacology 20081101

• Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).

  International journal of radiation oncology, biology, physics 20081101

• The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.

  Lung cancer (Amsterdam, Netherlands) 20081101

• Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20081101

• Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.

  European journal of haematology 20081101

• Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.

  Acta radiologica (Stockholm, Sweden : 1987) 20081101

• A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081101

• Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.

  Cancer science 20081101

• Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.

  Nature chemical biology 20081101

• HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

  Molecular cancer therapeutics 20081101

• Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.

  Molecular cancer therapeutics 20081101

• Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.

  Archives of dermatology 20081101

• [Hand-foot syndrome: A new side effect of erlotinib].

  Annales de dermatologie et de venereologie 20081101

• [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20081101

• Severe acneiform eruption induced by cetuximab (Erbitux).

  Yonsei medical journal 20081031

• Pharmaceutical futures: a fiendish puzzle.

  Nature 20081030

• First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

  American journal of respiratory and critical care medicine 20081015

• Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?

  American journal of respiratory and critical care medicine 20081015

• Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.

  Cancer research 20081015

• Gefitinib maintenance in stage III non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010

• SWOG S0023: what meets the eye may be only half the truth.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010

• A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.

  British journal of cancer 20081007

• Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

  Clinical & experimental metastasis 20081001

• Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma.

  Carcinogenesis 20081001

• Advances in the treatment of non-small cell lung cancer.

  Cancer treatment reviews 20081001

• Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

  Journal of neuro-oncology 20081001

• Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.

  Journal of neuro-oncology 20081001

• Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.

  Clinical and experimental nephrology 20081001

• Homology models of the mutated EGFR and their response towards quinazoline analogues.

  Journal of molecular graphics & modelling 20081001

• [Targeted therapy for metastatic bladder cancer].

  Der Urologe. Ausg. A 20081001

• The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.

  European journal of cancer (Oxford, England : 1990) 20081001

• Novel human antibody therapeutics: the age of the Umabs.

  Biotechnology journal 20081001

• Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.

  Cancer investigation 20081001

• EGFR inhibition as a therapy for head and neck squamous cell carcinoma.

  Expert opinion on investigational drugs 20081001

• An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001

• Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001

• A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001

• Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

  Cancer research 20081001

• [Cutaneous toxicities].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• [Stage III NSCLC. The role of the chemotherapist].

  Revue des maladies respiratoires 20081001

• Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

  Current pharmaceutical design 20081001

• Docetaxel in the treatment of squamous cell carcinoma of the head and neck.

  Therapeutics and clinical risk management 20081001

• Multi-targeted approach in the treatment of thyroid cancer.

  Therapeutics and clinical risk management 20081001

• Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

  British journal of cancer 20080916

• Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

  British journal of cancer 20080916

• Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.

  Cell cycle (Georgetown, Tex.) 20080915

• Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

  Cancer research 20080915

• DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.

  Cancer research 20080915

• Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080910

• Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080910

• Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080910

• Speeding up the evaluation of new agents in cancer.

  Journal of the National Cancer Institute 20080903

• Role of LKB1 in lung cancer development.

  British journal of cancer 20080902

• Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

  British journal of cancer 20080902

• Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

  Breast cancer research and treatment 20080901

• Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.

  Lung cancer (Amsterdam, Netherlands) 20080901

• Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.

  Journal of cellular physiology 20080901

• Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

  Journal of neuro-oncology 20080901

• Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080901

• Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.

  Cancer science 20080901

• Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?

  The Journal of urology 20080901

• Immunohistochemical assessment of protein phosphorylation state: the dream and the reality.

  Histochemistry and cell biology 20080901

• Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front.

  Histochemistry and cell biology 20080901

• Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.

  Cancer research 20080901

• Lung cancer response to gefitinib, then erlotinib, then gefitinib again.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901

• Targeted therapies in head and neck cancer: past, present and future.

  Reviews on recent clinical trials 20080901

• Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.

  Reviews on recent clinical trials 20080901

• Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?

  The oncologist 20080901

• Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail.

  Molecular cancer therapeutics 20080901

• Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood.

  Journal of internal medicine 20080901

• [Advances in chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• [A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080901

• Evolving therapies in the treatment of hepatocellular carcinoma.

  Biologics : targets & therapy 20080901

• [Sequential administration of gefitinib and docetaxel as second-line therapy for advanced non-small cell lung cancer: analysis of 82 cases].

  Zhonghua yi xue za zhi 20080819

• Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

  Cancer 20080815

• A study of the analytical behaviour of selected new molecular entities using electrospray ionisation ion trap mass spectrometry, liquid chromatography, gas chromatography and polarography and their determination in serum at therapeutic concentrations.

  Analytica chimica acta 20080815

• Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Resistance to chemotherapy: new treatments and novel insights into an old problem.

  British journal of cancer 20080805

• Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.

  British journal of cancer 20080805

• Factors affecting the clearance and biodistribution of polymeric nanoparticles.

  Molecular pharmaceutics 20080804

• Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20080801

• Gefitinib potentiates myeloid cell differentiation by ATRA.

  Leukemia 20080801

• Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20080801

• Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.

  The Laryngoscope 20080801

• The development of HKI-272 and related compounds for the treatment of cancer.

  Archiv der Pharmazie 20080801

• EGFR polymorphism of the kinase domain in Japanese lung cancer.

  The Journal of surgical research 20080801

• The epithelial cholinergic system of the airways.

  Histochemistry and cell biology 20080801

• A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck.

  Anti-cancer drugs 20080801

• Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.

  Oncology reports 20080801

• Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801

• Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801

• Drug interaction between complementary herbal medicines and gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801

• Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.

  Cancer research 20080801

• The role of inhibitors of the epidermal growth factor in management of head and neck cancer.

  Journal of the National Comprehensive Cancer Network : JNCCN 20080801

• [A case of survival--excellent response to chemotherapy in long-term postoperative recurrence of non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080801

• N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.

  Cancer science 20080801

• Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.

  Cancer science 20080801

• [Targeted therapies for lung cancer].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20080801

• Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.

  American journal of clinical oncology 20080801

• Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.

  American journal of clinical oncology 20080801

• Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.

  Current genomics 20080801

• Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.

  The New England journal of medicine 20080724

• Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

  British journal of cancer 20080722

• Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

  Cancer research 20080715

• Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.

  Cancer letters 20080708

• EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

  British journal of cancer 20080708

• Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.

  British journal of cancer 20080708

• Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

  British journal of cancer 20080708

• Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

  British journal of cancer 20080708

• Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.

  Breast cancer research and treatment 20080701

• The relative bioavailability of gefitinib administered by granular formulation.

  Cancer chemotherapy and pharmacology 20080701

• Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors.

  European journal of medicinal chemistry 20080701

• Analysis of duration of response in oncology trials.

  Contemporary clinical trials 20080701

• Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.

  Lung cancer (Amsterdam, Netherlands) 20080701

• Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.

  Head & neck 20080701

• Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

  Lung cancer (Amsterdam, Netherlands) 20080701

• Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.

  Antiviral research 20080701

• EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.

  International journal of cancer 20080701

• Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?

  Current opinion in oncology 20080701

• Response of malignant thymoma to erlotinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.

  Carcinogenesis 20080701

• Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

  The Journal of clinical investigation 20080701

• Mechanisms of resistance to ErbB-targeted cancer therapeutics.

  The Journal of clinical investigation 20080701

• Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• [Targeted therapy for locally advanced and/or metastatic bladder cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701

• Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

  Molecular cancer therapeutics 20080701

• A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080701

• [EGFR and gefitinib (Iressa)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.

  Clinical lung cancer 20080701

• Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.

  Cancer letters 20080628

• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

  Oncogene 20080626

• [Effects of paclitaxel and gefitinib on the proliferation and cell cycle of human lung adenocarcinoma cell SPC-A1.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20080620

• Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

  American journal of respiratory and critical care medicine 20080615

• Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

  The Prostate 20080615

• From nihilism to individualism: the evolution of lung cancer therapy.

  American journal of respiratory and critical care medicine 20080615

• Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.

  American journal of respiratory and critical care medicine 20080615

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Translational research: the full cycle.

  Nature 20080612

• A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

  British journal of cancer 20080603

• A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.

  Cancer chemotherapy and pharmacology 20080601

• In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines.

  Cancer chemotherapy and pharmacology 20080601

• Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20080601

• BCRP/ABCG2 in the placenta: expression, function and regulation.

  Pharmaceutical research 20080601

• Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.

  European journal of nuclear medicine and molecular imaging 20080601

• Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.

  Journal of cellular physiology 20080601

• EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.

  Anti-cancer drugs 20080601

• Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1.

  Cancer science 20080601

• Implications of EGFR inhibition in ovarian cancer cell proliferation.

  Gynecologic oncology 20080601

• EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.

  American journal of physiology. Lung cellular and molecular physiology 20080601

• The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

  Journal of mammary gland biology and neoplasia 20080601

• Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.

  Head & neck 20080601

• CYP450 pharmacogenetics for personalizing cancer therapy.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20080601

• Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.

  Oncology reports 20080601

• Early clinical studies of novel therapies for thyroid cancers.

  Endocrinology and metabolism clinics of North America 20080601

• Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.

  International journal of molecular medicine 20080601

• Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080601

• The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.

  Lung cancer (Amsterdam, Netherlands) 20080601

• EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.

  Lung cancer (Amsterdam, Netherlands) 20080601

• Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

  Lung cancer (Amsterdam, Netherlands) 20080601

• Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.

  Clinical journal of oncology nursing 20080601

• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601

• Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601

• Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings.

  Clinics (Sao Paulo, Brazil) 20080601

• [Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20080601

• Systemic treatments for mesothelioma: standard and novel.

  Current treatment options in oncology 20080601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080601

• Clearing the brain's cobwebs: the role of autophagy in neuroprotection.

  Current neuropharmacology 20080601

• The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.

  Current genomics 20080601

• Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.

  Biologics : targets & therapy 20080601

• Gefitinib: a consideration of cost.

  Expert review of pharmacoeconomics & outcomes research 20080601

• Does gefitinib shorten lung cancer survival? Chaos redux.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080520

• Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080520

• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080520

• Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.

  British journal of cancer 20080520

• Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks.

  Cell 20080516

• Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.

  British journal of cancer 20080506

• Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype.

  British journal of cancer 20080506

• Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.

  Cancer chemotherapy and pharmacology 20080501

• Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.

  Journal of cancer research and clinical oncology 20080501

• Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer.

  Histochemistry and cell biology 20080501

• Human cervical carcinomas and EGF-R tyrosine kinase inhibitors.

  Gynecologic oncology 20080501

• Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

  Cancer 20080501

• Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.

  Cancer science 20080501

• The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.

  Experimental cell research 20080501

• Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.

  Current opinion in oncology 20080501

• Peritoneal carcinomatosis in lung cancer.

  Respirology (Carlton, Vic.) 20080501

• Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.

  Microvascular research 20080501

• Gefitinib-associated Propionibacterium acnes pleural empyema.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080501

• Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

  Cancer research 20080501

• Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080501

• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  Mayo Clinic proceedings 20080501

• Second-line and third-line chemotherapy for lung cancer: use and cost.

  The American journal of managed care 20080501

• [Non-small-cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).

  Onkologie 20080501

• New insights in drug development for the non-small cell lung cancer therapy.

  Frontiers in bioscience : a journal and virtual library 20080501

• Targeted therapy in the treatment of solid tumors: practice contradicts theory.

  Biochemistry. Biokhimiia 20080501

• [Successful treatment of non-small cell lung cancer by gefitinib in an elderly patient with poor performance status].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20080501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080501

• Erlotinib hydro-chloride: an anti-cancer agent.

  Acta crystallographica. Section E, Structure reports online 20080501

• The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.

  British journal of cancer 20080422

• [Analysis of Treatment Response and Chest CT Characteristics for Patients treated by EGFR-TKI in Relapse Advanced Lung Adenocarcinoma.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20080420

• [Evaluation of efficacy of gefitinib on advanced non-small-cell lung cancer(NSCLC) resisted to chemotherapy.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20080420

• [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].

  Nederlands tijdschrift voor geneeskunde 20080419

• EGFR and VEGFR as potential target for biological therapies in HCC cells.

  Cancer letters 20080418

• Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.

  The Journal of biological chemistry 20080418

• Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu.

  International journal of cancer 20080415

• Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.

  Cancer research 20080415

• Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080415

• Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

  The pharmacogenomics journal 20080401

• Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.

  Cancer chemotherapy and pharmacology 20080401

• Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080401

• EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.

  Annals of surgical oncology 20080401

• Strategies to optimize the use of targeted agents for tumor therapy.

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20080401

• Chemotherapeutic agents and the skin: An update.

  Journal of the American Academy of Dermatology 20080401

• Epidermal growth factor receptor inhibitors and hair.

  Journal of the American Academy of Dermatology 20080401

• Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling.

  Proteomics 20080401

• Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

  Molecular cancer therapeutics 20080401

• Structure and clinical relevance of the epidermal growth factor receptor in human cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401

• [Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis].

  Clinical calcium 20080401

• Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• Clinical experience with gefitinib in Indian patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• Second-line treatment of advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

  Cancer research 20080401

• Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

  Cancer research 20080401

• 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

  Molecular cancer therapeutics 20080401

• Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.

  Molecular cancer therapeutics 20080401

• EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.

  Onkologie 20080401

• Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.

  The Tohoku journal of experimental medicine 20080401

• A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.

  The oncologist 20080401

• Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan.

  International journal of clinical oncology 20080401

• Effects of gefitinib on radiation-induced lung injury in mice.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080401

• [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].

  Zhonghua nei ke za zhi 20080401

• Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells.

  British journal of cancer 20080325

• High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer.

  British journal of cancer 20080325

• Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

  British journal of cancer 20080325

• A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.

  International journal of radiation oncology, biology, physics 20080315

• Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.

  British journal of cancer 20080311

• Cortactin expression predicts poor survival in laryngeal carcinoma.

  British journal of cancer 20080311

• Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

  British journal of cancer 20080311

• Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.

  British journal of cancer 20080311

• A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.

  Cancer chemotherapy and pharmacology 20080301

• Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.

  Clinical pharmacology and therapeutics 20080301

• Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080301

• A phase II study of gefitinib in patients with advanced thyroid cancer.

  Thyroid : official journal of the American Thyroid Association 20080301

• Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.

  Biochemical pharmacology 20080301

• Predictors of survival in patients with bone metastasis of lung cancer.

  Clinical orthopaedics and related research 20080301

• Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

  Cancer 20080301

• Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

  The Journal of molecular diagnostics : JMD 20080301

• Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.

  Human pathology 20080301

• Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.

  Cancer science 20080301

• Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.

  Current opinion in oncology 20080301

• Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301

• Small cell lung cancer.

  Mayo Clinic proceedings 20080301

• Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

  Expert opinion on investigational drugs 20080301

• Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.

  General thoracic and cardiovascular surgery 20080301

• Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.

  Molecular cancer therapeutics 20080301

• Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.

  Molecular cancer therapeutics 20080301

• Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds.

  Molecular cancer therapeutics 20080301

• EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines.

  Pathology oncology research : POR 20080301

• Systemic therapies for recurrent and/or metastatic salivary gland cancers.

  Expert review of anticancer therapy 20080301

• Commentary: Novel therapies for cancer: why dirty might be better.

  The oncologist 20080301

• [Targeted therapies in the treatment of non-small cell lung cancer].

  Bulletin du cancer 20080301

• [A case of lung adenocarcinoma effectively treated with sivelestat and corcicosteroid for drug-induced lung disease due to gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20080301

• [Effect of gefinitib on airway mucus hypersecretion induced by acrolein in rats].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20080301

• [Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080301

• Erlotinib in the treatment of advanced pancreatic cancer.

  Biologics : targets & therapy 20080301

• A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).

  British journal of cancer 20080226

• Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.

  British journal of cancer 20080226

• [Advance of second-line chemotherapy in advanced non-small cell lung cancer.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20080220

• [Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20080220

• Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080215

• Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080215

• EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.

  Oncogene 20080207

• Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.

  Cancer chemotherapy and pharmacology 20080201

• Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

  Journal of cellular biochemistry 20080201

• Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells.

  Pharmaceutical research 20080201

• Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.

  Journal of cellular physiology 20080201

• Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080201

• Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080201

• Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

  Annals of surgical oncology 20080201

• E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.

  Oncology reports 20080201

• Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy.

  Oncology reports 20080201

• Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.

  Cell proliferation 20080201

• EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.

  Seminars in oncology nursing 20080201

• Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201

• Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

  Cancer research 20080201

• Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.

  Cancer science 20080201

• Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines.

  Molecular cancer therapeutics 20080201

• Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.

  Molecular cancer therapeutics 20080201

• [Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• Severe purpuric xerotic dermatitis associated with gefitinib therapy.

  Archives of dermatology 20080201

• Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080201

• Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.

  British journal of cancer 20080129

• EGFR and beta1 integrins utilize different signaling pathways to activate Akt.

  Experimental cell research 20080115

• A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.

  British journal of cancer 20080115

• A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.

  British journal of cancer 20080115

• Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.

  British journal of cancer 20080115

• Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

  British journal of cancer 20080115

• Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

  Cancer research 20080115

• Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

  Cancer research 20080115

• The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080101

• Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20080101

• A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.

  BJU international 20080101

• Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?

  Nature clinical practice. Oncology 20080101

• 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment.

  Molecular pharmacology 20080101

• A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.

  Gynecologic oncology 20080101

• Erosive pustular dermatosis of the scalp after gefitinib and radiotherapy for brain metastases secondary to lung cancer.

  Clinical and experimental dermatology 20080101

• Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.

  Clinical and experimental dermatology 20080101

• KL-6 and poor prognosis in NSCLC patients treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20080101

• Targeting the epidermal growth factor receptor in metastatic colorectal cancer.

  Critical reviews in oncology/hematology 20080101

• Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.

  Current opinion in oncology 20080101

• Will targeted therapy hold its promise? An evidence-based review.

  Current opinion in oncology 20080101

• Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.

  Oncology reports 20080101

• Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

  Medical oncology (Northwood, London, England) 20080101

• Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib.

  Cancer cell international 20080101

• Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha.

  The Journal of endocrinology 20080101

• Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.

  BMC cancer 20080101

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.

  Breast cancer research : BCR 20080101

• [Molecular targeted therapy and tailor-made therapy for lung cancer].

  Kyobu geka. The Japanese journal of thoracic surgery 20080101

• Drosophila cbl is essential for control of cell death and cell differentiation during eye development.

  PloS one 20080101

• Epidermal growth factor receptor structural alterations in gastric cancer.

  BMC cancer 20080101

• Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

  Molecular cancer therapeutics 20080101

• Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.

  Journal of translational medicine 20080101

• Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080101

• Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

  PLoS medicine 20080101

• Incorporating molecular tools into early-stage clinical trials.

  PLoS medicine 20080101

• Molecule of the month. Overcoming resistance.

  Current topics in medicinal chemistry 20080101

• Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone.

  The oncologist 20080101

• Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

  The oncologist 20080101

• Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.

  The oncologist 20080101

• Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland.

  The Ulster medical journal 20080101

• From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

  Current medicinal chemistry 20080101

• Protein tyrosine phosphatases: new markers and targets in oncology?

  Current oncology (Toronto, Ont.) 20080101

• Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.

  PloS one 20080101

• Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status.

  Genome biology 20080101

• siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.

  Pathobiology : journal of immunopathology, molecular and cellular biology 20080101

• Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1.

  Current medicinal chemistry 20080101

• Recurrent gefitinib-induced interstitial lung disease.

  Internal medicine (Tokyo, Japan) 20080101

• Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling.

  Cancer cell international 20080101

• Evaluation of the current knowledge limitations in breast cancer research: a gap analysis.

  Breast cancer research : BCR 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer.

  BMC cancer 20080101

• NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

  Breast cancer research : BCR 20080101

• [Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study].

  Gynakologisch-geburtshilfliche Rundschau 20080101

• A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.

  BMC cancer 20080101

• Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

  Journal of translational medicine 20080101

• Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.

  PloS one 20080101

• Access to high cost medicines in Australia: ethical perspectives.

  Australia and New Zealand health policy 20080101

• Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression.

  Cancer cell international 20080101

• Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.

  Molecular cancer 20080101

• High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.

  BMC cancer 20080101

• Her-2/neu-induced 'cytokine signature' in breast cancer.

  Advances in experimental medicine and biology 20080101

• Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer.

  PPAR research 20080101

• Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers.

  Molecular cancer 20080101

• Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.

  PPAR research 20080101

• A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

  BMC cancer 20080101

• Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma.

  BMC medical genomics 20080101

• Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.

  PloS one 20080101

• Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.

  Journal of receptor and signal transduction research 20080101

• PPARgamma and MEK Interactions in Cancer.

  PPAR research 20080101

• The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.

  Breast cancer research : BCR 20080101

• Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.

  PloS one 20080101

• Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.

  International journal of medical sciences 20080101

• Molecular targeted therapies for breast cancer treatment.

  Breast cancer research : BCR 20080101

• Promising newer molecular-targeted therapies in head and neck cancer.

  Drugs 20080101

• HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

  PloS one 20080101

• Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.

  BMC cancer 20080101

• P68 RNA helicase (DDX5) alters activity of cis- and trans-acting factors of the alternative splicing of H-Ras.

  PloS one 20080101

• EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.

  BMC cancer 20080101

• Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells.

  PPAR research 20080101

• Refractory pleural small cell carcinoma in never smoker. A case report.

  Tumori 20080101

• Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model.

  BMC cancer 20080101

• Review. EGFR mutations in non-small cell lung cancer--clinical implications.

  In vivo (Athens, Greece) 20080101

• Pooling overdispersed binomial data to estimate event rate.

  BMC medical research methodology 20080101

• Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.

  Oncology 20080101

• Trichomegaly induced by erlotinib.

  Orbit (Amsterdam, Netherlands) 20080101

• Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20080101

• Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

  PloS one 20080101

• Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.

  Sarcoma 20080101

• Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.

  Journal of experimental therapeutics & oncology 20080101

• Germline polymorphisms as modulators of cancer phenotypes.

  BMC medicine 20080101

• Functional copy-number alterations in cancer.

  PloS one 20080101

• Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK.

  Molecular cancer 20080101

• Neuropsychological testing and biomarkers in the management of brain metastases.

  Radiation oncology (London, England) 20080101

• A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.

  Radiation oncology (London, England) 20080101

• Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.

  Breast cancer research : BCR 20080101

• EGFR expression in gallbladder carcinoma in North America.

  International journal of medical sciences 20080101

• Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.

  Journal of medical case reports 20080101

• Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.

  Oncology 20080101

• Novel therapies in breast cancer: what is new from ASCO 2008.

  Journal of hematology & oncology 20080101

• Overview of advanced non-small-cell lung cancer treatment in Mexico.

  BMC proceedings 20080101

• First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.

  BMC proceedings 20080101

• Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option.

  BMC proceedings 20080101

• Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines.

  Chemotherapy 20080101

• Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.

  Chemotherapy 20080101

• EGFR-targeted therapeutics: focus on SCCHN and NSCLC.

  TheScientificWorldJournal 20080101

• Distinguishing compounds with anticancer activity by ANN using inductive QSAR descriptors.

  Bioinformation 20080101

• Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

  Breast cancer research : BCR 20080101

• The prince and the pauper. A tale of anticancer targeted agents.

  Molecular cancer 20080101

• Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.

  BMC cancer 20080101

• Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status.

  BMC research notes 20080101

• Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.

  PloS one 20080101

• Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.

  Journal of experimental & clinical cancer research : CR 20080101

• [Molecular diagnosis in oncology].

  Molekuliarnaia biologiia 20080101

• Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.

  PloS one 20080101

• Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.

  PloS one 20080101

• Standardized high-throughput evaluation of cell-based compound screens.

  BMC bioinformatics 20080101

• ErbB3 is required for ductal morphogenesis in the mouse mammary gland.

  Breast cancer research : BCR 20080101

• The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.

  PloS one 20080101

• A functional Notch-survivin gene signature in basal breast cancer.

  Breast cancer research : BCR 20080101

• Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.

  Anticancer research 20080101

• Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

  Breast cancer research : BCR 20080101

• Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.

  Seminars in thoracic and cardiovascular surgery 20080101

• Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

  Breast cancer research : BCR 20080101

• The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population.

  BMC cancer 20080101

• Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.

  BMC cancer 20080101

• ErbB antagonists patenting: 'playing chess with cancer'.

  Recent patents on biotechnology 20080101

• Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).

  PloS one 20080101

• PPARgamma, PTEN, and the Fight against Cancer.

  PPAR research 20080101

• The management of cancer in the elderly: targeted therapies in oncology.

  Immunity & ageing : I & A 20080101

• Clinical Use of PPARgamma Ligands in Cancer.

  PPAR research 20080101

• Integration of endocrine therapy with targeted agents.

  Breast cancer research : BCR 20080101

• Evaluation of biological agents targeted at early-stage disease.

  Breast cancer research : BCR 20080101

• Optimizing the implementation of future treatment using surrogate end-points.

  Breast cancer research : BCR 20080101

• Molecular underpinnings of the targeted therapy for cancer.

  Acta poloniae pharmaceutica 20080101

• [Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].

  Pneumonologia i alergologia polska 20080101

• [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention].

  Pneumologia (Bucharest, Romania) 20080101

• Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.

  Journal of carcinogenesis 20080101

• Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report.

  Chang Gung medical journal 20080101

• Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.

  Clinical lung cancer 20080101

• Predicting differences in gene regulatory systems by state space models.

  Genome informatics. International Conference on Genome Informatics 20080101

• Sorafenib in the treatment of advanced hepatocellular carcinoma.

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20080101

• Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

  Gene regulation and systems biology 20080101

• Gene copy number analysis for family data using semiparametric copula model.

  Bioinformatics and biology insights 20080101

• Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.

  Drug design, development and therapy 20080101

• Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.

  Journal of cancer epidemiology 20080101

• The epidermal growth factor receptor family in breast cancer.

  OncoTargets and therapy 20080101

• Targeted treatment of advanced and metastaticbreast cancer with lapatinib.

  OncoTargets and therapy 20080101

• Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.

  Molecular medicine reports 20080101

• Two allele-specific PCR assays for screening epidermal growth factor receptor gene hotspot mutations in lung adenocarcinoma.

  Molecular medicine reports 20080101

• HER1-4 expression status correlates with the efficacy of gefitinib treatment and tumor cell proliferative activity in non-small cell lung cancer.

  Molecular medicine reports 20080101

• Cancer care in China: A general review.

  Biomedical imaging and intervention journal 20080101

• Found in translation: Integrating laboratory and clinical oncology research.

  Biomedical imaging and intervention journal 20080101

• Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation.

  Clinical medicine. Oncology 20080101

• A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.

  Clinical medicine. Oncology 20080101

• Serum messenger RNA as a biomarker and its clinical usefulness in malignancies.

  Clinical medicine. Oncology 20080101

• Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.

  Ecancermedicalscience 20080101

• 2007 EORTC-NCI-ASCO annual meeting: molecular markers in cancer.

  Ecancermedicalscience 20080101

• [VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20071220

• [Relationship between mutations of epidermal growth factor receptor in the plasma and pleural effusion and responses to gefitinib in advanced pretreated non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20071220

• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

  Proceedings of the National Academy of Sciences of the United States of America 20071218

• Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.

  Cancer 20071215

• Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.

  Cancer 20071215

• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  Cancer research 20071215

• 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.

  British journal of cancer 20071203

• Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

  Breast cancer research and treatment 20071201

• A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.

  Investigational new drugs 20071201

• Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20071201

• Gefitinib administration in a patient with lung cancer undergoing hemodialysis.

  Lung cancer (Amsterdam, Netherlands) 20071201

• Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.

  Leukemia 20071201

• EGFR exon 20 insertion mutation in Japanese lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20071201

• Targeting EGFR in bladder cancer.

  World journal of urology 20071201

• Differential expression of novel tyrosine kinase substrates during breast cancer development.

  Molecular & cellular proteomics : MCP 20071201

• Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.

  Cancer science 20071201

• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

  Cancer science 20071201

• Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20071201

• Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development.

  Diabetologia 20071201

• Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.

  Journal of magnetic resonance imaging : JMRI 20071201

• Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.

  International journal of oncology 20071201

• Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• [Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].

  Ai zheng = Aizheng = Chinese journal of cancer 20071201

• [Effect of gefitinib on radiosensitivity of gastric cancer cell lines].

  Ai zheng = Aizheng = Chinese journal of cancer 20071201

• [In these days molecule target drug in advanced non-small cell lung cancer].

  Kyobu geka. The Japanese journal of thoracic surgery 20071201

• The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells.

  Molecular cancer therapeutics 20071201

• Livedo reticularis with retiform purpura associated with gefitinib (Iressa).

  International journal of dermatology 20071201

• [A case of lung cancer with alkaline phosphatase flare phenomenon during gefitinib therapy].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20071201

• [Adverse drug reactions induced by molecular target therapy].

  Arerugi = [Allergy] 20071201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071201

• Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.

  Oncology (Williston Park, N.Y.) 20071201

• Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.

  Growth factors (Chur, Switzerland) 20071201

• [Gefitinib in the treatment of refractory non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071201

• [Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071201

• Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.

  Therapeutics and clinical risk management 20071201

• Review of erlotinib in the treatment of advanced non-small cell lung cancer.

  Biologics : targets & therapy 20071201

• Targeted therapies in the management of metastatic bladder cancer.

  Biologics : targets & therapy 20071201

• Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

  World journal of gastroenterology 20071128

• [Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].

  Zhonghua yi xue za zhi 20071120

• Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.

  Cancer letters 20071118

• Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.

  Bioorganic & medicinal chemistry letters 20071115

• Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

  Cancer research 20071115

• Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a 'never-smoked' female patient with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20071101

• Hydrocortisone and indomethacin negatively modulate EGF-R signaling in human fetal intestine.

  Pediatric research 20071101

• Diffuse glioma growth: a guerilla war.

  Acta neuropathologica 20071101

• PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

  International journal of oncology 20071101

• Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression.

  Oncology reports 20071101

• Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.

  Oncology reports 20071101

• Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071101

• Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

  Cancer research 20071101

• Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.

  Journal of pediatric hematology/oncology 20071101

• Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics.

  Molecular cancer therapeutics 20071101

• Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.

  Expert review of molecular diagnostics 20071101

• [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives.

  Anti-cancer agents in medicinal chemistry 20071101

• Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.

  Current cancer drug targets 20071101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071101

• [Drug-induced pulmonary edema].

  Nihon rinsho. Japanese journal of clinical medicine 20071028

• [Predictive factors of gefitinib response and survival in Chinese patients with local advanced or metastatic non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20071020

• [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.

  British journal of cancer 20071008

• Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.

  British journal of cancer 20071008

• Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

  British journal of cancer 20071008

• ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.

  British journal of cancer 20071008

• Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20071001

• Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

  Lung cancer (Amsterdam, Netherlands) 20071001

• Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.

  Lung cancer (Amsterdam, Netherlands) 20071001

• Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

  Lung cancer (Amsterdam, Netherlands) 20071001

• GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  Cancer science 20071001

• A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.

  BJU international 20071001

• A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.

  Cancer research 20071001

• Femara and the future: tailoring treatment and combination therapies with Femara.

  Breast cancer research and treatment 20071001

• Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.

  Molecular cancer therapeutics 20071001

• Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.

  Molecular cancer therapeutics 20071001

• Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20071001

• Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.

  PLoS medicine 20071001

• Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.

  Archives of otolaryngology--head & neck surgery 20071001

• [An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

  PLoS medicine 20071001

• Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.

  PLoS medicine 20071001

• Why do cancer cells become 'addicted' to oncogenic epidermal growth factor receptor?

  PLoS medicine 20071001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071001

• [Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer].

  Annales de pathologie 20071001

• [Tyrosine kinase inhibitors in the management of non-small cell lung cancer].

  Revue des maladies respiratoires 20071001

• Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.

  Journal of medicinal chemistry 20070920

• Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.

  British journal of cancer 20070911

• Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

  British journal of cancer 20070911

• Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

  British journal of cancer 20070911

• The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.

  European journal of pharmacology 20070910

• [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].

  Ugeskrift for laeger 20070910

• Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

  Cancer letters 20070908

• Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.

  Pediatric blood & cancer 20070901

• Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.

  Oral oncology 20070901

• Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.

  Lung cancer (Amsterdam, Netherlands) 20070901

• Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.

  Journal of cellular physiology 20070901

• Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.

  International journal of cancer 20070901

• Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20070901

• Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.

  Gynecologic oncology 20070901

• Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.

  Journal of radiation research 20070901

• Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells.

  American journal of physiology. Gastrointestinal and liver physiology 20070901

• A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.

  Current medical research and opinion 20070901

• Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.

  Anti-cancer drugs 20070901

• EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.

  International journal of oncology 20070901

• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Protein expression and mutational analysis of epidermal growth factor receptor in renal angiomyolipomas.

  Pathology international 20070901

• Detection of gene point mutation in paraffin sections using in situ loop-mediated isothermal amplification.

  Pathology international 20070901

• Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20070901

• Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations.

  Applied immunohistochemistry & molecular morphology : AIMM 20070901

• From cell signaling to cancer therapy.

  Acta pharmacologica Sinica 20070901

• Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070901

• Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070901

• The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070901

• Pulmonary toxicity associated with erlotinib.

  Chest 20070901

• A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

  Journal of Korean medical science 20070901

• On the diversity of biological therapeutics.

  Biologics : targets & therapy 20070901

• Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab.

  Biologics : targets & therapy 20070901

• Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.

  Biologics : targets & therapy 20070901

• Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma.

  Biologics : targets & therapy 20070901

• EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.

  Oncogene 20070823

• Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.

  British journal of cancer 20070820

• Targeting HER proteins in cancer therapy and the role of the non-target HER3.

  British journal of cancer 20070820

• Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.

  International journal of pharmaceutics 20070816

• First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.

  Cancer 20070815

• Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.

  Cancer research 20070815

• Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

• [Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)].

  Orvosi hetilap 20070812

• Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.

  Human mutation 20070801

• Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20070801

• Chemical radiosensitizers for use in radiotherapy.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801

• Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

  Cancer science 20070801

• Are MAP kinases drug targets? Yes, but difficult ones.

  ChemMedChem 20070801

• Gene expression profiling in sarcomas.

  Critical reviews in oncology/hematology 20070801

• To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.

  Lung cancer (Amsterdam, Netherlands) 20070801

• Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

  Cancer 20070801

• Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.

  Oncology reports 20070801

• Personalized medicine and proteomics: lessons from non-small cell lung cancer.

  Journal of proteome research 20070801

• Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells.

  Acta pharmacologica Sinica 20070801

• Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells.

  Acta pharmacologica Sinica 20070801

• Necrotizing vasculitis due to gefitinib (Iressa).

  International journal of dermatology 20070801

• Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.

  Cancer investigation 20070801

• Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.

  Cornea 20070801

• Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.

  Molecular cancer therapeutics 20070801

• HKI-272 in non small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• The place of targeted therapy in the patient management of non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20070801

• How could pharmacogenomics help improve patient survival?

  Lung cancer (Amsterdam, Netherlands) 20070801

• [Gefitinib and epidermal growth factor receptor gene mutation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070801

• EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.

  Neoplasia (New York, N.Y.) 20070801

• Targeted therapy in rectal cancer.

  Oncology (Williston Park, N.Y.) 20070801

• [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070801

• A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.

  Therapeutics and clinical risk management 20070801

• The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

  Current genomics 20070801

• Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.

  British journal of cancer 20070716

• Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.

  Cancer research 20070715

• Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.

  British journal of cancer 20070702

• Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.

  British journal of cancer 20070702

• The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

  European radiology 20070701

• Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: application to a trans-epithelial transport study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070701

• Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.

  Gynecologic oncology 20070701

• An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

  International journal of molecular medicine 20070701

• Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.

  Current medical research and opinion 20070701

• Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells.

  Proteomics 20070701

• Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?

  Current oncology reports 20070701

• An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.

  Onkologie 20070701

• Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070701

• Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070701

• Endothelial growth factor receptor inhibition after radiotherapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070701

• EGFR targeting of solid tumors.

  Cancer control : journal of the Moffitt Cancer Center 20070701

• Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.

  Cancer research 20070701

• Lessons learned in the development of targeted therapy for malignant gliomas.

  Molecular cancer therapeutics 20070701

• Erlotinib in non-small cell lung cancer treatment: current status and future development.

  The oncologist 20070701

• [Head and neck: molecular-targeted therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070701

• Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation.

  Experimental & molecular medicine 20070630

• Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells.

  Cancer letters 20070628

• [Predictive markers in breast cancer treatment--focusing on a recent topic 'basal-like breast cancer'].

  Nihon rinsho. Japanese journal of clinical medicine 20070628

• Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells.

  Biochemical and biophysical research communications 20070622

• Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070620

• Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070620

• [Target therapy of gefitinib in advanced adenocarcinoma of the lung].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20070620

• Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

  Cancer research 20070615

• Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070615

• Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070615

• [What is drug-epidemiology?].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070610

• [Major drug-induced lung diseases: adverse effects of newly developed molecular targeted drugs].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070610

• Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?

  Journal of the National Cancer Institute 20070606

• Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

  Journal of the National Cancer Institute 20070606

• A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.

  British journal of cancer 20070604

• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.

  Journal of cellular physiology 20070601

• EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20070601

• Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.

  BJU international 20070601

• Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20070601

• Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

  Bioorganic & medicinal chemistry 20070601

• Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070601

• Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070601

• Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

  Molecular cancer therapeutics 20070601

• The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• [Medical treatment for stage III non-small-cell lung cancer (NSCLC)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• Canadian recommendations for the treatment of glioblastoma multiforme.

  Current oncology (Toronto, Ont.) 20070601

• Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer.

  Journal of Korean medical science 20070601

• [Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].

  Revue de pneumologie clinique 20070601

• Take-home message: are we 'off target'?

  Drug news & perspectives 20070601

• Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).

  Therapeutics and clinical risk management 20070601

• Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors.

  Biomarkers in medicine 20070601

• Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.

  British journal of cancer 20070521

• Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.

  British journal of cancer 20070521

• MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

  Science (New York, N.Y.) 20070518

• Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.

  Oncogene 20070517

• KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

• Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

• AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

• Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

  Journal of the National Cancer Institute 20070502

• AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.

  Breast cancer research and treatment 20070501

• Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats.

  The Prostate 20070501

• Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.

  The Prostate 20070501

• Identification of endosomal epidermal growth factor receptor signaling targets by functional organelle proteomics.

  Molecular & cellular proteomics : MCP 20070501

• Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.

  Cancer 20070501

• The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.

  Histochemistry and cell biology 20070501

• CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

  Virchows Archiv : an international journal of pathology 20070501

• Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.

  European journal of cancer (Oxford, England : 1990) 20070501

• Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.

  Cancer 20070501

• An unusual terminal hair growth on the nose tip associated with gefitinib therapy.

  The British journal of dermatology 20070501

• Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.

  Oncology reports 20070501

• Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.

  Diagnostic cytopathology 20070501

• Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.

  Pharmacogenetics and genomics 20070501

• Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070501

• Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070501

• The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070501

• Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070501

• Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.

  Expert review of molecular diagnostics 20070501

• Epidermal growth factor receptor mutations in lung cancers.

  Pathology international 20070501

• Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas.

  Pathology international 20070501

• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

  Cancer biology & therapy 20070501

• [Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients.

  European journal of cancer care 20070501

• ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway.

  Molecular cancer therapeutics 20070501

• [Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer].

  Yi chuan = Hereditas 20070501

• [Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].

  Zhonghua nei ke za zhi 20070501

• [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].

  Nederlands tijdschrift voor geneeskunde 20070428

• Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.

  British journal of cancer 20070423

• Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070420

• Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.

  Journal of the National Cancer Institute 20070418

• Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.

  Experimental cell research 20070415

• Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070415

• Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  British journal of cancer 20070410

• Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.

  Cancer chemotherapy and pharmacology 20070401

• Gefitinib concentrations in human glioblastoma tissue.

  Journal of neuro-oncology 20070401

• Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).

  Gynecologic oncology 20070401

• Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

  International journal of cancer 20070401

• Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070401

• Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070401

• EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

  Critical reviews in oncology/hematology 20070401

• A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

  Cancer 20070401

• Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.

  Nature chemical biology 20070401

• Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.

  Molecular cancer therapeutics 20070401

• Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401

• The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401

• [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].

  Ai zheng = Aizheng = Chinese journal of cancer 20070401

• [Outpatient chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.

  The American journal of the medical sciences 20070401

• [Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status].

  Pneumologie (Stuttgart, Germany) 20070401

• Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.

  PLoS medicine 20070401

• Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

  Neoplasia (New York, N.Y.) 20070401

• Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.

  Cancer biology & therapy 20070401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• [EGFR gene mutation status among lung cancer patients in China].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070401

• [EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070401

• Synthesis of gefitinib from methyl 3-hydroxy-4-methoxy-benzoate.

  Molecules (Basel, Switzerland) 20070328

• Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

  British journal of cancer 20070326

• Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.

  British journal of cancer 20070326

• The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.

  International journal of cancer 20070315

• Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.

  British journal of cancer 20070312

• hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.

  British journal of cancer 20070312

• EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

  Oncogene 20070308

• A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20070301

• Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

  Journal of cancer research and clinical oncology 20070301

• Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

  Journal of medical genetics 20070301

• Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy.

  Journal of the American Academy of Dermatology 20070301

• Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells.

  ChemMedChem 20070301

• Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.

  Cancer science 20070301

• Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.

  Cancer science 20070301

• Small cell lung cancer and targeted therapies.

  Current opinion in oncology 20070301

• Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

  Cancer biology & therapy 20070301

• Why we will need to learn new skills to control cancer.

  Internal medicine journal 20070301

• Clairvoyance or reliable prediction of the future?

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

  Cancer research 20070301

• Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.

  Cancer research 20070301

• [Lung cancer: targeted therapy].

  Pneumologie (Stuttgart, Germany) 20070301

• The EGF receptor Hokey-Cokey.

  Cancer cell 20070301

• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  Cancer cell 20070301

• [Lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.

  Molecular cancer therapeutics 20070301

• Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.

  Molecular cancer therapeutics 20070301

• Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.

  Urology 20070301

• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  The oncologist 20070301

• Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.

  DNA and cell biology 20070301

• [A case of juvenile lung cancer with suspected progeroid syndrome and mental retardation].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20070301

• Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.

  Internal and emergency medicine 20070301

• Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.

  Cancer research and treatment : official journal of Korean Cancer Association 20070301

• A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.

  British journal of cancer 20070226

• Medicalisation of race.

  Lancet (London, England) 20070224

• New insights into oncogene addiction found.

  Journal of the National Cancer Institute 20070221

• Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.

  Cancer research 20070215

• A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

  British journal of cancer 20070212

• Lung cancer in never smokers: a review.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070210

• Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070210

• Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.

  The Journal of biological chemistry 20070209

• Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.

  Cancer chemotherapy and pharmacology 20070201

• Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients.

  Journal of cancer research and clinical oncology 20070201

• Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.

  Molecular pharmacology 20070201

• Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.

  Annals of surgical oncology 20070201

• Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.

  Journal of cellular physiology 20070201

• Identification of EGFR mutations in esophageal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20070201

• Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.

  Oncology reports 20070201

• New agents in development for breast cancer.

  Current opinion in obstetrics & gynecology 20070201

• Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer.

  Cancer science 20070201

• Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.

  Cancer science 20070201

• Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.

  Expert opinion on investigational drugs 20070201

• p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.

  Cancer research 20070201

• Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.

  Cancer research 20070201

• EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors.

  Cancer genetics and cytogenetics 20070201

• [Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].

  Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 20070201

• Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

• [A case of multidrug-resistant non-small cell lung cancer responding to TS-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• [International clinical trials for a medical oncologist in Japan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• From bytes to bedside: data integration and computational biology for translational cancer research.

  PLoS computational biology 20070201

• [A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20070201

• Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.

  Clinical lung cancer 20070201

• [Gefitinib target treatment in non-small cell lung cancer].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20070201

• [New biological treatments for lung cancer].

  Revue de pneumologie clinique 20070201

• 'Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?'.

  Current treatment options in oncology 20070201

• Optimal duration of chemotherapy in advanced non-small cell lung cancer.

  Current treatment options in oncology 20070201

• Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity.

  British journal of cancer 20070129

• Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?

  British journal of cancer 20070129

• c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays.

  British journal of cancer 20070129

• Evaluating the activity of temsirolimus in neuroendocrine cancer.

  British journal of cancer 20070115

• Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.

  Cancer research 20070115

• Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• Acute drug induced hepatitis due to erlotinib.

  JOP : Journal of the pancreas 20070109

• Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.

  The European respiratory journal 20070101

• Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.

  International journal of cancer 20070101

• Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells.

  Pulmonary pharmacology & therapeutics 20070101

• Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).

  International journal of cancer 20070101

• Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.

  Lung cancer (Amsterdam, Netherlands) 20070101

• EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).

  Lung cancer (Amsterdam, Netherlands) 20070101

• Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.

  BJU international 20070101

• Detection of epidermal growth factor receptor variations by partially denaturing HPLC.

  Clinical chemistry 20070101

• Druggable signaling proteins.

  Methods in molecular biology (Clifton, N.J.) 20070101

• SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

  The American journal of pathology 20070101

• Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.

  BMC cancer 20070101

• From actually toxic to highly specific--novel drugs against poxviruses.

  Virology journal 20070101

• Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas.

  Breast cancer research : BCR 20070101

• Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20070101

• [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].

  Bulletin du cancer 20070101

• Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system.

  Molecular cancer therapeutics 20070101

• Molecular correlates of gefitinib responsiveness in human bladder cancer cells.

  Molecular cancer therapeutics 20070101

• [Associations of tyrosine kinase inhibitors with chemotherapy].

  Revue de pneumologie clinique 20070101

• An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.

  Breast cancer research : BCR 20070101

• Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.

  Molecular cancer research : MCR 20070101

• [Drug-induced lung injury].

  Arerugi = [Allergy] 20070101

• HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

  Breast cancer research : BCR 20070101

• Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

  The oncologist 20070101

• Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• [A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20070101

• Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.

  Harvard health letter 20070101

• Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20070101

• Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

  BMC cancer 20070101

• The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism.

  Annals of the New York Academy of Sciences 20070101

• Contribution of oncoproteomics to cancer biomarker discovery.

  Molecular cancer 20070101

• Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070101

• Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070101

• A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII.

  Molecular cancer 20070101

• Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.

  BMC cancer 20070101

• Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.

  PloS one 20070101

• Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.

  The International journal of biological markers 20070101

• Pharmacology of epidermal growth factor inhibitors.

  The International journal of biological markers 20070101

• The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor.

  The International journal of biological markers 20070101

• The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.

  The International journal of biological markers 20070101

• Epidermal growth factor receptor inhibitors in non-small cell lung cancer.

  Drugs 20070101

• Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.

  Breast cancer research : BCR 20070101

• [Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070101

• Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

  BMC cancer 20070101

• EGFR and HER-2 antagonists in breast cancer.

  Anticancer research 20070101

• Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer.

  Anticancer research 20070101

• A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers.

  BMC genomics 20070101

• [Clinical importance of angiogenesis and angiogenic factors in oncohematology].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20070101

• Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.

  The Journal of steroid biochemistry and molecular biology 20070101

• Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.

  BMC cancer 20070101

• Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.

  Anticancer research 20070101

• [Role of targeted therapy in the treatment of squamous cell head and neck cancer].

  Magyar onkologia 20070101

• EGFR associated expression profiles vary with breast tumor subtype.

  BMC genomics 20070101

• Identification of structural aberrations in cancer by SNP array analysis.

  Genome biology 20070101

• Targeting the epidermal growth factor receptor in colorectal carcinoma.

  Cancer nursing 20070101

• Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

  BMC cancer 20070101

• Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

  Breast cancer research : BCR 20070101

• Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.

  Anticancer research 20070101

• A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.

  Anticancer research 20070101

• Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

  PloS one 20070101

• Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.

  Skin therapy letter 20070101

• The complement of protein kinases of the microsporidium Encephalitozoon cuniculi in relation to those of Saccharomyces cerevisiae and Schizosaccharomyces pombe.

  BMC genomics 20070101

• Exfoliative eruption secondary to gefitinib (ZD1839).

  Dermatology (Basel, Switzerland) 20070101

• Gefitinib-induced pneumonitis in non-small cell lung cancer: radiological and clinical findings in five patients.

  Clinical imaging 20070101

• The LeFE algorithm: embracing the complexity of gene expression in the interpretation of microarray data.

  Genome biology 20070101

• Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer.

  International journal of radiation oncology, biology, physics 20070101

• Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.

  Breast cancer research : BCR 20070101

• Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.

  Molecular cancer 20070101

• EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

  Drugs 20070101

• Protein kinase inhibitors: structural insights into selectivity.

  Current pharmaceutical design 20070101

• Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis.

  Internal medicine (Tokyo, Japan) 20070101

• Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.

  Acta oncologica (Stockholm, Sweden) 20070101

• Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome.

  World journal of surgical oncology 20070101

• Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.

  Molecular cancer 20070101

• Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors.

  Radiation oncology (London, England) 20070101

• Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20070101

• [Targeting ErbB receptors in breast cancer].

  Bulletin du cancer 20070101

• [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].

  Bulletin du cancer 20070101

• Withdrawn paper: Li, M.D.; Zheng, Y.G.; Ji, M. Synthesis of gefitinib from methyl 3-hydroxy-4-methoxybenzoate. Molecules 2007,12,673-678.

  Molecules (Basel, Switzerland) 20070101

• Neurotrophin receptors expression and JNK pathway activation in human astrocytomas.

  BMC cancer 20070101

• Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

  Breast cancer research : BCR 20070101

• Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

  Breast cancer research : BCR 20070101

• Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.

  Molecular systems biology 20070101

• Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report.

  Journal of medical case reports 20070101

• Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations.

  PloS one 20070101

• Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease.

  Internal medicine (Tokyo, Japan) 20070101

• Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.

  Molecular systems biology 20070101

• [NSCLC: update on second line therapy following ASCO 2007].

  Wiener medizinische Wochenschrift (1946) 20070101

• Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.

  Oncology 20070101

• Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.

  Oncology research 20070101

• Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer.

  Anticancer research 20070101

• Long-term survivors after chemotherapy in advanced non-small cell lung cancer.

  Anticancer research 20070101

• Late fatal recurrence in gefitinib-treated NSCLC patients.

  Tuberkuloz ve toraks 20070101

• Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors.

  Endocrine pathology 20070101

• Peroxisome proliferator-activated receptors in lung cancer.

  PPAR research 20070101

• Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.

  Clinical & developmental immunology 20070101

• Molecular targeting in pancreatic cancer.

  Reviews on recent clinical trials 20070101

• Epidermal growth factor receptor-directed therapy in esophageal cancer.

  Oncology 20070101

• Personalized medicine: challenging pharmaceutical and diagnostic company business models.

  McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 20070101

• Personalized medicine.

  McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 20070101

• Neglected respiratory toxicity caused by cancer therapy.

  The open respiratory medicine journal 20070101

• Cancer as a system failure.

  Cancer informatics 20070101

• Data mining for gene networks relevant to poor prognosis in lung cancer via backward-chaining rule induction.

  Cancer informatics 20070101

• Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays.

  Cancer informatics 20070101

• Methodology and applications of disease biomarker identification in human serum.

  Biomarker insights 20070101

• Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.

  Biomarker insights 20070101

• New therapeutic targets in the treatment of prostate cancer.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061215

• Update on epidermal growth factor receptor mutations in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061215

• Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061215

• Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210

• CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.

  Journal of the National Cancer Institute 20061206

• Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

  Journal of the National Cancer Institute 20061206

• Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.

  British journal of cancer 20061204

• Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.

  British journal of cancer 20061204

• Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells.

  Molecular endocrinology (Baltimore, Md.) 20061201

• Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.

  International journal of radiation oncology, biology, physics 20061201

• Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.

  International journal of cancer 20061201

• Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?

  Cancer treatment reviews 20061201

• Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder.

  Laboratory investigation; a journal of technical methods and pathology 20061201

• Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.

  Lung cancer (Amsterdam, Netherlands) 20061201

• Should every lung cancer patient be tested for EGFR mutation?

  Expert opinion on therapeutic targets 20061201

• New approaches to molecular cancer therapeutics.

  Nature chemical biology 20061201

• Chemotherapy and the treatment of brain metastases.

  Hematology/oncology clinics of North America 20061201

• Aromatase and breast cancer.

  The Journal of steroid biochemistry and molecular biology 20061201

• Lung cancer: computerized quantification of tumor response--initial results.

  Radiology 20061201

• Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.

  The FEBS journal 20061201

• Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061201

• Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061201

• Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.

  Cancer research 20061201

• Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

  Cancer research 20061201

• [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].

  Ai zheng = Aizheng = Chinese journal of cancer 20061201

• Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

  PLoS medicine 20061201

• Resistance to gefitinib.

  International journal of clinical oncology 20061201

• Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.

  Molecular cancer research : MCR 20061201

• Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases.

  Thyroid : official journal of the American Thyroid Association 20061201

• Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).

  Onkologie 20061201

• Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.

  Onkologie 20061201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061201

• Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.

  Clinical lung cancer 20061201

• Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.

  Clinical lung cancer 20061201

• Growth factor receptor interplay and resistance in cancer.

  Endocrine-related cancer 20061201

• Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.

  Endocrine-related cancer 20061201

• Role of erlotinib in the management of pancreatic cancer.

  Therapeutics and clinical risk management 20061201

• EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

  British journal of cancer 20061120

• Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.

  British journal of cancer 20061120

• Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.

  International journal of cancer 20061115

• A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

  British journal of cancer 20061106

• Mathematical models of targeted cancer therapy.

  British journal of cancer 20061106

• Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

  British journal of cancer 20061106

• BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20061101

• Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.

  Cancer chemotherapy and pharmacology 20061101

• Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.

  Journal of cancer research and clinical oncology 20061101

• Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations.

  Proteins 20061101

• Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061101

• Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

  Lung cancer (Amsterdam, Netherlands) 20061101

• Biology and management of malignant pleural mesothelioma.

  European journal of cancer (Oxford, England : 1990) 20061101

• Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061101

• Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.

  International journal of oncology 20061101

• Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.

  The British journal of dermatology 20061101

• Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.

  Respirology (Carlton, Vic.) 20061101

• Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.

  Respirology (Carlton, Vic.) 20061101

• Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma.

  Respirology (Carlton, Vic.) 20061101

• Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

  Langenbeck's archives of surgery 20061101

• Erlotinib-induced breast cancer regression.

  The Annals of pharmacotherapy 20061101

• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061101

• Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061101

• Defining clinically relevant molecular subsets of lung cancer.

  Cancer chemotherapy and pharmacology 20061101

• Protein kinases as drug targets in cancer.

  Current cancer drug targets 20061101

• [Meningeal carcinomatosis in patients with lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20061101

• Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib.

  Systems biology 20061101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061101

• The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management.

  Revue des maladies respiratoires 20061101

• Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.

  Cancer biology & therapy 20061101

• The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• Predicted mechanisms of resistance to mTOR inhibitors.

  British journal of cancer 20061023

• A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

  British journal of cancer 20061023

• Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.

  British journal of cancer 20061023

• Molecular on/off switch.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• [Primary result of the efficacy and tolerance of gefitinib in advanced non-small cell lung cancer patients with brain metastasis].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20061020

• [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20061020

• Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.

  Cancer 20061015

• Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

  Cancer 20061015

• [Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].

  Zhonghua yi xue za zhi 20061010

• Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

  British journal of cancer 20061009

• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  The Journal of clinical investigation 20061002

• Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.

  Cancer chemotherapy and pharmacology 20061001

• Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.

  European journal of nuclear medicine and molecular imaging 20061001

• L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061001

• Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.

  Laboratory investigation; a journal of technical methods and pathology 20061001

• Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis.

  American journal of clinical pathology 20061001

• Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ('Iressa') and trastuzumab ('Herceptin').

  International journal of radiation oncology, biology, physics 20061001

• Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.

  Cancer biology & therapy 20061001

• [Molecular diagnostic and targeted therapy--'Barking dogs are going to bite': presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].

  Zentralblatt fur Gynakologie 20061001

• Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.

  The American journal of pathology 20061001

• Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

  Journal of the American Academy of Dermatology 20061001

• Treatment of gefitinib-associated folliculitis.

  Journal of the American Academy of Dermatology 20061001

• Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice.

  Journal of clinical gastroenterology 20061001

• HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta.

  Cancer research 20061001

• Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.

  Cancer research 20061001

• A case of acute promyelocytic leukemia during gefitinib treatment.

  International journal of hematology 20061001

• Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• [Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• A case of leukemic pleural infiltration in atypical chronic myeloid leukemia.

  Journal of Korean medical science 20061001

• Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20061001

• Effect of gefitinib on brain metastases from non-small cell lung cancer.

  Neurologia medico-chirurgica 20061001

• [Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].

  Actas dermo-sifiliograficas 20061001

• [Anti-EGFR therapy: towards a 'à la carte' targeting of hepatocellular carcinoma].

  Gastroenterologie clinique et biologique 20061001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061001

• Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061001

• Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061001

• Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061001

• Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061001

• Social medicine in the twenty-first century.

  PLoS medicine 20061001

• Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060920

• Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

  British journal of cancer 20060918

• Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.

  British journal of cancer 20060918

• Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

  Bioorganic & medicinal chemistry letters 20060915

• Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.

  Cancer 20060915

• Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910

• Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.

  British journal of cancer 20060904

• Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.

  Pediatric blood & cancer 20060901

• Gefitinib prevents bleomycin-induced lung fibrosis in mice.

  American journal of respiratory and critical care medicine 20060901

• Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

  Lung cancer (Amsterdam, Netherlands) 20060901

• Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060901

• Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.

  Lung cancer (Amsterdam, Netherlands) 20060901

• Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.

  Oncology reports 20060901

• Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer.

  International journal of oncology 20060901

• Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060901

• New molecular targeted therapies in thyroid cancer.

  Anti-cancer drugs 20060901

• Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20060901

• Pharmacy benefit spending on oral chemotherapy drugs.

  Journal of managed care pharmacy : JMCP 20060901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060901

• Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

  Clinical colorectal cancer 20060901

• [Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20060901

• [Is it possible to treat bronchial carcinoma without chemotherapy?].

  Revue des maladies respiratoires 20060901

• PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Current status of clinical trials for glioblastoma.

  Reviews on recent clinical trials 20060901

• Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.

  World journal of gastroenterology 20060828

• Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.

  The Journal of biological chemistry 20060825

• Influence of whole-brain radiotherapy on remission of brain metastases.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060820

• Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

  Cancer research 20060815

• Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification.

  Cancer research 20060815

• Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

  Cancer research 20060815

• Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060815

• Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma.

  British journal of cancer 20060807

• In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.

  The Biochemical journal 20060801

• Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.

  Journal of cellular physiology 20060801

• Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.

  Bioorganic & medicinal chemistry letters 20060801

• 5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity.

  Bioorganic & medicinal chemistry letters 20060801

• Gefitinib efficacy in relapsed small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Predicting the outcome of chemotherapy for lung cancer.

  Current opinion in pharmacology 20060801

• Synchronous multiple primary lung cancers with different response to gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Targeted induction of apoptosis for cancer therapy: current progress and prospects.

  Trends in molecular medicine 20060801

• Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.

  Japanese journal of clinical oncology 20060801

• Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.

  The Journal of urology 20060801

• Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.

  Journal of the American Academy of Dermatology 20060801

• EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

  Cancer science 20060801

• Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

  Molecular cancer research : MCR 20060801

• Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.

  Cancer research 20060801

• Epidermal growth factor receptor targeting in cancer.

  Seminars in oncology 20060801

• Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma.

  Journal of neuropathology and experimental neurology 20060801

• Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060801

• Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.

  International journal of dermatology 20060801

• [Lung cancer with bone metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.

  Anti-cancer drugs 20060801

• [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801

• [Epithelial growth factor receptor (EGFR) exon double-sequencing analysis in NSClC].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801

• Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.

  British journal of cancer 20060717

• Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.

  International journal of cancer 20060715

• Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Xenografts of human hepatocellular carcinoma: a useful model for testing drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Genomic approaches to lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

  Neurology 20060711

• Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model.

  The Journal of surgical research 20060701

• Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.

  Investigational new drugs 20060701

• Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.

  Lung cancer (Amsterdam, Netherlands) 20060701

• Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20060701

• Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060701

• [New substances in the therapy of head and neck cancer].

  Laryngo- rhino- otologie 20060701

• Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development.

  PLoS medicine 20060701

• Biological agents versus chemotherapy in the treatment of colorectal cancer.

  Expert opinion on pharmacotherapy 20060701

• Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060701

• Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060701

• Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060701

• Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060701

• A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

  The Journal of molecular diagnostics : JMD 20060701

• High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.

  Cancer science 20060701

• [Current status and problems of anticancer drug-induced lung injuries].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

  Cancer cell 20060701

• Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.

  Cancer cell 20060701

• Gefitinib: a cause of pyogenic granulomalike lesions of the nail.

  Archives of dermatology 20060701

• K-ras mutations in lung cancer: the 'mysterious mutation'.

  Clinical lung cancer 20060701

• Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

  Molecular cancer therapeutics 20060701

• [Gefitinib in the treatment of advanced non-small-cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701

• Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060701

• Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060701

• [Iressa in the treatment of 24 cases of advanced non-small cell lung cancer patients who had failed to previous chemotherapy].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20060620

• Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer.

  British journal of cancer 20060619

• [Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].

  Ugeskrift for laeger 20060612

• Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060610

• [Diffuse lung diseases and biological markers in serum].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060610

• [Drug induced lung injuries in Japanese population].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060610

• [Diagnosis of and therapy for diffuse lung diseases (discussion)].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060610

• Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

  World journal of gastroenterology 20060607

• A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.

  British journal of cancer 20060605

• The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.

  British journal of cancer 20060605

• Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

  British journal of cancer 20060605

• [Cutaneous side effects of EGF-receptor inhibition and their management].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20060601

• Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

  Breast cancer research and treatment 20060601

• EGFR mutation in gefitinib-responsive small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.

  Critical reviews in oncology/hematology 20060601

• Targeting of EGFR tyrosine kinase by ZD1839 ('Iressa') in androgen-responsive prostate cancer in vitro.

  Molecular genetics and metabolism 20060601

• A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions.

  The Journal of pharmacology and experimental therapeutics 20060601

• A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20060601

• Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

  Virchows Archiv : an international journal of pathology 20060601

• Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060601

• A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060601

• Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.

  Oncology reports 20060601

• Canonical WNT signaling pathway and human AREG.

  International journal of molecular medicine 20060601

• Impact of genetic diagnostics on drug development strategy.

  Nature reviews. Drug discovery 20060601

• Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

  Genes & development 20060601

• Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.

  Human pathology 20060601

• Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601

• Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.

  Cancer research 20060601

• Where next for gefitinib in patients with lung cancer?

  The Lancet. Oncology 20060601

• Perspectives in central nervous system malignancies.

  IDrugs : the investigational drugs journal 20060601

• Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage.

  Prescrire international 20060601

• Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery.

  Journal of Korean medical science 20060601

• Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.

  Japanese journal of clinical oncology 20060601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060601

• [Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma].

  Hinyokika kiyo. Acta urologica Japonica 20060601

• [Molecular-targeted therapy for hormone-refractory prostate cancer].

  Hinyokika kiyo. Acta urologica Japonica 20060601

• Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

  Current cancer drug targets 20060601

• Targeted therapies in gynecologic cancers.

  Current cancer drug targets 20060601

• Methodological aspects of current problems in target-based anticancer drug development.

  International journal of clinical oncology 20060601

• Biological and clinical implications of EGFR mutations in lung cancer.

  International journal of clinical oncology 20060601

• Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib.

  International journal of clinical oncology 20060601

• Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060601

• [Drug-induced lung diseases].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20060601

• [Epidermal growth factor receptor inhibitors side effects].

  Actas dermo-sifiliograficas 20060601

• Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  Osaka city medical journal 20060601

• [Gefitinib in the treatment of advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060601

• Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060601

• Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060601

• Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060601

• Emerging role of MAP kinase pathways as therapeutic targets in COPD.

  International journal of chronic obstructive pulmonary disease 20060601

• Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction.

  FEBS letters 20060529

• Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.

  British journal of cancer 20060522

• Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.

  British journal of cancer 20060522

• Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Gefitinib-sensitizing mutations in esophageal carcinoma.

  The New England journal of medicine 20060518

• Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20060515

• PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.

  Cancer research 20060515

• Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060515

• Cell cycle- and apoptosis-regulatory protein-1 is involved in apoptosis signaling by epidermal growth factor receptor.

  The Journal of biological chemistry 20060512

• Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060510

• The place of VEGF inhibition in the current management of renal cell carcinoma.

  British journal of cancer 20060508

• Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.

  British journal of cancer 20060508

• Biomolecular markers of breast cancer.

  Frontiers in bioscience : a journal and virtual library 20060501

• The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

  Journal of cellular physiology 20060501

• Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck.

  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20060501

• Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.

  Molecular carcinogenesis 20060501

• Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20060501

• Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.

  Cancer 20060501

• Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.

  Lung cancer (Amsterdam, Netherlands) 20060501

• Gefitinib accumulation in glioblastoma tissue.

  Cancer biology & therapy 20060501

• Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines.

  Oncology reports 20060501

• Gefitinib: an adverse effects profile.

  Expert opinion on drug safety 20060501

• Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.

  American journal of hematology 20060501

• Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.

  Respirology (Carlton, Vic.) 20060501

• Expect the unexpected.

  The Lancet. Oncology 20060501

• Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.

  Nature medicine 20060501

• Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.

  Cancer research 20060501

• Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060501

• [A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.

  Japanese journal of clinical oncology 20060501

• Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

  Molecular cancer therapeutics 20060501

• Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.

  Clinical lung cancer 20060501

• Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.

  Clinical lung cancer 20060501

• Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.

  Oncology (Williston Park, N.Y.) 20060501

• Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.

  Clinical colorectal cancer 20060501

• Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.

  Clinical lung cancer 20060501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060501

• Second-line chemotherapy for non-small cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060501

• Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity.

  Reviews on recent clinical trials 20060501

• Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.

  British journal of cancer 20060424

• HER2 expression as a potential marker for response to therapy targeted to the EGFR.

  British journal of cancer 20060424

• Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060420

• Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060415

• Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060410

• Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

  Molecules (Basel, Switzerland) 20060410

• A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

  Cancer chemotherapy and pharmacology 20060401

• Interstitial lung disease associated with gefitinib.

  Respiratory medicine 20060401

• EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.

  Gynecologic oncology 20060401

• Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.

  Lung cancer (Amsterdam, Netherlands) 20060401

• Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.

  Cancer treatment reviews 20060401

• Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060401

• EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

  Neuro-oncology 20060401

• The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.

  International journal of oncology 20060401

• Clinical experience with gefitinib: an update.

  Critical reviews in oncology/hematology 20060401

• Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.

  Anti-cancer drugs 20060401

• Aspirin reduces adverse effects of gefitinib.

  Anti-cancer drugs 20060401

• Tailor-made chemotherapy for non-small cell lung cancer patients.

  Future oncology (London, England) 20060401

• High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.

  Human pathology 20060401

• Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060401

• Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

  Cancer research 20060401

• EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.

  Nature clinical practice. Oncology 20060401

• Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060401

• [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060401

• [A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060401

• [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060401

• [Inhibitory effects of iressa on hepatocellular carcinoma Hep-3B and HepG2 cell xenografts in nude mice].

  Ai zheng = Aizheng = Chinese journal of cancer 20060401

• The need for an individual approach to lung cancer treatment.

  PLoS medicine 20060401

• The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line.

  DNA and cell biology 20060401

• Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

  Journal of drugs in dermatology : JDD 20060401

• [Molecular targets in colon cancer].

  Therapeutische Umschau. Revue therapeutique 20060401

• Epidermal growth factor receptor-targeted agents for lung cancer.

  Cancer control : journal of the Moffitt Cancer Center 20060401

• Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.

  Oncology (Williston Park, N.Y.) 20060401

• Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

  Oncology (Williston Park, N.Y.) 20060401

• Nondermatologic adverse events associated with anti-EGFR therapy.

  Oncology (Williston Park, N.Y.) 20060401

• [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].

  Revue des maladies respiratoires 20060401

• [Gefitinib-induced perforating dermatosis].

  Actas dermo-sifiliograficas 20060401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060401

• Ethical guideposts to clinical trials in oncology.

  Current oncology (Toronto, Ont.) 20060401

• Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.

  British journal of cancer 20060327

• Preclinical study of a 'tailor-made' combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.

  International journal of cancer 20060315

• What's the rush? The dissemination and adoption of preliminary research results.

  Journal of the National Cancer Institute 20060315

• Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.

  Cancer research 20060315

• EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.

  Cancer research 20060315

• Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

  Biochemical pharmacology 20060314

• Targeted therapy for metastatic renal cell carcinoma.

  British journal of cancer 20060313

• Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer.

  British journal of cancer 20060313

• Tumours and tremors: how PTEN regulation underlies both.

  British journal of cancer 20060313

• [Present status of and new trends in therapy for lung cancer].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060310

• Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

  Cancer letters 20060308

• Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.

  Journal of cellular biochemistry 20060301

• Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

  Breast cancer research and treatment 20060301

• EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20060301

• PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.

  Lung cancer (Amsterdam, Netherlands) 20060301

• Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.

  BJU international 20060301

• Molecular targeted therapy: a strategy of disillusions or optimism?

  The Journal of laboratory and clinical medicine 20060301

• YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060301

• EGFR regulates the side population in head and neck squamous cell carcinoma.

  The Laryngoscope 20060301

• [Chemotherapy for lung cancer patients].

  Journal of UOEH 20060301

• [Palliative chemotherapy of head and neck cancer: present status and future development].

  Laryngo- rhino- otologie 20060301

• Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.

  Respirology (Carlton, Vic.) 20060301

• Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

  The oncologist 20060301

• Analgesic effect of gefitinib in the treatment of non-small cell lung cancer.

  The journal of supportive oncology 20060301

• A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.

  Current medical research and opinion 20060301

• [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].

  Actas dermo-sifiliograficas 20060301

• Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?

  Endocrine-related cancer 20060301

• Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.

  Endocrine-related cancer 20060301

• Role of exon-16-deleted HER2 in breast carcinomas.

  Endocrine-related cancer 20060301

• Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060301

• Peptide hormones and lung cancer.

  Panminerva medica 20060301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060301

• Bronchioloalveolar carcinoma: a review.

  Clinical lung cancer 20060301

• Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.

  Clinical lung cancer 20060301

• Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.

  Investigational new drugs 20060301

• [Skin signs associated with epidermal growth factor inhibitors].

  Annales de dermatologie et de venereologie 20060301

• EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Renal cell carcinoma and the use of sorafenib.

  Therapeutics and clinical risk management 20060301

• Mutation of the PIK3CA oncogene in human cancers.

  British journal of cancer 20060227

• Targeting insulin-like growth factor pathways.

  British journal of cancer 20060227

• Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.

  Oncogene 20060223

• Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

  Journal of medicinal chemistry 20060223

• Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library.

  Journal of the American Chemical Society 20060222

• Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.

  International journal of cancer 20060215

• Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.

  International journal of cancer 20060215

• Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.

  International journal of cancer 20060215

• Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

  Cancer research 20060215

• C-fos assessment as a marker of anti-epidermal growth factor receptor effect.

  Cancer research 20060215

• Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?

  British journal of cancer 20060213

• Response of glioblastomas to EGFR kinase inhibitors.

  The New England journal of medicine 20060202

• Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.

  Thorax 20060201

• Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.

  Cancer biology & therapy 20060201

• Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060201

• Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.

  Cancer science 20060201

• Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060201

• Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

  Cancer research 20060201

• A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060201

• Second-line treatment options in advanced non-small cell lung cancer: current status.

  Seminars in oncology 20060201

• Use of novel second-line targeted therapies in non-small cell lung cancer.

  Seminars in oncology 20060201

• Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.

  Seminars in oncology 20060201

• Optimizing therapy in previously treated non-small cell lung cancer.

  Seminars in oncology 20060201

• Geographic variation in the second-line treatment of non-small cell lung cancer.

  Seminars in oncology 20060201

• Changing paradigms--an update on the multidisciplinary management of malignant glioma.

  The oncologist 20060201

• [Long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer; report of a case].

  Kyobu geka. The Japanese journal of thoracic surgery 20060201

• Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.

  Molecular cancer therapeutics 20060201

• Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro.

  Acta medica Okayama 20060201

• Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.

  Oncology (Williston Park, N.Y.) 20060201

• Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.

  Journal of gastroenterology 20060201

• Clinical experience with anti-EGFR therapy.

  Seminars in oncology nursing 20060201

• Common side effects of anti-EGFR therapy: acneform rash.

  Seminars in oncology nursing 20060201

• [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].

  Revue de pneumologie clinique 20060201

• [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20060201

• COSMIC 2005.

  British journal of cancer 20060130

• Gefitinib for refractory advanced non-small-cell lung cancer.

  Lancet (London, England) 20060128

• Gefitinib for refractory advanced non-small-cell lung cancer.

  Lancet (London, England) 20060128

• Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.

  British journal of cancer 20060116

• Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

  International journal of cancer 20060115

• Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

  Cancer research 20060115

• Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.

  Cancer research 20060115

• Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.

  Chinese medical journal 20060105

• EGFR and erbB2 mutation status in Japanese lung cancer patients.

  International journal of cancer 20060101

• Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

  International journal of cancer 20060101

• A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060101

• Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.

  Lung cancer (Amsterdam, Netherlands) 20060101

• Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060101

• EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060101

• EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.

  PLoS medicine 20060101

• Targeted kinase inhibitors in lung cancer: from EGFR to patients.

  European journal of cancer (Oxford, England : 1990) 20060101

• Advances in molecular diagnostics and therapeutics in head and neck cancer.

  Current treatment options in oncology 20060101

• Emerging approaches to advanced bronchioloalveolar carcinoma.

  Current treatment options in oncology 20060101

• The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers.

  Journal of surgical oncology 20060101

• Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

  European journal of cancer (Oxford, England : 1990) 20060101

• Radiation combined with EGFR signal inhibitors: head and neck cancer focus.

  Seminars in radiation oncology 20060101

• First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060101

• Lung Cancer Highlights from ASCO 2005.

  The oncologist 20060101

• Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.

  Nature clinical practice. Oncology 20060101

• Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.

  Breast cancer research : BCR 20060101

• Gefitinib-induced lung injury successfully treated with high-dose corticosteroids.

  Respirology (Carlton, Vic.) 20060101

• Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells.

  Anticancer research 20060101

• Cutaneous reactions to chemotherapy and their management.

  American journal of clinical dermatology 20060101

• Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

  Xenobiotica; the fate of foreign compounds in biological systems 20060101

• Application of DETECTER, an evolutionary genomic tool to analyze genetic variation, to the cystic fibrosis gene family.

  BMC genomics 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.

  Drugs in R&D 20060101

• Rapid screening for EGFR mutations: pros and cons.

  Cancer journal (Sudbury, Mass.) 20060101

• Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations.

  Anticancer research 20060101

• Cancer and kinases: reports from the front line.

  Genome biology 20060101

• Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.

  Molecular pharmaceutics 20060101

• Gemcitabine and acute myocardial infarction--a case report.

  Angiology 20060101

• Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.

  BMC cancer 20060101

• Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.

  Clinical pharmacokinetics 20060101

• Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

  Medical oncology (Northwood, London, England) 20060101

• The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.

  Radiation oncology (London, England) 20060101

• Tyrphostins and other tyrosine kinase inhibitors.

  Annual review of biochemistry 20060101

• Epidermal growth factor receptor inhibition and non-small cell lung cancer.

  Critical reviews in clinical laboratory sciences 20060101

• ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.

  Oncology research 20060101

• Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.

  Cancer investigation 20060101

• Why do oncologists prescribe--or not prescribe--conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer?

  The journal of supportive oncology 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.

  Diagnostic pathology 20060101

• Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.

  ONS news 20060101

• Three case reports of hand-foot syndrome with gefitinib.

  Cancer investigation 20060101

• The role of the epidermal growth factor receptor in breast cancer.

  Journal of mammary gland biology and neoplasia 20060101

• Acute renal failure associated with gefitinib therapy.

  Lung 20060101

• Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.

  Molecular cancer 20060101

• Overprotective caregivers of elderly cancer patients: a case report.

  Tumori 20060101

• Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions.

  Chang Gung medical journal 20060101

• Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer.

  Anticancer research 20060101

• Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity.

  Anticancer research 20060101

• Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.

  BMC genomics 20060101

• HER2 therapy: molecular mechanisms of trastuzumab resistance.

  Breast cancer research : BCR 20060101

• The epidermal growth factor family has a dual role in deciding the fate of cancer cells.

  Scandinavian journal of clinical and laboratory investigation 20060101

• Protein kinase inhibitors.

  Folia biologica 20060101

• [Lung cancer in women: a different entity?].

  Revista portuguesa de pneumologia 20060101

• Double vision worth a double take.

  Survey of ophthalmology 20060101

• Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

  BMC cancer 20060101

• A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.

  BMC cancer 20060101

• Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?

  World journal of surgical oncology 20060101

• Targeting the EGFR pathway for cancer therapy.

  Current medicinal chemistry 20060101

• Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.

  BMC cancer 20060101

• High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

  BMC cancer 20060101

• Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray.

  Anticancer research 20060101

• The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.

  Anticancer research 20060101

• Effect of EGFR antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line.

  In vivo (Athens, Greece) 20060101

• Anticipating the 1,000 dollar genome.

  Genome biology 20060101

• Gefitinib (IRESSA, ZD 1839) as a salvage treatment for patients with advanced non-small cell lung cancer.

  The West Virginia medical journal 20060101

• Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060101

• A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.

  Oncology 20060101

• [Role of predictive pathology in oncology--example of new therapies targeting EGFR].

  Verhandlungen der Deutschen Gesellschaft fur Pathologie 20060101

• Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

  Reviews on recent clinical trials 20060101

• Update on clinical radiobiology.

  Biomedical imaging and intervention journal 20060101

• Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

  Cancer research 20051215

• Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

• Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

• [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].

  Medizinische Klinik (Munich, Germany : 1983) 20051215

• HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.

  British journal of cancer 20051212

• Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.

  Cancer letters 20051208

• Re: Cetuximab therapy and symptomatic hypomagnesemia.

  Journal of the National Cancer Institute 20051207

• Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  Journal of cellular physiology 20051201

• Role of tyrosine kinase inhibitors in cancer therapy.

  The Journal of pharmacology and experimental therapeutics 20051201

• A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.

  Cancer chemotherapy and pharmacology 20051201

• Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051201

• Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20051201

• Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.

  Journal of cancer research and clinical oncology 20051201

• Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Targeted agents for the treatment of advanced renal cell carcinoma.

  Cancer 20051201

• First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.

  Oncology reports 20051201

• Severe cutaneous toxicity following treatment with gefitinib (ZD1839).

  The British journal of dermatology 20051201

• Molecularly-targeted therapies for non-small cell lung cancer.

  Expert opinion on pharmacotherapy 20051201

• Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.

  American journal of clinical oncology 20051201

• An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer.

  Expert opinion on pharmacotherapy 20051201

• Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

  Endocrine-related cancer 20051201

• Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

  Endocrine-related cancer 20051201

• EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients.

  Onkologie 20051201

• [Lung cancer in women].

  Revue des maladies respiratoires 20051201

• Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.

  Chest 20051201

• Molecular mechanisms and targeting of colorectal cancer.

  Seminars in oncology 20051201

• The role of EGFR-TK inhibition in non-small cell lung cancer.

  Onkologie 20051201

• Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.

  Molecular cancer therapeutics 20051201

• Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.

  Molecular cancer therapeutics 20051201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051201

• Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.

  Cancer biology & therapy 20051201

• Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study.

  Journal of chemotherapy (Florence, Italy) 20051201

• Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Optimizing chemotherapy and targeted agent combinations in NSCLC.

  Lung cancer (Amsterdam, Netherlands) 20051201

• Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.

  Cancer research and treatment : official journal of Korean Cancer Association 20051201

• Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?

  British journal of cancer 20051128

• Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.

  Biochemical pharmacology 20051125

• Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051120

• [Antineoplastic agents targeting tyrosine kinases].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20051117

• Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.

  Cancer research 20051115

• Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051115

• Glioblastoma multiforme and the epidermal growth factor receptor.

  The New England journal of medicine 20051110

• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  The New England journal of medicine 20051110

• National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.

  Pharmacoepidemiology and drug safety 20051101

• Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.

  Lung cancer (Amsterdam, Netherlands) 20051101

• Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051101

• Gefitinib is also active for carcinomatous meningitis in NSCLC.

  Lung cancer (Amsterdam, Netherlands) 20051101

• Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051101

• Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

  PLoS medicine 20051101

• Role of nuclear receptors in lung tumourigenesis.

  European journal of cancer (Oxford, England : 1990) 20051101

• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051101

• When clinical trials are compromised: a perspective from a patient advocate.

  PLoS medicine 20051101

• The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.

  Anti-cancer drugs 20051101

• Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

  Anti-cancer drugs 20051101

• Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.

  Expert opinion on emerging drugs 20051101

• Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor.

  Cancer research 20051101

• Resistance to endocrine therapy in breast cancer.

  Cancer chemotherapy and pharmacology 20051101

• Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051101

• New approaches in the management of lung cancer.

  Journal of the National Comprehensive Cancer Network : JNCCN 20051101

• [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [Genetic alterations and chemoresistance].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• Inhibition of EGFR signaling: all mutations are not created equal.

  PLoS medicine 20051101

• Targeted agents for the treatment of advanced renal cell carcinoma.

  Current drug targets 20051101

• Allele-specific amplification in cancer revealed by SNP array analysis.

  PLoS computational biology 20051101

• Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.

  Clinical colorectal cancer 20051101

• Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

  Clinical lung cancer 20051101

• [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20051101

• EGFR inhibitors in lung cancer.

  Oncology (Williston Park, N.Y.) 20051101

• [Advances in the molecular target therapy in lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051101

• [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

  Zhonghua bing li xue za zhi = Chinese journal of pathology 20051101

• Drug resistance in cancer.

  British journal of cancer 20051031

• Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051020

• Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051020

• Erlotinib in lung cancer.

  The New England journal of medicine 20051020

• Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.

  British journal of cancer 20051017

• Gefitinib induces myeloid differentiation of acute myeloid leukemia.

  Blood 20051015

• Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.

  Cancer research 20051015

• Epidermal growth factor receptor inhibitors: a moving target?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051015

• Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051015

• Drug discovery: playing dirty.

  Nature 20051013

• High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.

  Journal of molecular biology 20051007

• Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib.

  Chinese medical journal 20051005

• Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.

  British journal of cancer 20051003

• Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20051001

• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20051001

• Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20051001

• Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines.

  Cancer biology & therapy 20051001

• Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.

  European journal of cancer (Oxford, England : 1990) 20051001

• Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

  Annals of oncology : official journal of the European Society for Medical Oncology 20051001

• Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.

  Apoptosis : an international journal on programmed cell death 20051001

• Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.

  Onkologie 20051001

• Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Biomarkers to predict response to epidermal growth factor receptor inhibitors.

  Cell cycle (Georgetown, Tex.) 20051001

• EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.

  Pharmaceutical research 20051001

• Second-generation kinase inhibitors.

  Expert opinion on therapeutic targets 20051001

• Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.

  European journal of endocrinology 20051001

• Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051001

• Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

  Cancer research 20051001

• A specific and sensitive assay for gefitinib using the enzyme-linked immunosorbent assay in human serum.

  Biological & pharmaceutical bulletin 20051001

• Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20051001

• Molecular targeted therapy for lung cancer.

  Lancet (London, England) 20051001

• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  Lancet (London, England) 20051001

• How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.

  The oncologist 20051001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051001

• Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.

  Onkologie 20051001

• Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?

  Cancer biology & therapy 20051001

• [Current status and prospect of neoplasm targeted therapy].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051001

• Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050910

• Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.

  British journal of cancer 20050905

• EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050901

• Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Targeted therapies for non-small cell lung cancer.

  International journal of clinical practice 20050901

• Epidermal growth factor inhibition in solid tumours.

  Expert opinion on biological therapy 20050901

• Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901

• Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

  Cancer research 20050901

• Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Hair growth after gefitinib treatment.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20050901

• Conflicting signals on US accelerated approvals.

  Nature biotechnology 20050901

• [Anti-angiogenic therapy of a renal angiomyolipoma in a seriously disabled patient suffering from multiple sclerosis].

  Aktuelle Urologie 20050901

• The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

  Molecular cancer therapeutics 20050901

• Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.

  Molecular cancer therapeutics 20050901

• Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.

  PLoS medicine 20050901

• Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

  The oncologist 20050901

• Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.

  Clinical lung cancer 20050901

• Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.

  Clinical lung cancer 20050901

• Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.

  Clinical lung cancer 20050901

• [Molecular targeted therapy for malignant brain tumors].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.

  Internal medicine (Tokyo, Japan) 20050901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050901

• Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20050901

• [Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].

  Clinical calcium 20050901

• [Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20050901

• [Acneiform eruption from epidermal growth factor receptor inhibitors].

  Actas dermo-sifiliograficas 20050901

• Gefitinib in colorectal cancer: if wishes were horses.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• [The role of epidermal growth factor receptor inhibitor, gefitinib, in improvement of quality of life of patients with non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20050820

• Gefitinib versus cetuximab in lung cancer: round one.

  Journal of the National Cancer Institute 20050817

• Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

  Journal of the National Cancer Institute 20050817

• An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

  Cancer research 20050815

• Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

  Cancer research 20050815

• Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

  International journal of cancer 20050810

• Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810

• Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.

  Cancer letters 20050808

• Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.

  British journal of cancer 20050808

• Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.

  Lung cancer (Amsterdam, Netherlands) 20050801

• Recent developments related to the EGFR as a target for cancer chemotherapy.

  Current opinion in pharmacology 20050801

• The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050801

• Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.

  Cell cycle (Georgetown, Tex.) 20050801

• Drug interaction between gefitinib and warfarin.

  Japanese journal of clinical oncology 20050801

• ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.

  FEBS letters 20050801

• Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.

  Anti-cancer drugs 20050801

• Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.

  Anti-cancer drugs 20050801

• Myocarditis temporally related to the use of gefitinib (Iressa).

  Archives of pathology & laboratory medicine 20050801

• Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

  The Journal of molecular diagnostics : JMD 20050801

• Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.

  Cancer research 20050801

• Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.

  American journal of clinical oncology 20050801

• HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

  Journal of neuro-oncology 20050801

• The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

  The oncologist 20050801

• [Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20050801

• [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].

  Ai zheng = Aizheng = Chinese journal of cancer 20050801

• Recent advances and future perspectives in the management of lung cancer.

  Current problems in surgery 20050801

• BiDil raises questions about race as a marker.

  Nature reviews. Drug discovery 20050801

• Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.

  Cancer science 20050801

• Simultaneous bilateral spontaneous pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple lung metastases.

  Internal medicine (Tokyo, Japan) 20050801

• Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20050801

• [Pancreatic adenocarcinoma: therapeutical update].

  Anales de medicina interna (Madrid, Spain : 1984) 20050801

• [Pharmacological skills for targeting EGFR and VEGF].

  Bulletin du cancer 20050801

• [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results].

  Bulletin du cancer 20050801

• Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.

  Future oncology (London, England) 20050801

• Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. A 20050729

• New studies look beyond EGFR mutations for clues to sensitivity to erlotinib.

  Journal of the National Cancer Institute 20050720

• Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.

  Cancer research 20050715

• EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

  The New England journal of medicine 20050714

• Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors.

  The New England journal of medicine 20050714

• Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients.

  British journal of cancer 20050711

• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

  Cancer letters 20050708

• Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.

  Eye (London, England) 20050701

• Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

  International journal of cancer 20050701

• Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050701

• Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?

  Critical reviews in oncology/hematology 20050701

• Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?

  European journal of cancer (Oxford, England : 1990) 20050701

• Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.

  European journal of cancer (Oxford, England : 1990) 20050701

• Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.

  Current oncology reports 20050701

• Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.

  Lung cancer (Amsterdam, Netherlands) 20050701

• Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?

  Journal of clinical pathology 20050701

• Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.

  Breast cancer research and treatment 20050701

• Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma.

  The British journal of dermatology 20050701

• Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

  Endocrine-related cancer 20050701

• Overview of tyrosine kinase inhibitors in clinical breast cancer.

  Endocrine-related cancer 20050701

• Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.

  Endocrine-related cancer 20050701

• Development of strategies for the use of anti-growth factor treatments.

  Endocrine-related cancer 20050701

• Inhibitors of growth factor signalling.

  Endocrine-related cancer 20050701

• Perspectives on salvage therapy for non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20050701

• Drug targeting: is race enough?

  Nature 20050623

• Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.

  British journal of cancer 20050620

• Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.

  Cancer letters 20050616

• Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.

  The Prostate 20050615

• Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma.

  Cancer 20050615

• Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

  Journal of the National Cancer Institute 20050615

• Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

  Cancer research 20050615

• Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050615

• The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050615

• [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].

  Deutsche medizinische Wochenschrift (1946) 20050610

• Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.

  Cancer chemotherapy and pharmacology 20050601

• High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.

  Cancer 20050601

• Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy.

  Anti-cancer drugs 20050601

• Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050601

• Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.

  Fundamental & clinical pharmacology 20050601

• Gefitinib has the potential of activating cell immunity against malignant cells.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601

• Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

  The Lancet. Oncology 20050601

• ZD6474--clinical experience to date.

  British journal of cancer 20050601

• Role of novel targeted therapies in the clinic.

  British journal of cancer 20050601

• Targeted antitumour therapy--future perspectives.

  British journal of cancer 20050601

• ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.

  British journal of cancer 20050601

• Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?

  Journal of the American Geriatrics Society 20050601

• Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20050601

• Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis.

  Endocrine-related cancer 20050601

• Gefitinib in non-small cell lung cancer.

  Expert opinion on pharmacotherapy 20050601

• Erlotinib in non-small cell lung cancer: a review.

  Expert opinion on pharmacotherapy 20050601

• Features of selective kinase inhibitors.

  Chemistry & biology 20050601

• [Translational research on lung cancer--EGFR gene mutation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [Chemotherapy for advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• Current management of advanced non-small cell lung cancer: targeted therapy.

  Seminars in oncology 20050601

• Factors predicting response to EGFR tyrosine kinase inhibitors.

  Seminars in respiratory and critical care medicine 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?

  Nature clinical practice. Oncology 20050601

• EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer.

  Nature clinical practice. Oncology 20050601

• Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.

  British journal of cancer 20050523

• Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.

  British journal of cancer 20050523

• A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.

  British journal of cancer 20050523

• EGFR mutation and response of lung cancer to gefitinib.

  The New England journal of medicine 20050519

• Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050515

• HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.

  Cancer research 20050515

• Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050510

• Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050510

• Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.

  British journal of cancer 20050509

• Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.

  British journal of cancer 20050509

• Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

  British journal of cancer 20050509

• Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050505

• A curious link between epidermal growth factor receptor amplification and survival: effect of 'allele dilution' on gefitinib sensitivity?

  Journal of the National Cancer Institute 20050504

• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  Journal of the National Cancer Institute 20050504

• Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050501

• Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

  Oncogene 20050501

• EGFR mutation is specific for terminal respiratory unit type adenocarcinoma.

  The American journal of surgical pathology 20050501

• Small molecules with EGFR-TK inhibitor activity.

  Current drug targets 20050501

• Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.

  Current drug targets 20050501

• The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

  Cancer research 20050501

• Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.

  Japanese journal of clinical oncology 20050501

• Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

  Thrombosis and haemostasis 20050501

• [Non-small-cell lung cancer third-line therapy with gefitinib].

  Pneumologie (Stuttgart, Germany) 20050501

• [Anticancer drugs and ABC transporters].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050501

• Therapy of breast cancer with molecular targeting agents.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Emerging drugs for ovarian cancer.

  Expert opinion on emerging drugs 20050501

• Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.

  Clinical lung cancer 20050501

• Updated data from the Iressa survival in lung cancer trial.

  Clinical lung cancer 20050501

• A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.

  Clinical lung cancer 20050501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050501

• Will lung cancer targeting hit its mark?

  JAMA 20050427

• EGFR tyrosine kinase domain mutations in human gliomas.

  Neurology 20050426

• State-of-the-art management of locally advanced head and neck cancer.

  British journal of cancer 20050425

• Lack of clinical efficacy of imatinib in metastatic melanoma.

  British journal of cancer 20050425

• Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells.

  British journal of cancer 20050425

• Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.

  The New England journal of medicine 20050421

• Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

  Cancer research 20050415

• Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

  Cancer research 20050415

• Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.

  British journal of cancer 20050411

• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• FDA Oncology Committee debates Iressa's status following negative trial results.

  Journal of the National Cancer Institute 20050406

• Gefitinib ('Iressa', ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.

  Cancer chemotherapy and pharmacology 20050401

• Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach.

  The American journal of surgical pathology 20050401

• Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050401

• Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050401

• Current status of small peripheral adenocarcinomas of the lung and their importance to pathologists.

  Annals of diagnostic pathology 20050401

• Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

  Molecular cancer therapeutics 20050401

• Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.

  Onkologie 20050401

• The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.

  Cell proliferation 20050401

• Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?

  Journal of the Chinese Medical Association : JCMA 20050401

• Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.

  Journal of the Chinese Medical Association : JCMA 20050401

• Current and future perspectives on fulvestrant.

  Clinical breast cancer 20050401

• Epidermal growth factor receptor as a target for chemotherapy.

  Clinical colorectal cancer 20050401

• Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.

  Neoplasia (New York, N.Y.) 20050401

• Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.

  Seminars in oncology 20050401

• An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies.

  Seminars in oncology 20050401

• Epidermal growth factor receptor inhibitors in cancer treatment.

  Future oncology (London, England) 20050401

• Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

  British journal of cancer 20050328

• Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.

  British journal of cancer 20050328

• Erlotinib (Tarceva) for advanced non-small cell lung cancer.

  The Medical letter on drugs and therapeutics 20050328

• Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.

  The Journal of biological chemistry 20050318

• Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

  Journal of the National Cancer Institute 20050316

• A man whose scapula was spared a drug-associated rash.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050315

• Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.

  Cancer research 20050315

• Predictors of the response to gefitinib in refractory non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Gefitinib does not increase survival in lung cancer patients.

  Drug discovery today 20050315

• Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.

  World journal of gastroenterology 20050307

• Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.

  Journal of cancer research and clinical oncology 20050301

• A small molecule-kinase interaction map for clinical kinase inhibitors.

  Nature biotechnology 20050301

• Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.

  Lung cancer (Amsterdam, Netherlands) 20050301

• Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer.

  Current opinion in oncology 20050301

• Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials.

  Current opinion in oncology 20050301

• EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.

  Advances in anatomic pathology 20050301

• Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancer.

  Respiratory medicine 20050301

• Innovations in antineoplastic therapy.

  The Nursing clinics of North America 20050301

• EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.

  PLoS medicine 20050301

• Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

  PLoS medicine 20050301

• High-throughput screening for kinase inhibitors.

  Chembiochem : a European journal of chemical biology 20050301

• A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

  Investigational new drugs 20050301

• A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

  Investigational new drugs 20050301

• Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

  Cancer research 20050301

• Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.

  Cancer biology & therapy 20050301

• Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20050301

• [Molecular diagnosis of solid tumors].

  Nihon rinsho. Japanese journal of clinical medicine 20050301

• High throughput screening for protein kinase inhibitors.

  Combinatorial chemistry & high throughput screening 20050301

• Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy.

  Cell research 20050301

• Computer-assisted image analysis of bronchioloalveolar carcinoma.

  Clinical lung cancer 20050301

• [Treatment of non-small cell lung cancer with gefitinib].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20050301

• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  The New England journal of medicine 20050224

• Chasing mutations in the epidermal growth factor in lung cancer.

  The New England journal of medicine 20050224

• APL during gefitinib treatment for non-small-cell lung cancer.

  The New England journal of medicine 20050224

• [Molecular target therapy for malignant tumors].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050220

• Failing survival advantage in crucial trial, future of Iressa is in jeopardy.

  Journal of the National Cancer Institute 20050216

• Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

  Cancer research 20050215

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

  Cancer research 20050215

• Somatic mutations of epidermal growth factor receptor in colorectal carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Scientists hopeful as they uncover molecular clues to prostate cancer.

  Journal of the National Cancer Institute 20050202

• Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.

  The Prostate 20050201

• How cancer could be cured by 2015.

  Cell cycle (Georgetown, Tex.) 20050201

• Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.

  Anti-cancer drugs 20050201

• New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

  Anti-cancer drugs 20050201

• Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.

  Hepatology (Baltimore, Md.) 20050201

• Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Keeping pace with innovation.

  The Lancet. Oncology 20050201

• Purpuric drug eruption possibly due to gefinitib (Iressa).

  International journal of dermatology 20050201

• Endocrine treatment options for advanced breast cancer--the role of fulvestrant.

  European journal of cancer (Oxford, England : 1990) 20050201

• Iressa's fall from grace points to need for better clinical trials.

  Nature medicine 20050201

• Gefitinib in advanced non-small cell lung cancer.

  Internal medicine journal 20050201

• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050201

• The epidermal growth factor receptor as a target for colorectal cancer therapy.

  Seminars in oncology 20050201

• Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.

  International journal of clinical oncology 20050201

• Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.

  Journal of neuro-oncology 20050201

• Targeted cancer therapies.

  Bulletin du cancer 20050201

• Iressa failure raises fears about accelerated approvals.

  Nature reviews. Drug discovery 20050201

• Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.

  British journal of cancer 20050117

• A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

  British journal of cancer 20050117

• Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.

  British journal of cancer 20050117

• Cellular targets of gefitinib.

  Cancer research 20050115

• Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.

  International journal of cancer 20050101

• Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.

  Investigational new drugs 20050101

• Practical management of patients with non-small-cell lung cancer treated with gefitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050101

• Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20050101

• Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050101

• Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.

  Lung cancer (Amsterdam, Netherlands) 20050101

• Gefitinib therapy for non-small cell lung cancer.

  Current treatment options in oncology 20050101

• Neuro-oncology: the growing role of chemotherapy in glioma.

  The Lancet. Neurology 20050101

• Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050101

• Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease.

  The American journal of pathology 20050101

• Gefitinib therapy for life-threatening laryngeal papillomatosis.

  Archives of otolaryngology--head & neck surgery 20050101

• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  Cancer research 20050101

• [Second-line treatment for advanced non-small-cell lung cancers].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• [A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

  Drug safety 20050101

• A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.

  Breast cancer research and treatment 20050101

• Variation in tissue-specific gene expression among natural populations.

  Genome biology 20050101

• Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.

  Clinical lung cancer 20050101

• Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.

  Clinical lung cancer 20050101

• Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy.

  PLoS medicine 20050101

• KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

  PLoS medicine 20050101

• Molecular therapy of head and neck cancer.

  Cancer metastasis reviews 20050101

• [Gefitinib therapy in non-small-cell lung cancer].

  Duodecim; laaketieteellinen aikakauskirja 20050101

• [Gefitinib as targeted treatment for non-small-cell lung cancer].

  Duodecim; laaketieteellinen aikakauskirja 20050101

• Cytochrome P450-dependent metabolism of gefitinib.

  Xenobiotica; the fate of foreign compounds in biological systems 20050101

• Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells.

  BMC gastroenterology 20050101

• Spotlight on gefitinib in non-small-cell lung cancer.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• EGFR pharmacogenomics: the story continues to mutate and evolve.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.

  Anticancer research 20050101

• Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.

  Anticancer research 20050101

• Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?

  Anticancer research 20050101

• Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer.

  Molecular cancer 20050101

• Promiscuous drugs compared to selective drugs (promiscuity can be a virtue).

  BMC clinical pharmacology 20050101

• Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• Medical treatment of non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050101

• Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.

  Breast cancer research : BCR 20050101

• Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer.

  Genetic vaccines and therapy 20050101

• Cancer cell adaptation to chemotherapy.

  BMC cancer 20050101

• Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma.

  Anticancer research 20050101

• Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin.

  Anticancer research 20050101

• Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.

  Cancer investigation 20050101

• Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

  Oncology research 20050101

• Clinical trial of Iressa.

  FDA consumer 20050101

• Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model.

  Urologia internationalis 20050101

• Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines.

  Oncology 20050101

• Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).

  Anticancer research 20050101

• Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models.

  Breast cancer research : BCR 20050101

• Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.

  Breast cancer research : BCR 20050101

• Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

  Clinical pharmacokinetics 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• The future of fulvestrant ('Faslodex').

  Cancer treatment reviews 20050101

• Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer.

  BMC cancer 20050101

• Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.

  Acta oncologica (Stockholm, Sweden) 20050101

• Single-dose clinical pharmacokinetic studies of gefitinib.

  Clinical pharmacokinetics 20050101

• Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.

  Breast cancer research and treatment 20050101

• Adjuvant chemotherapy for non-small cell lung cancer.

  Seminars in thoracic and cardiovascular surgery 20050101

• Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.

  Cancer journal (Sudbury, Mass.) 20050101

• Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.

  Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20050101

• Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

  Breast cancer research : BCR 20050101

• Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.

  Dermatology (Basel, Switzerland) 20050101

• Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis.

  Pathophysiology of haemostasis and thrombosis 20050101

• Reduction of cisplatin dosage by ZD 1839.

  Anticancer research 20050101

• Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.

  Cancer nursing 20050101

• Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.

  Anticancer research 20050101

• Cancer diagnostics: decision criteria for marker utilization in the clinic.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling.

  Journal of translational medicine 20050101

• [Assessment of the presence of mutations of the epidermal growth factor receptors in tumors of various histologies].

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20050101

• Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice.

  Breast cancer research : BCR 20050101

• High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.

  Breast cancer research : BCR 20050101

• The personal genome project.

  Molecular systems biology 20050101

• [Problems in the current target therapy of malignancies].

  Voprosy onkologii 20050101

• Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.

  Cold Spring Harbor symposia on quantitative biology 20050101

• Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.

  Cold Spring Harbor symposia on quantitative biology 20050101

• Somatic mutations of EGFR in colorectal cancers and glioblastomas.

  The New England journal of medicine 20041230

• Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

  Human molecular genetics 20041215

• Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

  Cancer research 20041215

• An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

  Cancer research 20041215

• High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.

  British journal of cancer 20041213

• A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

  British journal of cancer 20041213

• Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.

  Cell cycle (Georgetown, Tex.) 20041201

• Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.

  European journal of cancer (Oxford, England : 1990) 20041201

• Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

  Journal of the National Cancer Institute 20041201

• Gefitinib--a novel targeted approach to treating cancer.

  Nature reviews. Cancer 20041201

• Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

  Journal of hepatology 20041201

• A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models.

  Cancer science 20041201

• Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.

  Seminars in oncology 20041201

• EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.

  Cancer biology & therapy 20041201

• Epidermal growth factor receptor inhibition strategies in oncology.

  Endocrine-related cancer 20041201

• Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

  Endocrine-related cancer 20041201

• Chemoradiotherapy for lung cancer: current status and perspectives.

  International journal of clinical oncology 20041201

• Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.

  Clinical lung cancer 20041201

• Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.

  Clinical lung cancer 20041201

• Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.

  Clinical lung cancer 20041201

• Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.

  Clinical lung cancer 20041201

• Treatment of patients with advanced lung cancer and poor performance status.

  Clinical lung cancer 20041201

• Signaling mechanisms that mediate invasion in prostate cancer cells.

  Annals of the New York Academy of Sciences 20041201

• Top 10 health stories of 2004.

  Harvard health letter 20041201

• [IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041201

• [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].

  Bulletin du cancer 20041201

• Biomarkers of response to gefitinib in non-small-cell lung cancer.

  Nature clinical practice. Oncology 20041201

• Kinase inhibitors in cancer therapy.

  Veterinary and comparative oncology 20041201

• Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.

  British journal of cancer 20041129

• [New era in cancer therapy. Gefitinib: small molecule--strong action].

  MMW Fortschritte der Medizin 20041118

• [Successes in late solid tumors. New therapy offer].

  MMW Fortschritte der Medizin 20041118

• Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041115

• Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041115

• Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20041101

• Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20041101

• Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.

  British journal of cancer 20041101

• Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ('Iressa', ZD1839).

  Oncology reports 20041101

• Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.

  Journal of hepatology 20041101

• Gefitinib does not improve survival when combined with gemcitabine and cisplatin in people with advanced non-small-cell lung cancer.

  Cancer treatment reviews 20041101

• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  Cancer treatment reviews 20041101

• Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041101

• [The place of targeted treatments: receptor tyrosine kinase inhibitors].

  Revue de pneumologie clinique 20041101

• ERBB2 kinase mutations in lung-cancer tumours.

  The Lancet. Oncology 20041101

• Trichomegaly following treatment with gefitinib (ZD1839).

  The British journal of dermatology 20041101

• Combining targeted agents in lung cancer.

  Clinical lung cancer 20041101

• [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].

  Ai zheng = Aizheng = Chinese journal of cancer 20041101

• A molecular chink in the lung cancer armour.

  Respirology (Carlton, Vic.) 20041101

• [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].

  Revue des maladies respiratoires 20041101

• [French experience of gefitinib in non-small cell bronchial carcinoma].

  Revue des maladies respiratoires 20041101

• Challenges in breast cancer clinical trial design in the postgenomic era.

  Current opinion in oncology 20041101

• Molecular changes in gliomas.

  Current opinion in oncology 20041101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041101

• Innovative therapy for patients with brain metastases: oral treatments.

  Journal of chemotherapy (Florence, Italy) 20041101

• [Targeted drugs in radiation therapy].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20041101

• Reversing resistance to targeted therapy.

  Journal of chemotherapy (Florence, Italy) 20041101

• Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

  Journal of chemotherapy (Florence, Italy) 20041101

• The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.

  Nature clinical practice. Oncology 20041101

• Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

  Cancer research 20041015

• Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.

  Cancer research 20041015

• Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer.

  British journal of cancer 20041004

• Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

  Journal of cancer research and clinical oncology 20041001

• Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

  Journal of cellular physiology 20041001

• Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.

  Biochemical pharmacology 20041001

• Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• Targeted therapies for cancer 2004.

  American journal of clinical pathology 20041001

• Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.

  Prescrire international 20041001

• Approved use of gefitinib.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20041001

• Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs.

  Current medicinal chemistry 20041001

• Acute gefitinib-induced pneumonitis.

  International journal of clinical oncology 20041001

• Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.

  Clinical therapeutics 20041001

• Gefitinib: current status in the treatment of non-small cell lung cancer.

  Drugs of today (Barcelona, Spain : 1998) 20041001

• Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.

  Xenobiotica; the fate of foreign compounds in biological systems 20041001

• Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

  Xenobiotica; the fate of foreign compounds in biological systems 20041001

• Novel agents for the treatment of advanced kidney cancer.

  Clinical advances in hematology & oncology : H&O 20041001

• Lung cancer: intragenic ERBB2 kinase mutations in tumours.

  Nature 20040930

• EGFR mutations and sensitivity to gefitinib.

  The New England journal of medicine 20040916

• EGFR mutations and sensitivity to gefitinib.

  The New England journal of medicine 20040916

• EGFR mutations and sensitivity to gefitinib.

  The New England journal of medicine 20040916

• Research unveils the 'who' and 'why' of gefitinib.

  Journal of the National Cancer Institute 20040915

• Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040915

• The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.

  British journal of cancer 20040913

• Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.

  British journal of cancer 20040913

• EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.

  Proceedings of the National Academy of Sciences of the United States of America 20040907

• Protein kinase inhibitors: novel tools in cancer therapy.

  Der Urologe. Ausg. A 20040901

• Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells.

  Oncology reports 20040901

• 'Fast-track' drug approvals hit speed bumps in Japan.

  Nature medicine 20040901

• Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

• Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

• Gefitinib reverses breast cancer resistance protein-mediated drug resistance.

  Molecular cancer therapeutics 20040901

• [Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20040901

• Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.

  Clinical lung cancer 20040901

• Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.

  Anti-cancer drugs 20040901

• [Two cases of lung cancer in the third decade of life].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040901

• Recent developments in the discovery of protein kinase inhibitors from the urea class.

  Current opinion in drug discovery & development 20040901

• Immunity in medicine.

  JPMA. The Journal of the Pakistan Medical Association 20040901

• [Does molecular targeted therapy change the treatment for lung cancer?].

  Fukuoka igaku zasshi = Hukuoka acta medica 20040901

• Advances in radiosensitization.

  Clinical advances in hematology & oncology : H&O 20040901

• EGFR inhibition in NSCLC: the emerging role of cetuximab.

  Journal of the National Comprehensive Cancer Network : JNCCN 20040901

• Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.

  Science (New York, N.Y.) 20040827

• Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

  Science (New York, N.Y.) 20040820

• [Gefitinib is active in patients with brain metastasis from non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20040820

• [Iressa for refractory non-small cell lung cancer: A preliminary report].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20040820

• [The salvage regimen for patients with advanced non-small cell lung cancer who failed prior chemotherapy: once-daily single oral agent Iressa].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20040820

• [Gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20040820

• [Iressa for the non-small cell lung cancer patients who failed prior chemotherapy and radiotherapy].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20040820

• [Targeted Iressa therapy in patients with brain metastases from non-small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20040820

• Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.

  British journal of cancer 20040816

• Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

  Journal of the National Cancer Institute 20040804

• Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

  Journal of the National Cancer Institute 20040804

• Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer.

  British journal of cancer 20040802

• Targeting the epidermal growth factor receptor.

  British journal of cancer 20040802

• Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.

  Lung cancer (Amsterdam, Netherlands) 20040801

• Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.

  Expert review of anticancer therapy 20040801

• Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

  Cancer research 20040801

• Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.

  Molecular cancer therapeutics 20040801

• [Recurrence of non-small cell lung cancer after successful treatment with gefitinib--report of three cases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040801

• Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.

  British journal of cancer 20040801

• Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.

  British journal of cancer 20040801

• Interstitial lung disease associated with drug therapy.

  British journal of cancer 20040801

• Diagnosis and management of drug-associated interstitial lung disease.

  British journal of cancer 20040801

• Understanding the mechanisms of drug-associated interstitial lung disease.

  British journal of cancer 20040801

• Toxicogenomics data: the road to acceptance.

  Environmental health perspectives 20040801

• New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.

  Clinical journal of oncology nursing 20040801

• Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.

  Internal medicine (Tokyo, Japan) 20040801

• Early-stage lung cancer findings end a debate, put focus on next steps.

  Journal of the National Cancer Institute 20040721

• Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.

  British journal of cancer 20040719

• The story of gefitinib, an EGFR kinase that works in lung cancer.

  Drug discovery today 20040715

• Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040715

• Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040715

• Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040715

• Estrogen receptor pathways in lung cancer.

  Current oncology reports 20040701

• The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

  Biochemical pharmacology 20040701

• Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Severe myelotoxicity in a combination of gefitinib and vinorelbine.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.

  International journal of oncology 20040701

• Pharmacological background of EGFR targeting.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• The role of targeted therapy in non-small cell lung cancer.

  Critical reviews in oncology/hematology 20040701

• Gefitinib in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040701

• Cancer: understanding the target.

  Nature 20040701

• Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040701

• Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839).

  Cancer science 20040701

• Imatinib: paradigm or anomaly?

  Cell cycle (Georgetown, Tex.) 20040701

• Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

  The British journal of dermatology 20040701

• [Target molecules of molecular target therapy of cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20040701

• [The mechanisms of the resistance to molecular targeting agents].

  Nihon rinsho. Japanese journal of clinical medicine 20040701

• [Gefitinib in non-small cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20040701

• [Resistance to target-based therapy and its circumvention].

  Nihon rinsho. Japanese journal of clinical medicine 20040701

• The ErbB/HER receptor protein-tyrosine kinases and cancer.

  Biochemical and biophysical research communications 20040618

• Tamoxifen: Dr. Jekyll and Mr. Hyde?

  Journal of the National Cancer Institute 20040616

• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  Journal of the National Cancer Institute 20040616

• Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615

• Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• The role of gefitinib in lung cancer treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Molecularly targeted approaches to the chemoprevention of lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Epidermal growth factor receptor tyrosine kinase inhibitors.

  British journal of cancer 20040614

• From bench to bedside and back again?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20040608

• EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

  Science (New York, N.Y.) 20040604

• Cancer. A bull's eye for targeted lung cancer therapy.

  Science (New York, N.Y.) 20040604

• Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.

  Oncology reports 20040601

• High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

  Molecular pharmacology 20040601

• Acute lung injury as an adverse event of gefitinib.

  Anti-cancer drugs 20040601

• Look before you leap.

  Nature medicine 20040601

• Selecting the right patient for tumor therapy.

  Nature medicine 20040601

• EGFR inhibitors square off at ASCO.

  Nature biotechnology 20040601

• An image worth a thousand lives?

  Nature biotechnology 20040601

• Japanese chest physicians face hopes and enigmas of gefitinib, a molecular targeting drug for lung cancer.

  Respirology (Carlton, Vic.) 20040601

• Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.

  Critical reviews in oncology/hematology 20040601

• Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.

  Seminars in oncology 20040601

• Management of acneiform rashes related to gefitinib therapy.

  Clinical journal of oncology nursing 20040601

• New oncology strategy: molecular targeting of cancer cells.

  Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses 20040601

• [Interstitial pneumonia due to gefitinib followed in detail by high-resolution CT in a patient with adenocarcinoma of the lung].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040601

• [New advance of the molecular targeting agents in advanced non-small cell lung cancer].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20040601

• [Gefitinib for advanced bronchioloalveolar carcinoma].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20040601

• [Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)].

  Minerva medica 20040601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040601

• Second-line chemotherapy and beyond for non-small-cell lung cancer.

  Clinical advances in hematology & oncology : H&O 20040601

• Targeting targeted therapy.

  The New England journal of medicine 20040520

• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  The New England journal of medicine 20040520

• Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040515

• A deadly disease, a promising drug.

  U.S. news & world report 20040510

• Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.

  Sao Paulo medical journal = Revista paulista de medicina 20040506

• Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

  Journal of the National Cancer Institute 20040505

• Synthesis and biological evaluation of benzamides and benzamidines: structural requirement of a pyrimidine ring for inhibition of EGFR tyrosine kinase.

  Bioorganic & medicinal chemistry letters 20040503

• Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501

• Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

  Cancer treatment reviews 20040501

• New cytotoxic and molecular-targeted therapies of head and neck tumors.

  Current opinion in oncology 20040501

• Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study.

  Lung cancer (Amsterdam, Netherlands) 20040501

• Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040501

• Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040501

• Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040501

• [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor ZD1839 on nasopharyngeal carcinoma cells].

  Ai zheng = Aizheng = Chinese journal of cancer 20040501

• Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.

  Cancer cell 20040501

• Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040501

• Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.

  Cancer biology & therapy 20040501

• Epidermal growth factor receptor mutations: a new insight.

  Clinical lung cancer 20040501

• Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.

  Clinical lung cancer 20040501

• Mutations in the EGFR: the importance of genotyping.

  Cancer biology & therapy 20040501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040501

• Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.

  Bulletin du cancer 20040501

• Medicine. Why a new cancer drug works well, in some patients.

  Science (New York, N.Y.) 20040430

• Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients.

  British journal of cancer 20040419

• Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

  British journal of cancer 20040419

• [The effect of IRESSA on H22 mouse hepatocellular carcinoma].

  Zhonghua yi xue za zhi 20040417

• Predictors of clinical response of non-small cell cancer to gefitinib.

  JAMA 20040407

• Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.

  Anti-cancer drugs 20040401

• Gefitinib, a novel, orally administered agent for the treatment of cancer.

  Journal of clinical pharmacy and therapeutics 20040401

• Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.

  Urology 20040401

• Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040401

• Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

  Molecular cancer therapeutics 20040401

• Gefitinib for advanced or metastatic non-small cell lung cancer.

  Issues in emerging health technologies 20040401

• [Tumor biotherapy based on epidermal growth factor receptor as a target].

  Ai zheng = Aizheng = Chinese journal of cancer 20040401

• Tyrosine kinase receptors as attractive targets of cancer therapy.

  Critical reviews in oncology/hematology 20040401

• Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.

  Clinical journal of oncology nursing 20040401

• [Screening of antiangiogenic compound].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Structure-activity relationship analysis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• New targeted therapies in breast cancer.

  Seminars in oncology 20040401

• Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?

  Oncology (Williston Park, N.Y.) 20040401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040401

• New cancer therapeutics: target-specific in, cytotoxics out?

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401

• EGFR mutants render Iressa more effective in treating lung cancer.

  Discovery medicine 20040401

• Industry Analysis: Tarceva extends cancer patients survival in a phase III study.

  Discovery medicine 20040401

• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040315

• [Molecular pathogenesis of lung cancers and the preservative therapy].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20040310

• ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

  British journal of cancer 20040308

• As targeted therapies evolve, challenges remain.

  Journal of the National Cancer Institute 20040303

• The HER receptor family: a rich target for therapeutic development.

  International journal of radiation oncology, biology, physics 20040301

• Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.

  International journal of radiation oncology, biology, physics 20040301

• Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.

  International journal of radiation oncology, biology, physics 20040301

• Epidermal growth factor receptor inhibitors in clinical development.

  International journal of radiation oncology, biology, physics 20040301

• Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.

  Clinical and experimental dermatology 20040301

• Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301

• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301

• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301

• Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839).

  Anti-cancer drugs 20040301

• Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

  Current medicinal chemistry. Anti-cancer agents 20040301

• [Bronchioloalveolar carcinoma (BAC)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040301

• The role of EGFR inhibitors in nonsmall cell lung cancer.

  Current opinion in oncology 20040301

• Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040301

• Severe acute interstitial pnuemonia and gefitinib.

  Lung cancer (Amsterdam, Netherlands) 20040301

• Effect of gefitinib (ZD1839) on metastatic brain tumour.

  Lung cancer (Amsterdam, Netherlands) 20040301

• United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040215

• Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.

  British journal of cancer 20040209

• Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.

  Journal of cellular physiology 20040201

• Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.

  The Journal of urology 20040201

• Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells.

  The Journal of nutrition 20040201

• Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.

  Expert review of anticancer therapy 20040201

• 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).

  Seminars in cancer biology 20040201

• New drugs 04, part 1.

  Nursing 20040201

• A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.

  Seminars in oncology 20040201

• Gefitinib: phase II and III results in advanced non-small cell lung cancer.

  Seminars in oncology 20040201

• [Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040201

• Novel treatments in non-small cell lung cancer.

  Hematology/oncology clinics of North America 20040201

• Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer.

  Seminars in oncology 20040201

• [Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].

  Revue des maladies respiratoires 20040201

• Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.

  International journal of cancer 20040120

• The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase.

  The Journal of biological chemistry 20040116

• The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040115

• Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).

  British journal of cancer 20040112

• Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.

  British journal of cancer 20040112

• Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.

  Bioorganic & medicinal chemistry letters 20040105

• Phase II trial of gefitinib in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040101

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines.

  Oral oncology 20040101

• Smart drugs in prostate cancer.

  European urology 20040101

• Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.

  Breast cancer research : BCR 20040101

• AACR Special Conference: Advances in Breast Cancer Research--Genetics, Biology, and Clinical Implications, Huntington Beach, California, USA, 8-12 October 2003.

  Breast cancer research : BCR 20040101

• Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.

  Breast cancer (Tokyo, Japan) 20040101

• [A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040101

• HER1/EGFR targeting: refining the strategy.

  The oncologist 20040101

• [Transient liver injury caused by gefitinib].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040101

• Lung cancer: looking ahead in 2004.

  Clinical lung cancer 20040101

• Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.

  Oncology research 20040101

• 26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3-6 December 2003: update on preclinical and translational research.

  Breast cancer research : BCR 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung.

  Anticancer research 20040101

• Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.

  Acta dermato-venereologica 20040101

• Highlights from the Tenth World Conference on Lung Cancer.

  The oncologist 20040101

• Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.

  Surgery today 20040101

• New drugs of 2003.

  Journal of the American Pharmacists Association : JAPhA 20040101

• Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.

  International journal of radiation oncology, biology, physics 20040101

• Review of epidermal growth factor receptor biology.

  International journal of radiation oncology, biology, physics 20040101

• Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer.

  International journal of radiation oncology, biology, physics 20040101

• A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.

  BMC cancer 20040101

• The miracle of Iressa.

  The oncologist 20040101

• Pharmacogenomics arrives.

  Genome biology 20040101

• Gefitinib: a new agent in palliative care.

  The American journal of hospice & palliative care 20040101

• Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.

  Anticancer research 20040101

• New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.

  Breast cancer research : BCR 20040101

• Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.

  BMC cancer 20040101

• Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.

  Acta dermato-venereologica 20040101

• RNAi for research and therapy.

  Genome biology 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• [Predicting response to Iressa: unexpected mechanism].

  Medecine sciences : M/S 20040101

• Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

  Clinical & experimental metastasis 20040101

• Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.

  Drugs 20040101

• New targets for therapy in breast cancer: farnesyltransferase inhibitors.

  Breast cancer research : BCR 20040101

• Brain metastasis responding to gefitinib alone.

  Oncology 20040101

• Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.

  Journal of drugs in dermatology : JDD 20040101

• Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.

  Drug safety 20040101

• The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.

  BMC cancer 20040101

• Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.

  Novartis Foundation symposium 20040101

• PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).

  Breast cancer (Tokyo, Japan) 20040101

• [Impact of oncologic therapeutic concepts 2004].

  Acta medica Austriaca 20040101

• In vitro metabolism of gefitinib in human liver microsomes.

  Xenobiotica; the fate of foreign compounds in biological systems 20040101

• Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.

  International journal of cancer 20031220

• Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?

  Journal of the National Cancer Institute 20031217

• Investigational drug access taken to task in lawsuit against FDA.

  Journal of the National Cancer Institute 20031217

• Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

  Journal of the National Cancer Institute 20031217

• Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.

  Cancer research 20031215

• Pharmacy practice issues with targeted therapy for lung cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20031215

• Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20031215

• Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

  Cancer letters 20031208

• The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.

  Cancer chemotherapy and pharmacology 20031201

• Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.

  The Journal of urology 20031201

• [EGFR tyrosine kinase inhibitor 'gefitinib (Iressa)' for cancer therapy].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031201

• The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts.

  British journal of cancer 20031201

• Extensive experience of disease control with gefitinib and the role of prognostic markers.

  British journal of cancer 20031201

• Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.

  British journal of cancer 20031201

• Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.

  British journal of cancer 20031201

• Lessons from the ('Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.

  British journal of cancer 20031201

• Getting to grips with gefitinib.

  The Lancet. Oncology 20031201

• Targeting the epidermal growth factor receptor in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031201

• Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells.

  Molecular cancer therapeutics 20031201

• [Development of novel molecular targeted drug, 'Iressa', for the treatment of malignant diseases--its basic and clinical studies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031201

• Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.

  Annals of the New York Academy of Sciences 20031201

• Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.

  Cancer nursing 20031201

• Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells.

  Cancer letters 20031125

• Combinations of targeted therapies take aim at multiple pathways.

  Journal of the National Cancer Institute 20031119

• Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.

  British journal of cancer 20031117

• Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells.

  Cancer research 20031115

• The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.

  Cancer research 20031115

• A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).

  British journal of cancer 20031103

• The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.

  Endocrinology 20031101

• Gefitinib therapy for advanced non-small-cell lung cancer.

  The Annals of pharmacotherapy 20031101

• Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

  Cancer research 20031101

• [Targeted molecular therapy: the example of Iressa (ZD1839)].

  Medecine sciences : M/S 20031101

• [Current screening for molecular target therapy of cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

  Expert opinion on emerging drugs 20031101

• Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.

  Clinical lung cancer 20031101

• Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.

  Clinical lung cancer 20031101

• Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20031101

• Erlotinib: preclinical investigations.

  Oncology (Williston Park, N.Y.) 20031101

• Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

  Oncology (Williston Park, N.Y.) 20031101

• [EGF receptors in urological cancer. Molecular basis and therapeutic involvements].

  Annales de medecine interne 20031101

• [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].

  Bulletin du cancer 20031101

• [Targeting of epidermal growth factor receptor and applications in ORL cancer].

  Bulletin du cancer 20031101

• [Inhibitors of epidermal growth factor receptor and colorectal cancer].

  Bulletin du cancer 20031101

• [Therapeutic implications of epidermal growth factor receptor in lung cancer].

  Bulletin du cancer 20031101

• [Targeting epidermal growth factor receptor in cancer of the breast].

  Bulletin du cancer 20031101

• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  JAMA 20031022

• ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031015

• Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

  European journal of nuclear medicine and molecular imaging 20031001

• New targeted therapies in gastrointestinal cancers.

  Current treatment options in oncology 20031001

• The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.

  Lung cancer (Amsterdam, Netherlands) 20031001

• Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

  American journal of clinical oncology 20031001

• Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.

  Expert review of anticancer therapy 20031001

• Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?

  Internal medicine (Tokyo, Japan) 20031001

• [Significance of gefitinib combined with immunotherapy in tumor-bearing mice].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• Novel cancer therapies: targeting the molecules.

  JAAPA : official journal of the American Academy of Physician Assistants 20031001

• Small-molecule cyclin-dependent kinase modulators.

  Oncogene 20030929

• Selection bias, phase II trials, and the FDA accelerated approval process.

  Journal of the National Cancer Institute 20030917

• Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.

  Anti-cancer drugs 20030901

• The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030901

• [Angiogenesis and metastasis in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.

  Journal of experimental & clinical cancer research : CR 20030901

• Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

  Clinical lung cancer 20030901

• The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.

  Clinical lung cancer 20030901

• Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.

  Clinical lung cancer 20030901

• Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.

  Clinical lung cancer 20030901

• Molecular targeted agents in non-small-cell lung cancer.

  Clinical lung cancer 20030901

• Adjuvant systemic therapies in early-stage non-small-cell lung cancer.

  Clinical lung cancer 20030901

• Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.

  Clinical lung cancer 20030901

• Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin.

  Biochemical pharmacology 20030815

• Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.

  Cancer research 20030815

• Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

  British journal of cancer 20030804

• Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.

  British journal of cancer 20030804

• Targeted therapy in non-small cell lung cancer: myth or reality.

  Lung cancer (Amsterdam, Netherlands) 20030801

• EGF receptor as a therapeutic target.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Gefitinib (Iressa) trials in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

  Lung cancer (Amsterdam, Netherlands) 20030801

• Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

  Cancer research 20030801

• Fatal pneumopathy and gefitinib.

  Prescrire international 20030801

• Does hope match the hype for targeted drugs?

  The Lancet. Oncology 20030801

• Second-line chemotherapy for non-small cell lung cancer.

  Expert review of anticancer therapy 20030801

• [Iressa (gefitinib)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030801

• Molecular target-based cancer therapy: tyrosine kinase inhibitors.

  International journal of clinical oncology 20030801

• Oncogenic pathways implicated in ovarian epithelial cancer.

  Hematology/oncology clinics of North America 20030801

• [Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20030801

• An overview of targeted treatments in cancer.

  Clinical therapeutics 20030801

• Tumor specific activation of PKR as a non-toxic modality of cancer treatment.

  Seminars in cancer biology 20030801

• Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

  Investigational new drugs 20030801

• Gefitinib: current and future status in cancer therapy.

  Clinical advances in hematology & oncology : H&O 20030801

• ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.

  British journal of cancer 20030721

• Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.

  Oncogene 20030717

• Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030715

• [Non-small cell lung cancer: 1) Molecular-target therapy].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030710

• [Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030710

• Targeting epidermal growth factor receptor--are we missing the mark?

  Lancet (London, England) 20030705

• Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839.

  International journal of oncology 20030701

• Gefitinib.

  Nature reviews. Drug discovery 20030701

• Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

  The Journal of pathology 20030701

• Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

  The Lancet. Oncology 20030701

• A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Acute lung injury as a possible adverse drug reaction related to gefitinib.

  The European respiratory journal 20030701

• The benefits of achieving stable disease in advanced lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• [Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030701

• Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish.

  JAMA 20030625

• Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

  Journal of the National Cancer Institute 20030618

• Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030615

• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030615

• Clinical efficacy and toxicity of gefitinib in patients with lung cancer.

  Lancet (London, England) 20030607

• Clinical efficacy and toxiciy of gefitinib in patients with lung cancer.

  Lancet (London, England) 20030607

• Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601

• ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.

  Lung cancer (Amsterdam, Netherlands) 20030601

• Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030601

• Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.

  The Laryngoscope 20030601

• More haste, less speed.

  The Lancet. Oncology 20030601

• Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030601

• Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030601

• Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030601

• Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030601

• Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030601

• Development of ZD1839 in colorectal cancer.

  Seminars in oncology 20030601

• Protein kinase inhibitors as a therapeutic modality.

  Accounts of chemical research 20030601

• ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model.

  Molecular cancer therapeutics 20030601

• [Epidermal growth factor inhibitors].

  La Revue de medecine interne 20030601

• Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.

  Expert review of anticancer therapy 20030601

• [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20030601

• A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).

  Clinical breast cancer 20030601

• Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics.

  Current opinion in investigational drugs (London, England : 2000) 20030601

• Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20030601

• Biologists take tentative steps towards bespoke cancer drugs.

  Nature 20030515

• FDA announces fast track approval of new drug for lung cancer.

  BMJ (Clinical research ed.) 20030510

• Treatment of cultured glioma cells with the EGFR-TKI gefitinib ('Iressa', ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.

  European journal of nuclear medicine and molecular imaging 20030501

• A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

  Cancer science 20030501

• Gefitinib for non-small cell lung cancer: is the efficacy real?

  Clinical lung cancer 20030501

• Dermatologic side effects associated with gefitinib therapy: clinical experience and management.

  Clinical lung cancer 20030501

• Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients.

  Clinical lung cancer 20030501

• Apparent adverse drug reactions prompt concern about Iressa.

  Journal of the National Cancer Institute 20030416

• Overview of bladder cancer trials in the Cancer and Leukemia Group B.

  Cancer 20030415

• Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.

  Journal of cellular physiology 20030401

• A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030401

• Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.

  Lung cancer (Amsterdam, Netherlands) 20030401

• Commentary on ZD1839 (Iressa) in non small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030401

• Tyrosine kinases as targets in cancer therapy - successes and failures.

  Expert opinion on therapeutic targets 20030401

• ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030401

• Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030401

• Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).

  Molecular cancer therapeutics 20030401

• [From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].

  Il Giornale di chirurgia 20030401

• ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).

  Clinical advances in hematology & oncology : H&O 20030401

• Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy.

  British journal of cancer 20030324

• EGFR blockade with ZD1839 ('Iressa') potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.

  International journal of radiation oncology, biology, physics 20030301

• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  Endocrinology 20030301

• Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.

  Endocrine-related cancer 20030301

• Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

  The Journal of dermatology 20030301

• Molecular cancer therapeutics: recent progress and targets in drug resistance.

  Internal medicine (Tokyo, Japan) 20030301

• Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

  Journal of cancer research and clinical oncology 20030301

• Gateways to clinical trials. March 2003.

  Methods and findings in experimental and clinical pharmacology 20030301

• Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

  Bioorganic & medicinal chemistry letters 20030224

• [Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030210

• Receptor tyrosine kinases: the main targets for new anticancer therapy.

  Current drug targets 20030201

• Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• [Molecular-targeted therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030201

• Epidermal growth factor receptor as a therapeutic target in colorectal cancer.

  Clinical colorectal cancer 20030201

• Recurrent small cell lung cancer: update.

  Seminars in oncology 20030201

• The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

  Seminars in oncology 20030201

• Studies with ZD1839 in preclinical models.

  Seminars in oncology 20030201

• Phase I studies of ZD1839 in patients with common solid tumors.

  Seminars in oncology 20030201

• Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.

  Seminars in oncology 20030201

• Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.

  Seminars in oncology 20030201

• New directions for ZD1839 in the treatment of solid tumors.

  Seminars in oncology 20030201

• [14th EORTC-NCI-AAACR Symposium on New Molecular Targets and Cancer Therapeutics].

  Bulletin du cancer 20030201

• On target. A new generation of drugs offers customized cures.

  U.S. news & world report 20030120

• Severe acute interstitial pneumonia and gefitinib.

  Lancet (London, England) 20030111

• Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition.

  Swiss medical weekly 20030111

• Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.

  Expert opinion on investigational drugs 20030101

• Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030101

• Pathways for aberrant angiogenesis in pancreatic cancer.

  Molecular cancer 20030101

• BAD: a good therapeutic target?

  Breast cancer research : BCR 20030101

• 27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.

  European journal of cancer (Oxford, England : 1990) 20030101

• The application of basic science to translational cancer research.

  Genome biology 20030101

• The prolyl isomerase Pin1 in breast development and cancer.

  Breast cancer research : BCR 20030101

• Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.

  Breast cancer research : BCR 20030101

• 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research.

  Breast cancer research : BCR 20030101

• 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on clinical research.

  Breast cancer research : BCR 20030101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20030101

• Signal transduction modulators for cancer therapy: from promise to practice?

  The oncologist 20030101

• Signaling protein networks as targets of new antineoplastic drugs.

  The International journal of biological markers 20030101

• Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

  Cancer science 20030101

• Why Iressa failed: toward novel use of kinase inhibitors (outlook).

  Cancer biology & therapy 20030101

• The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.

  Breast cancer research : BCR 20030101

• 8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003.

  Breast cancer research : BCR 20030101

• Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

  Drugs in R&D 20030101

• FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

  The oncologist 20030101

• [Molecular therapy of breast carcinoma in the advanced phase].

  Tumori 20030101

• Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).

  Advances in experimental medicine and biology 20030101

• Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.

  Advances in experimental medicine and biology 20030101

• [Gefitinib (Iressa). Laboratory: AstraZeneca].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101

• Speedy approvals for new cancer treatments.

  FDA consumer 20030101

• The biology of antihormone failure in breast cancer.

  Breast cancer research and treatment 20030101

• Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.

  Dermatology (Basel, Switzerland) 20030101

• Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis.

  Breast cancer research : BCR 20030101

• Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

  Cancer control : journal of the Moffitt Cancer Center 20030101

• Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess.

  Radiographics : a review publication of the Radiological Society of North America, Inc 20030101

• Surrogate end points of quality of life assessment: have we really found what we are looking for?

  Health and quality of life outcomes 20030101

• Activation of tyrosine kinases in cancer.

  The oncologist 20030101

• Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.

  The oncologist 20030101

• Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

  Anticancer research 20030101

• Signal events: Cell signal transduction and its inhibition in cancer.

  The oncologist 20030101

• Recent advances of molecular targeted agents: opportunities for imaging.

  Cancer biology & therapy 20030101

• Pharmacology of oral chemotherapy agents.

  Clinical journal of oncology nursing 20030101

• Medication sheets for patients. Oral chemotherapy.

  Clinical journal of oncology nursing 20030101

• Response to gefitinib in pericardial effusion due to lung cancer.

  Acta medica (Hradec Kralove) 20030101

• Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.

  Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 20030101

• Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.

  The Journal of biological chemistry 20021220

• The simpleton's error in drug development.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021201

• What went wrong with Iressa?

  The Lancet. Oncology 20021201

• Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021201

• Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.

  Expert review of anticancer therapy 20021201

• Synthetic lethality: killing cancer with cancer.

  Journal of the National Cancer Institute 20021120

• Demand grows for early access to promising cancer drugs.

  Journal of the National Cancer Institute 20021120

• Despite concerns, FDA panel backs EGFR inhibitor.

  Journal of the National Cancer Institute 20021106

• The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just 'living large'?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021101

• Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021101

• Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021101

• Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.

  Clinical colorectal cancer 20021101

• Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.

  Seminars in oncology nursing 20021101

• The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review.

  Clinical lung cancer 20021101

• Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.

  Bioorganic & medicinal chemistry letters 20021021

• Oral cancer treatment: developments in chemotherapy and beyond.

  British journal of cancer 20021021

• Cancer drugs. Smart weapons prove tough to design.

  Science (New York, N.Y.) 20021018

• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  Cancer research 20021015

• The role of EGFR-directed therapy in the treatment of breast cancer.

  Breast cancer research and treatment 20021001

• Surprise phase III failure for ZD1839.

  The Lancet. Oncology 20021001

• Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021001

• Epidermal growth factor receptor-targeted therapy in colorectal cancer.

  Seminars in oncology 20021001

• Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.

  Seminars in oncology 20021001

• Epithelial growth factor receptor interacting agents.

  Hematology/oncology clinics of North America 20021001

• Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915

• Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.

  Cancer research 20020915

• Gefitinib (Iressa) for advanced non-small cell lung cancer.

  The Medical letter on drugs and therapeutics 20020902

• Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.

  The British journal of dermatology 20020901

• Erlotinib OSI/Roche/Genentech.

  Current opinion in investigational drugs (London, England : 2000) 20020901

• Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.

  The Journal of biological chemistry 20020802

• Epidermal growth factor receptor tyrosine kinase inhibitors.

  Current opinion in pharmacology 20020801

• Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).

  Cancer research 20020801

• [New therapeutic targets and strategies in lung cancer].

  Archivos de bronconeumologia 20020801

• A serum factor after intestinal resection stimulates epidermal growth factor receptor signaling and proliferation in intestinal epithelial cells.

  Surgery 20020801

• Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.

  Expert review of anticancer therapy 20020801

• Targeting epidermal growth factor receptor in lung cancer.

  Current oncology reports 20020701

• Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020701

• Activity of ZD1839 (Gefitinib, Iressa) in previously treated patients with recurrent and advanced non-small-cell lung cancer.

  Clinical lung cancer 20020701

• A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials.

  Journal of pharmaceutical and biomedical analysis 20020620

• Cancer medicine hits a target.

  U.S. news & world report 20020603

• ZD1839: targeting the epidermal growth factor receptor in cancer therapy.

  Expert opinion on investigational drugs 20020601

• Selective inhibition of the epidermal growth factor receptor impairs intestinal adaptation after small bowel resection.

  The Journal of surgical research 20020601

• Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.

  Annals of the New York Academy of Sciences 20020601

• Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.

  Onkologie 20020601

• HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

  Seminars in oncology 20020601

• Gateways to Clinical Trials. June 2002.

  Methods and findings in experimental and clinical pharmacology 20020601

• Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa').

  British journal of cancer 20020506

• ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

  Cancer research 20020501

• Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020501

• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020501

• Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• [ZD1839].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [New treatment strategy for stage III non-small-cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [Latest therapeutic strategy for stage IV non-small cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [Future trends in anticancer chemotherapy].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• Results of recent Japanese clinical trials in lung cancer.

  Clinical lung cancer 20020501

• ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

  British journal of cancer 20020408

• ZD1839 (IRESSA): a selective EGFR-TK inhibitor.

  Expert review of anticancer therapy 20020401

• ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.

  International journal of cancer 20020320

• [Progress in diagnosis and treatment of lung cancer].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20020320

• Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.

  International journal of cancer 20020310

• Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.

  British journal of cancer 20020304

• Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

• Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa').

  British journal of cancer 20020201

• ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

  Seminars in oncology 20020201

• [Non surgical new treatment modalities for lung cancer].

  Nihon Geka Gakkai zasshi 20020201

• [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].

  Nihon Geka Gakkai zasshi 20020201

• Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.

  Cancer research 20020101

• Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020101

• Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020101

• ZD1839 (Iressa): preclinical studies and pharmacology.

  Tumori 20020101

• The epidermal growth factor receptor: a new target for anticancer therapy.

  Current problems in cancer 20020101

• Finding the needle in the haystack: why high-throughput screening is good for your health.

  Breast cancer research : BCR 20020101

• 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, USA, 6-10 April 2002.

  Breast cancer research : BCR 20020101

• Cytotoxic agents in the era of molecular targets and genomics.

  The oncologist 20020101

• Why the epidermal growth factor receptor? The rationale for cancer therapy.

  The oncologist 20020101

• ZD1839 (Iressa) in non-small cell lung cancer.

  The oncologist 20020101

• ZD1839 (Iressa): for more than just non-small cell lung cancer.

  The oncologist 20020101

• ZD1839 (Iressa): what's in it for the patient?

  The oncologist 20020101

• Epidermal growth factor receptor dependence in human tumors: more than just expression?

  The oncologist 20020101

• Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).

  Oncology reports 20020101

• Gefitinib.

  Drugs 20020101

• The rational basis of using novel targeted biological agents in non-small cell lung cancer.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

• Tyrosine kinase signal transduction inhibitors. Clinical trials.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

• Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

• HER-targeted tyrosine-kinase inhibitors.

  Oncology 20020101

• Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.

  Cancer detection and prevention 20020101

• EGFR inhibitors: clinical results.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

• ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.

  International journal of cancer 20011215

• Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

  Cancer research 20011215

• Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Inhibitors of HER2/neu (erbB-2) signal transduction.

  Seminars in oncology 20011201

• Prospects for combining hormonal and nonhormonal growth factor inhibition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Tyrosine kinase inhibitors-ZD1839 (Iressa).

  Current opinion in oncology 20011101

• The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

  Cancer research 20011001

• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

• Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.

  Seminars in radiation oncology 20011001

• [Issues in cancer treatments--EBM, individuation, and standardization].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

  Seminars in oncology 20011001

• Anticancer therapy targeting the erbB family of receptor tyrosine kinases.

  Seminars in oncology 20011001

• Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.

  Seminars in oncology 20011001

• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  Cancer research 20010901

• Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

  Endocrine-related cancer 20010901

• Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

  Cancer research 20010801

• Growth factors and their receptors: new targets for prostate cancer therapy.

  Urology 20010801

• Scoring a bull's-eye against cancer genome targets.

  Current opinion in pharmacology 20010801

• Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

  Bioorganic & medicinal chemistry letters 20010723

• Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

  Endocrinology 20010701

• Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.

  Oncology (Williston Park, N.Y.) 20010601

• OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.

  Expert review of anticancer therapy 20010601

• The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis.

  Experimental eye research 20010501

• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• [Tumor angiogenesis and tumor angiogenesis inhibitors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• [Tyrosine kinase inhibitors--solid cancers].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges.

  Current cancer drug targets 20010501

• New drugs in gynecologic cancer.

  Current treatment options in oncology 20010401

• Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation.

  The British journal of surgery 20010301

• ZD-1839 (AstraZeneca).

  Current opinion in investigational drugs (London, England : 2000) 20010301

• The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.

  Clinical pharmacokinetics 20010101

• [3rd National Congress of Medical Oncology. Issues in Gynecologic Oncology. Naples, November 7, 2000].

  Tumori 20010101

• Genetics of glioblastoma: a window into its imaging and histopathologic variability.

  Radiographics : a review publication of the Radiological Society of North America, Inc